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Abstract 
Mild hyperhomocysteinemia is a risk factor for many diseases, including 
cardiovascular disease. We determined the effects of insulin resistance and of Type 2 
diabetes on homocysteine and amino acid metabolism using Zucker diabetic fatty rats 
(ZDF/Gmi-fa/fa and ZDF/Gmi +/?).Plasma total homocysteine was reduced in ZDF fa/fa 
rats by 24% in the pre-diabetic insulin-resistant stage while in the frank diabetic stage 
there was a 59% reduction. Hepatic activities of several enzymes that remove 
homocysteine: cystathionine P-synthase, cystathionine y-lyase and betaine:homocysteine 
methyltransferase were increased as well as methionine adenosyltransferase. 
Cystathionine P-synthase and betaine:homocysteine methyltransferase mRNA levels and 
the hepatic level of S-adenosylmethionine were also increased in the ZDF fa/fa rats. 
Studies with primary hepatocytes showed that homocysteine export and the 
transsulfuration flux in cells from ZDF fa/fa rats were particularly sensitive to the 
presence of betaine, which reduced these fluxes. Interestingly, the liver betaine 
concentration was found to be significantly lower in the ZDF fa/fa rats at both 5 and 11 
weeks. We conclude that the decreased insulin action and the elevation of the counter-
regulatory hormones observed in diabetes may be responsible for the more efficient 
homocysteine removal seen in the ZDF fa/fa rats. 
Amino acids were measured in plasma, liver and skeletal muscle and the ratios of 
plasma: liver and plasma: skeletal muscle, were calculated (Chapter 4). At the insulin-
resistant stage, the plasma concentrations of the gluconeogenic amino acids aspartate, 
serine, glutamine, glycine and histidine were decreased in the ZDF fa/fa rats while 
taurine, a-aminoadipic acid, methionine, phenylalanine, tryptophan and the three 
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branched-chain amino acids were significantly increased. At the diabetic stage, a larger 
number of gluconeogenic amino acids showed decreased plasma concentrations. The 
three branched chain amino acids again showed elevated plasma concentrations. In the 
liver and the skeletal muscles, many of the gluconeogenic amino acids showed lowered 
concentrations at both stages while the levels of one or all of the branched-chain amino 
acids were elevated. These changes in amino acid concentration are similar to changes 
seen in Type 1 diabetes. However, it is evident that insulin resistance alone is capable of 
bringing about many of the changes in amino acid metabolism observed in Type 2 
diabetes. 
The next part of the study focused on the effects of the insulin-sensitizing drug, 
Rosiglitazone, on homocysteine metabolism (Chapter 5). Rosiglitazone is an agonist of 
the peroxisome proliferator activated receptor y and is used as an anti-diabetic agent to 
treat Type 2 diabetes. Male ZDF fa/fa and ZDF fa/+ rats, aged 6 weeks were each divided 
into 2 groups: Rosiglitazone-treated (RSG) and untreated, and were killed at 12 weeks of 
age. Rosiglitazone treatment was able to maintain a normal plasma glucose level in the 
ZDF fa/fa (RSG) rats. At 12 weeks of age, ZDF fa/fa (untreated) rats developed type 2 
diabetes as indicated by a 3-fold increase in plasma glucose, while plasma insulin level 
was similar to ZDF fa/+ rats. The significant reduction observed in plasma homocysteine 
in the ZDF fa/fa (untreated) rats was returned towards normal by Rosiglitazone treatment. 
The elevated activity of the transsulfuration enzyme, cystathionine y-lyase, in the ZDF 
fa/fa (untreated) rats was corrected by Rosiglitazone treatment while cystathionine P-
synthase was unaffected. The elevated activity ofbetaine:homocysteine methyltransferase 
observed in the ZDF fa/fa (untreated) rats was further increased by Rosiglitazone 
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treatment. That the increased activity of betaine:homocysteine methyltransferase in the 
ZDF fa/fa (RSG) rats may be a function of increased lipid output from the liver in the 
face of the lipid redistribution seen with Rosiglitazone is supported by the changes that 
were observed in phospholipid metabolism. 
Type 1 and Type 2 diabetes as well as insulin resistance prior to the development 
of Type 2 diabetes have been reported to cause endothelial dysfunction. Hyperglycemia 
has been suggested to play a major role in this development of endothelial dysfunction. 
Hyperhomocysteinemia has also been identified as a causative agent of endothelial 
dysfunction. Our earlier studies (Chapter 3 and 5) showed plasma homocysteine to be 
lower in both insulin resistance and during Type 2 diabetes in ZDF fa/fa rats. We, 
therefore, designed a study to determine the effects of increased glucose and decreased 
homocysteine on the function of mesenteric arteries and the effects of normalization of 
these two parameters with the treatment of Rosiglitazone. 6 week old ZDF fa/+ and ZDF 
fa/fa rats were randomly assigned to RSG treated and untreated groups as in Chapter 3, 
and were killed at 6, 12 and 18 weeks of age. 
The endothelium dependent vasorelaxation m response to acetylcholine, the 
proteinase-activated receptor-2 (PAR2) agonist 2-furoyl-LIGRLO-amide (2fli) and 
arachidonic acid were preserved in the ZDF fa/fa mesenteric arteries despite the 
hyperinsulinemia at 6 weeks and the hyperglycemia at 12 and 18 weeks. Despite the 
normalization of plasma glucose and near normalization of plasma homocysteine with the 
treatment of Rosiglitazone the endothelium dependent vasorelaxation in response to the 
above agonists did not change, reflecting the lack of any endothelial defects in the 
mesenteric arteries of these rats. 
lV 
The inability of the nitric oxide synthase inhibitor Nro-Nitro-L-arginine methyl 
ester hydrochloride (L-NAME) to completely abolish vasorelaxation in response to both 
acetylcholine and 2fli demonstrates the important role played by endothelium-derived-
hyperpolarizing factor in the relaxation of small caliber blood vessels in response to these 
2 agonists. Studies conducted with inhibitors of cyclo-oxygenase 112 (COXl/2) and 
calcium activated potassium channels (Kca) to identify the possible nitric oxide synthase 
independent mechanisms of vasorelaxation indicated both COX and Kca channels to be 
involved. Kca channels however, were shown to play a greater role than COX 112 as 
previously reported. 
We also observed an increased sensitivity towards the P AR2 agonist 2fli by the 
ZDF fa/fa rat vessels. This may be consistent with the increase in pro-inflammatory 
substances in the ZDF rat model, as P AR2 expression has been shown to increase during 
stress to the blood vessels and in the presence of various cytokines and pro-inflammatory 
substances. 
Our data also did not indicate a reduction in vascular smooth muscle cell 
responsiveness to nitric oxide in the ZDF fa/fa rats compared to ZDF fa/+ rats. Both 
groups of rats however, displayed a reduced relaxation response to sodium Nitroprusside 
compared to previously reported values. Treatment with Rosiglitazone was able to 
successfully restore this responsiveness in both groups of rats. A similar increase in 
responsiveness was also seen in the ZDF fa!+ and ZDF fa/fa untreated rat vessels as well 
as ZDF fa/fa (RSG) vessels incubated with L-NAME. 
The normal endothelium dependent vasorelaxation displayed by the ZDF fa/fa rats 
despite the hyperglycemia indicates that hyperglycemia alone may not be able to cause 
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endothelial dysfunction. Since plasma homocysteine levels in these rats were decreased, it 
leaves us with the interesting possibility that homocysteine may act as a balance point for 
development of endothelial dysfunction in this model of Type 2 diabetes. 
Vl 
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Chapter 1 
Introduction 
1 
1.1 History and Epidemiology 
The original hypothesis linking hyperhomocysteinemia (HHcy) with 
atherothrombotic vascular disease was proposed after the observation of severe 
arteriosclerotic lesions in two children with elevated plasma homocysteine (Hey) 
concentrations and homocysteinuria (McCully, 1969). This led to the proposal that even 
less severe increases in plasma Hey may pose a risk. Since then, a plethora of prospective, 
retrospective and cross-sectional studies have appeared that link moderate HHcy to 
atherosclerotic disease. These studies show that patients with coronary, cerebrovascular 
or peripheral arterial occlusive disease have mean plasma total homocysteine (tHey) 
levels greater than control subjects. Kang et al (1992) reported mean plasma tHey to be 
significantly higher both in male and female patients with coronary artery disease when 
compared to controls with angiographically normal coronary arteries. Since cross-
sectional studies deal with patients who already exhibit disease characteristics, they do 
not answer the question whether HHcy gives rise to the coronary artery disease or vice 
versa (Stampfer and Malinow, 1995). Two large prospective studies address this question. 
The Physicians' Health Study, which studied male physicians in the United States, 
showed that a plasma Hey concentration only 1.7 J.lmole/liter or 12 % greater than the 
upper limit of normal was associated with a 3.4-fold increase in the risk of myocardial 
infarction (MI) (Stampfer et al, 1992). The Tromso study, which investigated over 21,000 
subjects between the ages of 12-61, showed a relative risk for coronary heart disease of 
1.32 for an increase in serum Hey of 4 J.lmol/liter after adjusting for possible confounders 
(Arnesen et al, 1995). Meta-analyses confirm Hey's status as an independent risk factor 
although they disagree on its strength. A meta-analysis of 27 studies relating Hey to 
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coronary, cerebrovascular and peripheral arterial vascular disease showed a very strong 
relationship between these diseases and tHey (Boushey eta!, 1995). It was concluded that 
a 5 llmol/liter increment in tHey was comparable to a 0.5 mmol/liter increment in 
cholesterol in increasing the incidence of coronary artery disease. A more recent meta-
analysis that examined 30 prospective and retrospective studies confirmed that increased 
plasma Hey is an independent predictor of ischemic heart disease but of only moderate 
strength (Hey studies collaboration, 2002). The same group (Klerk et al, 2002) has 
reported a meta-analysis of the MTHFR 677TT polymorphism, which tends to increase 
plasma Hey, particularly in the context of low folate. They found that individuals with the 
MTHFR 677TT genotype had a significantly higher risk of cardiovascular disease (CVD) 
especially when found in conjunction with a low folate status. The uncertainty about the 
degree of risk associated with elevated plasma Hey may be attributed to a number of 
factors, but Stamm and Reynolds (1999) have emphasized one important factor: tHey in 
plasma may not be the most appropriate marker of CVD risk. In particular, risk may be 
more closely linked to either cellular Hey or to a particular component of plasma Hey. 
There are certain situations in which the risk attributable to Hey may be elevated. 
Certainly, there is evidence that HHcy is a stronger risk factor in patients with Type 2 
diabetes (Hoogeveen et a!, 2000) and in patients with existing coronary disease. In the 
latter group, Nygard et al (1997 A) found a direct relationship between plasma Hey levels 
and overall mortality; after a follow up of years from the confirmation of coronary artery 
disease, Kaplan-Meier estimates of mortality were 3.8% for patients with tHey levels less 
than 9 llmol/liter, 8.6% for patients with Hey level between 9 and 14.9 llmol/liter, and 
24.7% for those with levels 15 llmol/liter or higher. 
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There is considerable evidence that the cardiovascular risk posed by Hey is 
graded; there does not appear to be a threshold effect. A cross sectional study of elderly 
subjects from the Framingham Heart Study clearly demonstrated a graded increase in the 
level of extra-cranial stenosis. Similar observations were made in several other studies 
with regard to different cardiovascular disease states (Arnesen et al, 1995, Genest et al, 
1990). 
1.2 Plasma Forms of Hey 
Although the term Hey is used generically, plasma contains several different 
forms of this amino acid. Plasma tHey is made up of free and protein-bound Hey. The 
free Hey consists of homocysteine, homocystine and cysteine-homocysteine mixed 
disulphides (Kang et al, 1992) and a protein-bound fraction is linked to proteins by 
disulphide linkage, principally to cysteine 34 of albumin (Figure 1.1). Typically, in 
humans, the protein-bound fraction makes up the bulk of plasma tHey accounting for 
>70%, homocystine and cysteine-homocysteine mixed disulphides make up 5-15% each, 
while only trace amounts (~ 1 %) are found as free reduced homocysteine (Jacobsen, 
2001). These different forms of Hey along with reduced, free-oxidized and protein bound 
forms of cysteine and cysteinylglycine comprise a dynamic system (Ueland et al, 1996). 
A change in any one of these species leads to alterations in the thiol redox status (Ueland 
et al, 1996). Despite the existence of these different forms, typically the parameter 
measured is "total plasma Hey'', since assays for the separate forms are not yet 
satisfactory for routine clinical measurement. HHcy is categorized as being moderate, 
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intermediate or severe with basal tHey values of between 15 and 30, between 31 and 100 
and greater than 100 ).tmol/liter respectively (Kang et al, 1992). 
"Total plasma Hey'' does not encompass all forms of Hey in plasma. Hey 
thiolactone (Figure 1.1) can be formed in all human cell types; in general, its 
concentration is markedly increased under conditions of elevated plasma Hey. It is a 
cyclic thioester formed as a result of an error-correcting process in aminoacyl-tRNA 
synthetase (Jakubowski and Fersht, 1981). Protein homocysteinylation, by means of the 
formation of an amide bond between the carbonyl group of Hey thiolactone and the c-
amino group of lysyl side chains in cellular and extracellular proteins also occurs and can 
change the function of the protein so modified (Jakubowski, 1999). Such 
homocysteinylation of proteins, such as low density lipoproteins, has been proposed as 
the basis for some of the pathological consequences of HHcy. TheN-linked Hey, which 
can account for up to 23% of plasma Hey, is not included in the calculation of plasma 
tHey (Jakubowski, 2002). Hey thiolactone is hydrolyzed to Hey by Hey thiolactonase, an 
enzyme associated with high density lipoprotein (Jakubowski, 2000). 
1.3 Metabolism 
The liver has been shown to play a significant role in the regulation of plasma Hey 
levels (Stead et al, 2000) because of its full complement of enzymes involved in 
methionine and Hey metabolism. Hey is an intermediate in the pathway of methionine 
metabolism. The only dietary-essential sulfur-containing amino acid in mammals, 
methionine contributes to a variety of fundamental biological processes, including protein 
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Figure 1.1. Plasma forms of Hey 
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synthesis, methylation reactions as S-adenosylmethionine (SAM), formation of the 
polyamines spermine and spermidine and the synthesis of cysteine. Hey is a key substrate 
in 3 essential biological processes: (1) recycling of intracellular folates; (2) catabolism of 
choline and betaine; and (3) formation of the non-essential amino acid cysteine and the 
anti-oxidant glutathione through the transsulfuration pathway (Finkelstein, 1998). 
The pathway of methionine metabolism (Figure 1.2) consists of the ubiquitous 
methionine cycle and the transsulfuration pathway, which has a more limited distribution. 
The methionine cycle is made up of the transmethylation and the remethylation pathways. 
In transmethylation, methionine is converted to the high energy sulfonium compound 
SAM in a reaction catalyzed by methionine adenosyltransferase (MAT) (EC 2.5.1.6). 
ATP provides the source of the adenosyl moiety. MAT exists in three isoenzymic forms 
MAT I, MAT II and MAT III, which are products of two different genes MAT 1 A and 
MAT 2A (Chou, 2000). MAT JA is expressed in mature liver while MAT 2A is expressed 
in all tissues and is induced during liver growth and dedifferentiation. The liver-specific 
isoenzymes MAT I and MAT III are coded for by MAT JA. MAT I, a tetramer, is also 
designated as an "intermediate Krn" isozyme (Krn for methionine ~ 40 ).!mol/liter) and is 
slightly inhibited by SAM. MAT III, a dimer which appears to be derived from MAT I by 
a post- translational modification (Cabrero and Alemany, 1988) is designated as a "high 
Krn" isoform (Krn for methionine ~ 200 ).!mol/liter) and is activated by its product SAM, 
demonstrating a strong, positive cooperative modulation at physiological methionine and 
SAM concentrations. MAT III allows the liver to adjust immediately to an excess influx 
of methionine with increased SAM formation. MAT II, found in extra-hepatic tissues and 
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Figure 1.2. Methionine metabolic Pathway 
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fetal liver and encoded by the gene MAT 2A, has a low Km ( ~8 IJ.mol/liter) for methionine 
and is inhibited by S-adenosylmethionine (Sullivan and Hoffman, 1983). 
SAM, once formed, appears to be retained by the cell of origin and serves as the 
methyl donor for virtually all known biological methylation reactions. This transfer of the 
methyl group of SAM to a suitable methyl acceptor is catalyzed by any one of a large 
number of methyltransferases, leading to the formation of such diverse cellular 
components as creatine, epinephrine, camitine, phospholipids as well as methylated 
proteins, DNA and RNA (Clarke and Banfield, 2001). Essentially all these 
methyltransferases are inhibited by the common product, S-adenosylhomocysteine 
(SAH). However, glycine N-methyltransferase (GNMT) which converts glycine to 
sarcosine has unique kinetic properties. It is only weakly inhibited by SAH, has a 
relatively high Km for SAM and shows a sigmoidal dependence on SAM concentration 
(Takata et al, 2003). GNMT thus functions as a benign high-capacity, SAM-dependent 
methyltransferase that is able to convert excess methionine/SAM to sarcosine, a non toxic 
product. Sarcosine is then transported into mitochondria where its metabolism regenerates 
glycine. 
The inhibition (albeit to different degrees) of essentially all of the different 
methyltransferases by SAH necessitates its rapid removal. S-adenosylhomocysteine 
hydrolase, which occurs in all cells, converts SAH to Hey and adenosine (Finkelstein, 
1998). Although the equilibrium of this reaction favors the formation of SAH it is driven 
forward under physiological conditions due to the rapid removal of the products, Hey and 
adenosine. Adenosine can be removed by either of 2 enzymes, adenosine deaminase (EC 
3.5.4.4) or adenosine kinase (EC 3.5.4.4). Hey, on the other hand, occupies a central 
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position in the pathway of methionine metabolism, lying at a cross-road between the 
transsulfuration and the remethylation pathways. SAH can also be removed by 
intracellular binding to specific, saturable protein sites and by export from the cell 
(Finkelstein, 1998). Once exported, the kidney appears to be active in the removal of 
SAH from the extracellular fluid (Finkelstein, 1998). Hey can also bind to intracellular 
proteins and can be exported from cells (Svardal et al, 1986). However, unlike SAH, Hey 
can be taken up by many tissues including the liver (Finkelstein, 1998). Plasma Hey, 
therefore, represents Hey that has been exported from the cells of origin, to be transported 
to other cells/tissues that would catabolize it. 
The remethylation of Hey to methionine completes the methionine cycle and in 
tum functions to conserve the carbon skeleton of methionine. Interestingly, the 
methylation of Hey to methionine is one exception where SAM does not provide the 
methyl group. Two different methyl donors, N5 -methyltetrahydrofolate or betaine, 
provide the methyl group necessary to convert Hey to methionine by two independent 
pathways. Methionine synthase which transfers a methyl group from N5-
methyltetrahydrofolate to Hey is widely distributed in mammalian tissue and contains 
methylcobalamin as an essential co-factor. The methyl group of N5-
methyltetrahydrofolate is synthesized by the folate coenzyme system using serine as the 
major donor of the one carbon units (Davis et al, 2004). N5 -methyltetrahydrofolate is 
formed by the irreversible reduction of N5•10 -methylenetetrahydrofolate, catalyzed by the 
flavoenzyme N5•10-methylenetetrahydrofolate reductase (MTHFR) (EC 1.1.1.68) which 
uses NADPH as the reducing agent. 
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Betaine:homocysteine methyltransferase (BHMT) catalyzes a second route by 
which Hey is converted to methionine, using pre-formed methyl groups from betaine, an 
intermediate in the pathway of choline oxidation (Finkelstein eta!, 1972). BHMT, a zinc 
metalloenzyme (Breksa and Garrow, 1999), has a more limited distribution, being present 
only in liver, kidney and lens in humans (Finkelstein et a!, 1972). BHMT is feed-back 
inhibited by its product N,N-dimethylglycine (Finkelstein et al, 1983). Dimethylglycine 
is converted to glycine in a series of reactions by which the methyl groups are oxidized 
and provide the methylene groups ofN5' 10-methylenetetrahydrofolate (Figure 1.3) 
If the carbon chain of methionine is not to be conserved, or if cysteine is 
required Hey can be irreversibly converted to cysteine through the transsulfuration 
pathway which is catalyzed by two pyridoxal 5 '-phosphate (PLP)-containing enzymes, 
cystathionine ~-synthase (CBS) (EC 4.2.1.22) and cystathionine y-lyase (CGL) (EC 
4.4.1.1 ). CBS catalyzes the condensation of Hey with serine to form cystathionine and 
commits the Hey moiety to the transsulfuration pathway (Finkelstein, 1998). 
Cystathionine is hydrolyzed by CGL to form cysteine, a-ketobutyrate and ammonium, 
thereby making cysteine a non-essential amino acid. Both the pyruvate dehydrogenase 
complex and the branched-chain a-keto acid dehydrogenase complex can catalyze the 
oxidative decarboxylation of a-ketobutyrate to propionyl CoA, which enters the Krebs' 
cycle at succinyl CoA (Stead et a!, 2000). Cysteine is a precursor of several essential 
molecules (e.g. glutathione, taurine, coenzyme A) as well as inorganic sulphate. 
The transsulfuration pathway has a limited tissue distribution in rat tissues; only 
liver, kidney, pancreas and small intestine are capable of synthesizing cysteine from 
methionine or Hey (Mudd eta!, 1965). CBS is absent from heart, lung, testes, adrenal and 
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Figure 1.3. The choline oxidation pathway 
Choline 
CH3 0 
-1: ~ ~ Betaine aldehyde H3C-N-CH2-C"-
I H 
NAD+ C!H3 
) Beatine aldehyde dehydmgenuse 
NADH+W 
CH3 
+I /o-
H3C-N-cH2c 
I ~o 
Betaine 
CH3 
Homocysteine i 
) Betaindomoeystelne methy/trunsferuse 
Methionine 
H n-
+1 / 
Dimethylglycine H3 C -N -CH2-C 
I ~0 CH3 
FADX.THF Dimethylglycine dehydrogenase 
FADifi C~THF 
H {Y 
+I r 
Sarcosine H3C~-CH2-C I ~ 
H 0 
FAD jc THF Sarcosine dehydrogenase 
FAD~ t C~THF 
Glycine 
H n-
+' / H-N-CH-c 
I 2 ~ 
H 0 
15 
spleen in rats [Finkelstein, 1998]. In humans, CBS was shown to be absent from heart 
muscle and primary aortic endothelial cells (Chen et al, 1999). The highest levels of CBS 
mRNA expression in human tissues have been observed in adult liver and fetal liver and 
fetal brain (Quere et al, 1999). Although CBS is present in the brain and adipose tissue of 
rats, CGL is absent from these tissues (Finkelstein, 1998). In agreement with this finding, 
very high levels of cystathionine have been found in human brains (Tallan et al, 1958). It 
may be that the function of CBS in the brain is to catalyze the production of H2S, a 
neuromodulator and a smooth muscle relaxant (Chen et al, 2004). 
1.4 Factors influencing methionine and Hey metabolism 
1.4.1 Gender and Age 
Plasma Hey has been shown to increase throughout life in both sexes (Refsum et 
al, 1998). In early childhood, both males and females have similar low plasma Hey levels, 
but sex differences become apparent at puberty (Schneede et al, 2000). The skewed 
distribution among the genders continues from puberty into adulthood with plasma Hey 
levels being 1-2 )lmole/liter higher in men than in women, and with a steady increase in 
both sexes with increasing age (Schneede et al, 2000). 
The gender differences could arise in a number of ways. It is possible that the 
differences are due to the higher formation of Hey in connection with increased creatine 
synthesis. Creatine synthesis is proportional to muscle mass and, therefore, is higher in 
men than in women (Mudd and Poole, 1975). A second possibility could be effects of sex 
steroids, as estrogens have been shown to lower plasma Hey levels (Kang et al, 1986). 
This is also consistent with the observation that, after menopause, the gender difference in 
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plasma Hey concentrations is attenuated. Post-menopausal women have been shown to 
have higher levels of plasma Hey than pre-menopausal women (Boers et al, 1983). The 
changes in the plasma Hey levels that have been observed in the male-to-female and 
female-to-male transsexuals treated with sex steroids also show the effect of sex 
hormones on plasma Hey levels (Giltay et al, 1998 A). Plasma Hey was reduced in male-
to-female transsexuals treated with ethinyl estradiol in combination with an anti-androgen 
while the female-to-male transsexuals treated with testosterone esters displayed an 
elevation in their plasma Hey (Giltay et a!, 1998 A). Women who are pregnant have 
significantly reduced plasma Hey levels with tHey decreasing between the first and the 
second trimesters and remaining low through the rest of the pregnacy (Andersson et al, 
1992). Malinow et a/ (1998) suggested an increased uptake of maternal Hey by the 
developing fetus as the reason for this lowered plasma Hey in the mother. 
A number of studies, conducted in different ethnic populations, have all 
demonstrated an age-related increase in plasma Hey, the increase being most marked in 
the oldest age-group (Selhub et a/, 1993). Plasma Hey is about 30% lower in children 
than in adults (Schneede et a/, 2000). The age-dependent increase in plasma Hey could 
arise in a number of ways. Renal function is known to decline with age (Norlund eta/, 
1998). It is well established that renal disease is associated with increased plasma Hey 
(Bostom et al, 1995 A). This may be due to metabolism of Hey by the kidneys (Bostom et 
a!, 1995 B), although the clear-cut data obtained in rats are not evident in humans (van 
Guldener et a/, 1998). Sub-optimal vitamin status, in particular impaired folate status 
(Koehler et al, 1997) and cobalamin deficiency (Lindenbaum et al, 1994), may also play 
major roles. 
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1.4.2 Lifestyle 
Several lifestyle factors are also known to affect plasma Hey levels. Chronic, high 
ethanol consumption (Crave et a!, 1996), smoking (Nygard et a!, 1995) and consumption 
of caffeinated coffee (Nygard et a!, 1997 B) are all associated with an increase in the 
concentration of plasma Hey. Interestingly, a moderate consumption of alcohol appears to 
lower the plasma Hey concentration (Vollset et al, 1997). The consumption of beer has 
also been shown to lower plasma Hey, probably because beer contains folate (Mayer et 
a!, 2001 ). HHcy associated with chronic alcoholism may arise due to impaired folate, 
vitamin B12 and B6 intake (Lindenbaum et al, 1994). Acute alcohol intoxication in 
alcoholics leads to a transient increase in plasma Hey, which may be a direct result of 
inhibition of methionine synthase by acetaldehyde (Kenyon et al, 1998). In the Hordaland 
Hey Study, individuals who consumed more than 6 cups of coffee per day exhibited 2 to 
3 ~-tmol/liter higher level of Hey than individuals who did not consume coffee (Nygard et 
al, 1997 B). Decaffeinated coffee does not have the same effect on plasma Hey as does 
regular coffee (Nygard et al, 1997 B). 
Physical training has been shown to play a positive role in the reduction of plasma 
Hey (Nygard eta!, 1995). The difference in Hey levels between subjects doing heavy 
training and those having a sedentary lifestyle was greater in an older age group (65-67 
years) where exercise was associated with an approximately 1 ~-tmole/liter reduction in 
Hey whereas those aged 40A2 years exhibited a reduction of 0.76 ~J.mole/liter. Acute 
exercise however, does not have any effect on the plasma Hey levels (Wright et al, 1998). 
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1.4.3 Diet 
SAM and SAH play a major role in the regulation of plasma Hey levels by 
affecting the distribution of Hey among competing pathways. Both these metabolites 
activate CBS (Finkelstein et a!, 1974, Finkelstein et a!, 1975). Finkelstein et a! (1974) 
also showed that SAH is capable of inhibiting BHMT. Kutzbach and Stokstad (1971) 
demonstrated that SAM is a strong allosteric inhibitor of MTHFR while SAH functioned 
to partially reverse this inhibition. This inhibition will lead to reduced synthesis of N5-
methyltetrahydrofolate which itself is a modulator of methionine metabolism by its ability 
to bind and inhibit GNMT (Wagner eta!, 1985). 
These mechanisms can combine to regulate methionine and Hey metabolism with 
regard to nutritional status, especially in response to protein and methionine intake, since 
increased methionine concentrations in the liver will lead to increased SAM levels. The 
fact that SAM activates MAT III (Cabrero and Alemany, 1988) makes this system highly 
sensitive to methionine concentrations. The increased SAM will promote disposal via the 
transsulfuration pathway by activation of CBS and will inhibit remethylation by 
inhibiting both BHMT and MTHFR. A quantitative study of the methionine cycle in vivo, 
in healthy young men who were supplied with methionine at a rate of 198 f1moles/kg/day, 
revealed a Hey synthesis through transmethylation of 238 11moles/kg; 38% of this Hey 
was channeled into remethylation and 62% underwent transsulfuration (Storch et a!, 
1988). These data agreed with the labile methyl balances conducted by Mudd and Poole 
(1975) who showed that remethylation could vary from 70% to 40% when changing from 
a restricted methionine intake to a diet containing increased amounts of methionine and 
choline. 
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1.4.4 Methylation Demand 
The contribution of the different reactions involved in the formation of Hey must 
also be considered. SAM is the methyl donor of virtually all known biological 
methylation reactions, ranging from such diverse processes as metal detoxification, 
biosynthesis of many small molecules and gene regulation via DNA methylation. Thirty 
nine different species of SAM-dependent methyltransferases have been well characterized 
in mammals (Clarke and Banfield, 2001), with the possibility that many more will be 
identified by means of genomic approaches which use conserved sequence motifs to 
detect methyltransferases in genomic open reading frames (Katz et al, 2003). In fact, Katz 
et a! (2003) calculated that class I methyltransferases make up ~0.6-1.6% of the genes in 
the yeast, human, mouse, Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis 
thaliana, and Escherichia coli genomes. 
The first demonstration of the importance of methylation to plasma Hey levels 
was provided by studies in patients with Parkinson's disease undergoing treatment with 
L-3, 4-dihydroxyphenylalanine (L-DOPA). Parkinson's disease is characterized by a 
severe depletion of nigro-striatal dopaminergic neurons resulting in the deficiency of 
dopamine in the basal ganglia and melanin in the substantia nigra (Hague et a!, 2005). 
These patients are treated with L-DOPA alone or in combination with a peripheral 
decarboxylase inhibitor (Cheng et a!, 1997). The dopamine deficiency is relieved by the 
decarboxylation ofL-DOPA in the brain. Parkinson's patients undergoing treatment with 
L-DOPA have been shown to have plasma Hey levels that are about 50% higher than 
controls [Muller et al, 2001]. This increase in plasma Hey arises from the wasteful 
methylation of L-DOPA by catechol-0-methyltransferase (COMT) which catalyzes the 
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SAM-dependent methylation of aromatic hydroxyl groups (Cheng eta!, 1997). Due to the 
removal of the administered L-DOPA through this reaction, patients need to be given 
quite high doses (up to several grams per day) to achieve therapeutic levels of L-DOPA. 
This phenomenon was also evident in rats; the increased plasma tHey was accompanied 
by decreased tissue levels of SAM (Miller et a!, 1997). Pre-treatment with a COMT 
inhibitor was shown to alleviate or attenuate this response. These studies showed that 
plasma Hey levels were sensitive to the methylation of an exogenous substance. 
Thereafter, studies conducted by the Brosnan group addressed the issue of the role 
of methylation demand imposed by physiological substrates on plasma Hey. Creatine 
synthesis, where SAM is used to methylate guanidinoacetic acid (GAA), has been 
considered to use more SAM than all of the other physiological methyltransferases 
combined (Mudd and Poole, 1975) accounting for about 75% of Hey formation. Creatine 
synthesis is an inter-organ pathway in which the two enzymes involved in creatine 
synthesis occur in two different organs: L-arginine:glycine amidinotransferase occurs in 
the kidney (AGAT; EC 2.1.4.1) and guanidinoacetate methyltransferase (GAMT; EC 
2.1.1.2) is localized to the liver. Stead et a! (200 1) studied the effect of changes in the 
methylation demand by modulating the rate of creatine synthesis by feeding rats GAA- or 
creatine- supplemented diets for 2 weeks. They found that Hey was significantly elevated 
in the plasma ofrats fed GAA and that it was decreased by -25% in the rats on a creatine-
supplemented diet (Stead et a!, 2001). Supplementation by either GAA or creatine 
resulted in a decrease in the activity of kidney AGAT. Incubation of hepatocytes with 
GAA resulted in the export of significantly higher amounts of Hey, giving further 
evidence for the dependence of the plasma Hey level on the demand for methylation by 
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physiological substrates. A separate series of studies showed that creatine 
supplementation was able to lower the plasma level of GAA as well as its arterio-venous 
difference across the kidney (Edison EE, Brosnan ME and Brosnan JT unpublished 
observations). 
Noga et al (2003) demonstrated the importance of another physiological 
methylation reaction on the plasma Hey level. Phosphatidylethanolamine N-
methyltransferase (PEMT), a liver-specific enzyme, is involved in the conversion of 
phosphatidylethanolamine (PE) to phosphatidylcholine (PC) (Vance and Ridgeway, 
1988). 70% of hepatic PC is produced from choline by the activity of the enzymes of the 
Kennedy pathway; PEMT is responsible for the formation of the remaining 30% (DeLong 
et al, 1999). The synthesis of one molecule of PC through the PEMT pathway requires 
three successive SAM-dependent methylations. Plasma Hey in pemr'- mice was decreased 
by about 50% (Noga et al, 2003). Hepatocytes isolated from the pemr'- mice secreted 
-50% less Hey than the cells isolated from the wild type mice. McArdle RH7777 (rat 
hepatoma) cells, over-expressing PEMT, produced significantly more Hey than the wild-
type cells. These results clearly demonstrated PC synthesis through the PEMT pathway to 
be a major contributor to the plasma Hey levels. 
1.4.5 Hormonal regulation of plasma Hey 
Most of the early literature on Hey metabolism focused on traditional factors such 
as nutrition and genetics. However, studies conducted in many laboratories have now 
added to our understanding of the hormonal regulation of Hey metabolism. Diabetes 
mellitus, both Type 1 and Type 2, leads to increased plasma levels of Hey when 
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accompanied by renal insufficiency (Hoogeveen et al, 1998, Hultberg et al, 1991). 
However, Type 1 diabetic patients with normal plasma creatinine levels have been shown 
to have plasma tHey levels significantly lower than healthy subjects (Robillon et al, 
1994). Studies conducted in our laboratory confirmed this observation in streptozotocin-
diabetic rats (Type 1 model) (Jacobs et al, 1998). In these rats the decreased Hey was 
accompanied by concomitant increases in the activities of the hepatic transsulfuration 
enzymes, CBS and CGL, which were restored to normal by insulin treatment, suggesting 
regulation of plasma Hey by insulin. Administration of glucagon to rats was shown to 
reduce plasma Hey and was accompanied by increased flux of methionine through the 
transsulfuration pathway and by increases in the activities of the transsulfuration enzymes 
(Jacobs et al, 2001). The concurrent increase in the activity and the mRNA of CBS 
suggested that glucagon may act at the level of gene transcription to alter Hey 
metabolism. This was directly confirmed by the experiments of Ratnam et al (2002). 
Glucocorticoids or cAMP increased, and insulin attenuated, the CBS mRNA and protein 
levels in H4IIE cells, a rat hepatoma cell line, while insulin treatment of HepG2 cells, a 
human hepatoma cell line, led to a decreased level of CBS protein. The 70% reduction in 
CBS-1 b promoter activity after insulin treatment further confirmed the effect of insulin, 
while the nuclear run-on experiments provided definitive evidence that both insulin and 
glucocorticoids act at the level of gene transcription. 
MAT is also under hormonal regulation. Adrenalectomy results in a 3-fold 
decrease in its enzyme activity, immunoreactive protein and mRNA levels in the liver; 
these effects could be reversed by triamcinolone treatment (Gil et al, 1997). MAT mRNA 
content was increased, in a time- and dose-dependent manner, by both triamcinolone and 
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dexamethasone., which effect was blocked by insulin. A direct effect of triamcinolone on 
the transcription of this gene was evident from experiments in which a luciferase reporter 
gene was driven by 1.4 kb of the 5'-flanking region of the hepatic MAT gene. 
Triamcinolone treatment resulted in a 3-fold increase in the promoter activity (Gil et al, 
1997). 
A recent study described the modulation of GNMT by insulin and glucocorticoids 
[Nieman et al, 2004]. Pre-treatment with insulin prevented the induction of GNMT by 
dexamethasone in rat pancreatic AR42J cells or in hepatoma H4IIE cells. It was also 
found that induction of diabetes by injection of streptozotocin leads to increased activity 
and abundance of GNMT. 
Early studies conducted by Finkelstein et al (1971) showed that hydrocortisone 
increased the activity of BHMT three-fold, whereas thyroxin treatment significantly 
reduced its activity. Methionine synthase was also shown to be responsive to hormones in 
tissues other than the liver; the kidney enzyme was increased by 151% by estrogen and 
decreased by 60% by growth hormone. Hydrocortisone treatment led to a 2-fold increase 
in the specific activity of methionine synthase in the pancreas (Finkelstein et al, 1971). 
It is evident therefore, that glucagon and glucocorticoids function to increase the 
disposal of methionine and/or Hey, whereas insulin counteracts these effects. 
1.4.6 Redox Regulation 
CBS is a unique enzyme, in that it depends on both heme and pyridoxal 5'-
phosphate for its function (Kery et al, 1994). The 63 Kd CBS subunit binds a molecule 
each of heme and PLP, and the presence of heme is required for PLP binding. Recently, 
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Taoka et al (1998) found evidence for redox-linked regulation of CBS, dependent on 
heme. Under reducing conditions generated by the addition of titanium citrate they 
observed a 41% decrease in the activity of CBS. Re-oxidation of the ferrous enzyme with 
ferricyanide reversed the inhibition. Transsulfuration, catalyzed by the two enzymes, CBS 
and CGL, leads to the synthesis of cysteine, which is required for glutathione synthesis. 
The Hey-dependent transsulfuration pathway plays a major role in the maintenance of the 
intracellular glutathione pool under oxidative stress conditions and, indeed, the flux 
through the transsulfuration pathway responds to the oxidant load (Mosharov et al, 2000). 
Approximately 50% of the intracellular glutathione pool in human liver cells is derived 
from cysteine produced by the transsulfuration pathway; thus the cellular redox 
environment may affect plasma Hey concentrations (Mosharov et al, 2000). 
Two other enzymes in the Hey metabolic pathway have also been shown to be 
responsive to redox changes. S-nitrosylation by nitric oxide, under conditions of septic 
shock or hypoxia, leads to the inactivation of both isoforms of MAT, MAT I and MAT III 
(Avila et al, 1997); this inactivation can be reversed by millimolar concentrations of 
glutathione. H202 also inactivates MAT by reversibly and covalently oxidizing cysteine 
121, located at a "flexible loop" over the active site cleft of MAT (Sanchez-Gongora et 
al, 1997). The GSH/GSSG ratio also modulates the redox state of MAT (Pajares et al, 
1992). The second enzyme responsive to redox conditions, methionine synthase, is 
inhibited by oxidative conditions, potentially due to the oxidation of the cob(I)alamin 
form of the cobalamine cofactor (Chen et al, 1995) This curtailment of remethylation can 
be understood as a means of increasing the conversion of Hey to cysteine for GSH 
synthesis. 
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1.5 Non-physiological causes of HHcy 
1.5.1 Vitamin Deficiency 
The original report linking HHcy to the occurrence of cardiovascular disease 
involved a patient who developed homocysteinuria due to a defect in cobalamin 
metabolism, now recognized as Cb1 C deficiency (Gaull, 1972). Since then, many studies 
have confirmed the relationship between vitamins and plasma Hey levels. Inadequate 
plasma concentrations of one or more of the B vitamins are responsible for the HHcy in 
about two thirds ofhyperhomocysteinemic cases (Selhub et al, 1996). 
The ability of folate supplementation to decrease urinary Hey excretion was 
documented in patients with homocystinuria and mental retardation as early as 1968 
(Carey et al, 1968). Kang et al (1987) showed that depletion of tissue folate leads to 
HHcy in non-homocystinuric subjects. Isolated deficiency of vitamin B12 also leads to 
moderate to intermediate fasting HHcy, with Hey levels exceeding that found in the 
obligate heterozygotes for CBS deficiency (Brattstrom et al, 1988). Vitamin B6, the 
cofactor for both enzymes of the transsulfuration pathway, is important in determining 
post-methionine load plasma Hey levels (Brattstrom et al, 1990). Data from the 
Framingham Heart Study cohort showed that plasma Hey exhibits a strong inverse 
association with plasma folate and weaker associations with plasma vitamin B12 and 
pyridoxal-5' -phosphate (Selhub et al, 1996). Vitamin intervention therapy with the three 
B vitamins alone and various combinations of them has been shown to reduce both basal 
plasma Hey as well as levels after a methionine load (Brattstrom, 1996). 
A few recent studies have tried to explain the mechanisms behind the Hey 
lowering effects of these B vitamins. Supplementation with vitamin B12 was shown to 
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increase the activity of methionine synthase, an effect ascribed by Gulati eta! (1996) to a 
posttranslational regulation of methionine synthase by vitamin B12 since the induction of 
activity of this enzyme correlates with increased levels of protein. They were later able to 
show that B12 supplementation induces translational up-regulation by shifting the mRNA 
from the ribonucleoprotein to the polysome pool. The B12-responsive element was 
localized to the 70 bp region located at the 3' end of the 5 '-untranslated region of 
methionine synthase mRNA (Oltean and Banerjee, 2003). Miller et al (1994) postulated 
that deficiency of folate leads to increased plasma Hey not only through the impairment 
of Hey remethylation but also by impairing Hey removal via the transsulfuration pathway 
due to lowered tissue SAM levels which are inadequate to stimulate CBS. 
1.5.2 Genetic Disorders 
The most frequently described genetic defects of HHcy are associated with the 
enzymes of transsulfuration. Plasma Hey levels are quite elevated in patients with 
homozygous CBS deficiency resulting in homocystinuria (Mudd et a!, 1985). However, 
this is a rare disorder with a frequency estimated between 1:58,000 and 1:1,000,000 in 
newborns and a worldwide birth prevalence of 1:300,000. Heterozygosity for CBS in the 
general population is less than 1% (Mudd et a!, 1995). The fasting Hey level in these 
individuals appears to be normal or only slightly elevated, although post-methionine load 
levels may be elevated (Tsai et a!, 1996). Genetically-determined defects have also been 
described in CGL which leads to cystathioninuria (Frimpter, 1965). 
On the other side of the spectrum are the patients with Down syndrome. Down 
syndrome or trisomy 21, is characterized by the failure of chromosome 21 to segregate 
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normally during meiosis (Epstein, 1995). The gene for CBS is located on chromosome 21 
and as a result is overexpressed in children with Down syndrome. A 157% increase in 
CBS enzyme activity in patients with Down syndrome is associated with reduced levels 
of plasma Hey (Chadefaux, 1985). However, the reduction in plasma Hey leads to a 
concurrent reduction in the folate-dependent re-synthesis of methionine, creating a 
functional intracellular folate deficiency known as the "methyl trap" (Pogribna et al, 
2001). 
MTHFR mutations are also associated with HHcy. Severe MTHFR deficiency 
(less than 2% of normal enzyme activity) is rare (Rozen, 1996). However, Kang et al 
(1991 A) identified a new variant of MTHFR, which displayed a distinctive 
thermolability with about 50% of the enzyme activity. This variant is associated with 
significantly higher levels of plasma Hey and is inherited as an autosomal recessive trait 
(Kang et al, 1991A). Patients who were postulated to be compound heterozygotes of the 
allele for the severe mutation and the allele for the thermolabile mutation have also been 
identified (Kang et al, 1991 B). 
Two common functional polymorphisms of the MTHFR gene were later 
identified. C677T polymorphism in exon 4, resulting in an alanine to valine substitution 
at codon 222 (Frosst et al, 1995) gives rise to the thermolability. Individuals homozygous 
for the C677T polymorphism (TT genotype) have about 30% of normal enzyme activity 
and results in intennediate HHcy (Kang et al, 1988); heterozygotes have about 65% of 
normal activity (Frosst et al, 1995). The phenotypic expression of the TT genotype 
appears to relate to the folate status. In the Hordeland Hey study, a majority of subjects 
with intermediate HHcy exhibited the TT genotype; 88% of these were folate deficient. 
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(Guttormsen et a!, 1996). The C677T mutation displays ethnic variability. Caucasians 
have a high (40%) allele frequency (van der Put eta!, 1997) while it is almost absent in 
African Americans (McAndrew eta!, 1996). A second polymorphism, A1298C in exon 7, 
results in a substitution of glutamate with alanine at codon 429 (van der Put eta!, 1998). 
Individuals with 1298CC genotype display 60% of the activity of those with AA 
genotype but it does not seem to give rise to HHcy. 
Cobalamin is bound to methionine synthase and acts as a methyl carrier between 
methyltetrahydrofolate and Hey. The methyl group of methyltetrahydrofolate is first 
transferred to the cobalamine cofactor to form methylcob(III)alamin which in tum 
becomes cob(I)alamin after transfer of the methyl group (Banerjee, 1997). Over time, 
cob(I)alamin may be oxidized to cob(II)alamin which renders the enzyme inactive. 
Cob(II)alamin needs to undergo a reductive methylation with SAM acting as the methyl 
donor to be converted back to its active state (Ludwig and Matthews, 1997). 
Two forms of methionine synthase deficiency are known which lead to the 
development of HHcy (Harding et a!, 1997). Patients from the cblG complementation 
group of folate/cobalamin metabolism have mutations in the methionine synthase gene 
(Leclerc et a!, 1996). The second complementation group, cblE, shows reduced 
methionine synthase activity, due to a defect in the reducing system which keeps the 
enzyme in the functional state (Gulati et a!, 1997). cblE patients have been shown to have 
defective NADPH-dependent reducing activity. Leclerc et a! (1998) isolated the eDNA 
corresponding to the reductive activation enzyme which they named methionine synthase 
reductase and also identified a number of mutations in 3 cblE patients, a 4-bp frame shift 
in two and a 3-bp deletion in one. 
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1.5.3 Renal Disorders 
Patients with diabetes mellitus, either Type 1 or Type 2, have decreased plasma 
Hey levels when kidney function is normal (Robillon et al, 1994, Jacobs et al, 1998, 
Wijekoon et al, 2005). However, with decreasing kidney function the concentration of 
plasma Hey changes and is elevated compared to controls. This has been observed in both 
Type 1 and Type 2 diabetes mellitus (Hoogeveen et al, 1998, Hultberg et al, 1991). 
Patients with end-stage renal disease with no diabetes also exhibit elevated plasma Hey 
(Bostom et al, 1995 A). These observations agree with the finding ofBostom et al (1995 
B) that the rat kidney is a major organ involved in Hey metabolism. They showed a 
positive renal arteriovenous difference for Hey slightly greater than 20% of the mean 
arterial plasma Hey concentration, which suggested that the loss of the Hey metabolizing 
capacity of the kidneys may be a major cause of the increased plasma Hey in renal 
patients. The transsulfuration pathway was shown to be the major route of catabolism of 
Hey taken up by rat kidneys, accounting for 78% of the disappearance of Hey (House et 
al, 1997). The important role played by the kidneys in maintaining plasma Hey 
homeostasis was shown by the ability of the kidneys to handle acute increases in plasma 
Hey (House et al, 1998). Kidneys were able to significantly increase the uptake of Hey 
from the plasma and still manage to metabolize it with no change in urinary excretion, 
demonstrating the capacity of the kidneys for Hey catabolism. 
1.5.4 Pharmacological intervention 
Intervention with a variety of pharmacological agents has been shown to disrupt 
plasma Hey metabolism. Many of these drugs act through their disruption of the 
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absorption or the metabolism of the various vitamins of Hey metabolism. Methotrexate, 
used in a variety of diseases, interferes with folate metabolism by inhibiting dihydrofolate 
reductase (Bertino, 1993), thereby reducing methyltetrahydrofolate levels in cells. The 
time course for the development of HHcy depends on the dose of methotrexate used; thus 
it varies in patients with different diseases such as cancer (Refsum eta!, 1991), psoriasis 
(Refsum eta!, 1989) and rheumatoid arthritis (Morgan eta!, 1998). Anticonvulsants also 
interfere with folate metabolism, thereby leading to HHcy (James et al, 1997). They are 
thought to deplete liver folate stores through inhibition of polyglutamation (Carl et a!, 
1991). Bile acid sequestrants interfering with the absorption of folate also cause HHcy. 
This has been observed in coronary patients treated with niacin and colestipol as they 
exhibit significantly higher Hey levels when compared with similar patients receiving a 
placebo (Blankenhorn et a!, 1991). Cholestyramine (Tonstad et a!, 1998), a bile acid 
sequestrant, and the antidiabetic drug metformin (Carlsen eta!, 1997) interfere with the 
absorption of cobalamine and folate, leading to the development of HHcy with long term 
use of these drugs. 
The anesthetic, nitrous oxide, is a well known pharmacological agent that causes 
rapid (within 90 minutes) elevations in plasma Hey (Ermens et al, 1991). It is known to 
oxidize cob(I)alamin to cob(II)alamin, thereby inactivating methionine synthase 
(Drummond and Matthews, 1994). Azuridine, which is no longer in use, caused HHcy in 
humans as well as animals probably through its interference with pyridoxal 5-phosphate 
(Drell and Welch, 1989). Isoniazid (Krishnaswamy, 1974), niacin (Basu and Mann, 1997) 
and theophylline (Ubbink et a!, 1996) also cause increases in plasma Hey by their 
interference with vitamin B6 metabolism. The treatment of Parkinson's disease with L-
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DOPA leads to increased plasma Hey, the mechanism of which was discussed in the 
section on methylation demand. 
Treatment with some other drugs has been shown to lead to reduction in plasma 
Hey. Oral penicillamine has been shown to reduce both free and plasma protein-bound 
Hey in homocystinuria patients (Kang et a!, 1982). Patients with acute lymphoblastic 
leukemia treated with 2-deoxycoformycin also have markedly reduced plasma Hey levels 
(Kredich et a!, 1981 ). 2-deoxycoformycin indirectly inhibits S-adenosylhomocysteine 
hydrolase by blocking adenosine deaminase. The use of estrogen-containing oral 
contraceptives has also been shown to lower plasma Hey levels (Steegers-Theunissen et 
a!, 1992). Cyclic variations in plasma Hey have been shown in oral contraceptive users 
with the variation in hormone levels in the contraceptives. 
1.6 Diabetes Mellitus 
Diabetes mellitus is one of the most common metabolic disorders affecting over 
100-million people worldwide (Spruce eta!, 2003) and is regarded as a major risk factor 
for cardiovascular disease (Wilson, 1998). The prevalence of atherosclerosis is 2-6 fold 
greater in diabetic patients compared to non-diabetic patients (Brand eta!, 1989). The 7-
year incidence for myocardial infarction (MI) for diabetic patients who have not 
experienced MI previously was similar to that of non-diabetic patients who have gone 
through a previous MI (Haffner et a!, 1998). Half of all diabetic patients are also likely to 
die within a year of their first cardiac event, giving rise to a higher mortality rate than non 
diabetics (Miettinen eta!, 1998). 
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Diabetes mellitus generally can be divided into two categories. Insulin-dependent 
diabetes mellitus or Type 1 diabetes mellitus usually develops in childhood or 
adolescence and results from the destruction of pancreatic beta cells by an auto-immune 
process that may be precipitated by a viral infection (Fajans, 1996). The second form of 
diabetes, Non-insulin dependent diabetes or Type 2 diabetes usually occurs in middle or 
later life and results from a highly complex pathogenetic process which has components 
that still defy biochemical explanation. Despite this complexity of its etiology the disease 
has two hallmark features: (i) insulin resistance, which is defined as an impaired ability of 
insulin to suppress hepatic glucose output and promote glucose entry into peripheral 
tissues and (ii) impaired function of pancreatic ~-cells leading to insufficient production 
of insulin to overcome the insulin resistance (McGarry, 2002). Insulin resistance precedes 
the development of fulminant diabetes and is characterized by a hyper-secretion of insulin 
by the ~ cells to maintain normoglycemia (McGarry, 2002). 
1. 7 Insulin resistance 
J. Dennis McGarry's 1992 article in Science titled "What if Minkowski had 
been ageusic? an alternative angle on diabetes" draws our attention to an important aspect 
of this disease ( McGarry, 1992). In calling for a more "lipocentric" approach to the 
diseases as opposed to the traditional "glucocentric" approach, McGarry drew attention to 
the fact that Type 2 diabetes is almost invariably accompanied by increased levels of 
circulating free fatty acids (FF A) and triglycerides (TG), and excessive deposition of fat 
in tissues, in addition to the hyperglycemia (McGarry, 2002). One of the major current 
33 
hypotheses as to the etiology of insulin resistance concerns the deranged lipid 
metabolism. 
Specific measurement of intramyocellular lipid (IMCL) with the use of 1 H-
magnetic resonance spectroscopy (1 H MRS) was able to uncover a very tight negative 
correlation between IMCL and whole-body insulin sensitivity (Stein et al, 1997, Krssak et 
al, 1999). This finding is interesting especially in the light of the tight association of Type 
2 diabetes with obesity. Artificial elevation of free fatty acids (FF A) in healthy human 
volunteers with concomitant increases in IMCL was also shown to reduce insulin 
mediated glucose disposal, clearly strengthening the cause and effect case between 
increased IMCL and insulin resistance (Brechtel et al, 2001, Boden et al, 1995). Roden et 
al (1996) showed that the FF A induced reduction of insulin sensitivity lead to a reduction 
in both oxidative glucose disposal and muscle glycogen synthesis by some 40-50% as 
measured by 13C-MRS in healthy humans. 
With the performance of a hyperglycemic, hyperinsulinemic clamp in healthy 
individuals and Type 2 diabetic patients, the rate of insulin-stimulated muscle glycogen 
synthesis as assessed by the incorporation of [13C] glucose into gastrocnemius/soleus 
muscle glycogen, was shown to be decreased by >50% in Type 2 diabetic patients 
compared with healthy age and weight-matched individuals (Shulman et al, 1990). 
Defects in insulin-stimulated muscle glycogen synthesis therefore could be attributed to 
almost all of the impaired glucose removal component of insulin resistance seen in Type 
2 diabetic patients (Petersen and Shulman 2006). 
The measurement of the intracellular concentration of glucose, glucose-6-
phosphate and glycogen in muscle of Type 2 diabetic patients and age and weight-
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matched controls with 13C and 31P MRS studies to identify the rate control step in this 
defective glycogen synthesis, revealed an approximately 0.1 mM increase in intracellular 
glucose-6-phosphate concentration in normal individuals but no change in patients with 
Type 2 diabetes under similar conditions of hyperglycemia and hyperinsulinemia 
(Rothman et al, 1992). Very interestingly, lean, normoglycemic but insulin-resistant 
offspring of parents with Type 2 diabetes also showed a 50% reduction in the rate of 
whole body glucose metabolism mainly due to reduced rates of muscle glycogen 
synthesis along with reduced increments of intramuscular glucose-6-phosphate in 
response to insulin (Rothman et al, 1995). These data show the primary nature of this 
effect with regards to insulin resistance and could arise due to either defects in glucose 
transport into muscle or hexokinase II activity. Measurement of intracellular glucose 
concentration with a 13C NMR method under hyperglycemic hyper-insulinemic 
conditions revealed that the intracellular glucose concentration was far lower in the 
diabetic subjects than the concentration expected if hexokinase II was the primary rate-
limiting step for glycogen synthesis (Cline et al, 1999). These data lead to the conclusion 
that glucose transport into muscle cells by GLUT 4 is the primary defect leading to the 
impaired glycogen synthesis by muscle tissue. 
These data stand in contrast to the classic Randle mechanism which suggested 
that fatty acid induced insulin resistance is brought about by the increased oxidation of 
fatty acids at the expense of glucose (Randle et al, 1963, Randle et al, 1965, Randle et al, 
1964). According to this hypothesis increased fatty acid oxidation leads to increased 
intramitochondrial acetylCoA/CoA and NADH/NAD+ ratios with subsequent inactivation 
of pyruvate dehydrogenase. The resultant increase in citrate inhibits phosphofructokinase 
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which then lead to the accumulation of glucose-6-phosphate and subsequent inhibition of 
hexokinase II leading to the accumulation of intracellular glucose. 
Since the measurement of both intra-cellular glucose and glucose-6-phosphate 
using the novel methods indicated a reduction in these molecules rather than an increase 
as suggested by the Randle mechanism the defect in glucose transport appears to be the 
more likely cause of the fatty acid induced insulin resistance. Dresner eta!, (1999) found 
that elevation of plasma fatty acid concentration abolished insulin stimulated, IRS-1 
associated PI3-kinase activity compared to a four-fold increase observed with infusion of 
glycerol. This effect of fatty acids on the activity of PI3 kinase could result from the effect 
of fatty acids on upstream insulin signaling as infusion of lipids into rats have been shown 
to reduce the insulin stimulated IRS-1 tyrosine phosphorylation associated with the 
activation of protein kinase C 8 (Griffin et al, 1999). Protein kinase C e is a serine kinase 
known to be activated by diacylglycerol (Chalkley eta!, 1998). 
With the help of these experiments a unifying hypothesis for the common forms 
of human insulin-resistance was proposed where increased intracellular fatty acid 
metabolites such as long chain fatty acyl CoA, diacylglycerol or ceramides activate 
protein kinase C 8 leading to the serine/threonine phosphorylation of IRS-1. Unlike the 
tyrosine phosphorylated forms of IRS, the serine/threonine phosphorylated forms fail to 
activate PI3 kinase with the result of failure of activation of GLUT 4 transporters in 
response to insulin (Shulman, 2000). Consistent with this hypothesis is the severe insulin-
resistance seen in a mouse model of severe lypodystrophy almost totally devoid of white 
adipose tissue. The intracellular fatty acyl-CoA levels in these mice are almost 2-fold 
higher in both muscle and liver and show defects in insulin activation of IRS-1 and IRS-2 
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associated PI3 kinase activity in muscle and liver respectively (Kim et al, 2000). Also in 
support of this hypothesis is the finding by Bell et al (2000) that the reversal observed in 
insulin-resistance in high fat fed rats after a single meal of high carbohydrate is associated 
with a reduction in muscle LCACoA levels and loss of membrane bound PKCS activity. 
Accumulation of intracellular fat metabolites in the liver has also been shown to 
activate a serine kinase cascade involving PKC-£, which leads to the decreased tyrosine 
phosphorylation of IRS-2- a key mediator of insulin action in the liver (Previs et al, 2000, 
Samuel eta!, 2004). Studies with mitochondrial glycerol phosphate acyl CoA transferase 
knockout mice indicates that diacylglycerol, an activator of PKC-£ is responsible for 
these effects (Neschen et al, 2005). 
All these findings emphasize the importance of the location of lipid deposition in 
the development of insulin resistance and indicate that it is not obesity per se that is the 
culprit. The ability of PPAR-y agonists to restore insulin sensitivity also bears witness to 
this fact, as discussed later. 
Age is also a factor in the development of insulin resistance (Petersen et al, 2003). 
It was noted that lean and otherwise healthy elderly people have increased fat 
accumulation in muscle and liver tissue and the increased intramyocellular lipid 
accumulation is accompanied by a 40% reduction in their mitochondrial oxidative 
phosphorylation activity compared with BMI and activity matched young individuals 
(Petersen et al, 2003). The insulin resistant offspring of parents with Type 2 diabetes were 
also shown to have impaired mitochondrial function with a 30% reduction in 
mitochondrial ATP synthesis and an 80% increase in intramyocellular lipid content 
(Petersen et al, 2004). Loss of mitochondrial function therefore also appears to be an 
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important factor in the development of insulin resistance and especially may be involved 
with the heritability of Type 2 diabetes (Petersen and Shulman, 2006). 
Despite playing a minor role in the insulin-stimulated glucose uptake, insulin 
action and glucose transport in adipose tissue are also important determinants of systemic 
insulin sensitivity and glucose homeostasis (Abel et al, 2001, Bluher et al, 2002). Similar 
to skeletal muscles the rate limiting step for utilization of glucose by adipose tissue is the 
trans-membrane transport of glucose by GLUT 4 (Cline et a!, 1999). GLUT 4 gene 
expression is down-regulated in adipocytes but not in skeletal muscles from humans with 
Type 2 diabetes and/or obesity (Carvalho et a!, 1999, Carvalho et al, 2001). The 
importance of this finding was emphasized by the adipose-specific GLUT 4 knockout 
mice that developed insulin resistance and had an increased risk of Type 2 diabetes (Abel 
et a!, 2001). Although the genetic defect was limited to adipose tissue, they developed 
insulin resistance secondarily in muscle and liver. Mice that over- express GLUT 4 
selectively in adipose tissue have enhanced glucose tolerance, insulin sensitivity, fasting 
hypoglycemia, and hypo-insulinemia (Shepherd et a!, 1999). Mice lacking GLUT 4 
selectively in muscle are insulin-resistant and diabetic and the insulin resistance confined 
initially to the muscle spreads later on to adipose tissue and liver (Kim et al, 2001, Zierath 
et al, 1996). Breeding muscle GLUT 4 knockout (MG4KO) mice to mice over-expressing 
GLUT 4 in adipose tissue (AG4Tg) was able to normalize the fasting hyperglycemia and 
reverse the whole body insulin resistance in MG4KO mice although it had no effect on 
the glucose transport in muscle (Carvalho et al, 2005). The crossbred animals were also 
able to suppress the hepatic glucose production in response to insulin (Carvalho et a!, 
2005). Although the adipose-selective deletion of GLUT 4 leads to secondary defects in 
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glucose action in muscle and liver, these muscles have a normal response to insulin ex-
vivo, indicating a circulating factor(s) as the cause of insulin resistance in these mice 
(Abel et al, 2001). 
In recent years our view of adipose tissue has deviated from its traditional role as 
an energy storage depot and we are seeing it as an organ with a secretory function 
expressing and secreting various peptide hormones and cytokines, including TNF-a, 
plasminogen activator inhibiter-!, angiotensinogen, leptin (Kahn and Flier, 2000), along 
with resistin and adiponectin (Scheen, 2003). TNF-a and resistin have clearly been shown 
to inhibit insulin action in rodents (Greenberg and McDaniel, 2002). Their effects in 
humans however have still not been fully elucidated. Adiponectin, synthesized 
exclusively in adipose tissue, is found at lower levels in the plasma in obesity, in contrast 
to the other adipocytokines and appears to be a major modulator of insulin action with 
low adiponectin levels contributing to insulin resistance (Scheen, 2003). Leptin, the other 
adipocytokine involved in enhancing insulin action, will be discussed in detail in the next 
section. Retinol binding protein-4 (RBP-4) is a novel adipocyte derived molecule which 
is elevated in the adipose tissue of adipose-Glut 4-/- mice and the serum of several insulin 
resistant states in mice and humans (Yang et al, 2005). Transgenic over-expression of 
human RBP4 or injection of recombinant RBP4 in normal mice causes insulin resistance 
while genetic deletion of RBP4 enhances insulin sensitivity (Yang et al, 2005). Increased 
serum RBP 4 was shown to induce the hepatic expression of the gluconeogenic enzyme 
phosphoenolpyruvate carboxykinase (PEPCK) and impair insulin signaling in muscle 
(Yang et al, 2005). 
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1.8 Leptin 
Leptin was first discovered in 1994 by positional cloning of a single gene 
mutation in the ob/ob mouse, a model of obesity and diabetes (Zhang et al, 1994).The 
obesity in these mice is caused by the deficiency of the ob gene product, leptin, and is 
reversible with the administration of the peptide (Pellymounter et al, 1995). These 
findings led to the categorization of leptin as an anti-obesity hormone. However, 
considering the fact that over-weight individuals have higher levels of leptin than non-
obese individuals it is now recognized that although leptin deficiency does lead to obesity 
the primary role of leptin is not the prevention of obesity (Unger et al, 1999). Leptin now 
is regarded to play a role in permitting over-nutrition and deposition of body fat to occur 
without causing metabolic injury to non-adipose tissue (Unger et a!, 1999). This is 
achieved by confining the storage of excess calories to adipose tissue and reducing 
ectopic fat accumulation and the resulting metabolic trauma or lipotoxicity of these non-
adipocytes (Shimabukuro eta!, 1997, Muoia eta!, 1997). 
1.9 Treatment of insulin resistance and diabetes with peroxisome proliferator 
activated receptor y (PP AR-y) agonists 
The peroxisome proliferator-activated receptors (PP AR) comprise a subfamily of 
nuclear receptors that heterodimerizes with the retinoid X receptor to regulate the 
transcription of many genes involved in lipid and glucose homeostasis in a ligand 
dependent manner (Jones eta!, 2005). PPAR-y, a member of this subfamily, is mainly 
expressed in white and brown adipose tissue and is expressed to a lesser extent in 
macrophages, colon, kidney and liver (Fajas eta!, 1997). PPAR-y has been shown to take 
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part in many biological processes such as adipocyte differentiation, glucose homeostasis, 
atherogenesis, inflammation and tumor suppression (Braissant et a!, 1996). 
A number of fatty acid metabolites including oxidized linoleic acid and 
arachidonic acid metabolites like 15-deoxy-~12' 14 prostaglandin J2 act as endogenous 
ligands for PPAR-y (Nagy eta!, 1998, Forman et al, 1995). Thiazolidinediones (TZD), a 
class of compounds known to enhance insulin sensitivity and improve metabolic control 
in patients with Type 2 diabetes act through the activation of PP AR y receptors (Saltiel 
and Olefsky, 1996). These agents have been shown to reduce plasma glucose as well as 
plasma insulin levels, thereby clearly improving insulin sensitivity in a variety of insulin-
resistant or diabetic rat and mice models (Olefsky 2000). The improvement in insulin 
sensitivity has also been directly demonstrated using the euglycemic glucose clamp 
technique where treatment with TZDs was shown to improve insulin-stimulated glucose 
disposal as well as insulin inhibition of hepatic glucose production in a wide array of 
insulin resistant and diabetic rat models (Olefsky, 2000). These studies clearly 
demonstrate the efficacy of TZDs in improving insulin sensitivity, however, the 
mechanisms by which the TZDs bring about this improvement of insulin sensitivity is 
unclear. 
Mutations in human PP AR receptors provide mixed results as to its function. 
Complete loss-of-function mutations cause insulin resistance, which suggests that these 
receptors are involved in insulin signaling (Barroso et al, 1999). However, quite in 
contrast to what was expected, individuals carrying the Pro12Ala mutation have been 
found to have greater insulin sensitivity although having decreased receptor activity 
(Deeb et al, 1998). Similarly, heterozygous PPAR-y null mice are more insulin sensitive 
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than their wild type littermates and are also protected from high-fat diet-mediated insulin 
resistance (Miles et a!, 2000, Kubota eta!, 1999). Jones et a! (2005) used the Cre/loxP 
strategy to develop an adipose specific PPAR-y knockout mouse, which was protected 
from developing insulin resistance, or glucose intolerance, probably due to the increased 
insulin stimulated glucose disposal by the liver in the face of an induction of hepatic 
PPAR-y. These results have led to the suggestion that the normal role of PPAR-y 
receptors and their endogenous ligands is to dampen insulin action, promoting a state of 
insulin resistance (Miles et al, 2000) and the insulin sensitizing effect of TZDs may 
reflect their ability to inhibit this dampening effect of the endogenous ligands (Olefsky, 
2000). 
Rosiglitazone (RSG) (Figure 1.4), one of the TZDs being currently used to treat 
human Type 2 diabetes, has been shown to reduce insulin resistance and prevent the loss 
of P-cell mass in obese ZDF rats by maintaining P-cell proliferation and preventing net P-
cell death (Finegood et a!, 2001). The insulin-sensitizing effect of RSG is also 
accompanied by a partitioning of fatty acid uptake into adipose tissue and away from the 
liver and muscle and a reduction in liver fatty acyl CoA accumulation (Ye et al, 2004). 
1.10 Cardiovascular disease, diabetes and insulin resistance 
The risk of CVD and mortality increases greatly with diabetes mellitus with an 
estimated 75% of Type 2 diabetic patients in the United States dying of cardiovascular 
complications (Audelin et a!, 2001 ). They are also likely to develop CVD at a younger 
age and have a higher rate of diffuse multi-vessel disease with 
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Figure 1.4 Chemical structure of Rosiglitazone 
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impaired coronary vasodilatory reserve and develop congestive heart failure (Audelin et 
a!, 2001). 
Glycation of extracellular matrix proteins leads to the formation of advanced 
glycosylation end products which then induce cross linking of collagen and extra-cellular 
matrix proteins in many tissues including blood vessel walls (Brownlee, 1992, Vlassara 
and Bucala, 1996). This glycation process results from exposure to hyperglycemia over a 
period of time as is the case with diabetic patients. Generation of reactive oxygen species 
(ROS) leading to increased oxidative stress together with a decreased synthesis and an 
increased inactivation of nitric oxide (NO) derived from the endothelium is also a result 
of the glycosylation process. NO plays a major role in the endothelium-dependent 
vasorelaxation of blood vessels. In addition, oxidative damage to the arterial wall also 
leads to increased blood vessel stiffness, oxidized LDL production and its uptake into 
macrophages, with the production of foam cells, the secretion of platelet derived growth 
factor and proliferation of vascular smooth muscle cells. Increased platelet adhesion and 
aggregation, increased fibrinogen and increased plasminogen activator inhibitor-! (PAI-
l) concentrations also result from theses changes, giving rise to a pro-thrombotic state 
(Audelin eta!, 2001). 
Insulin resistance per se, without the added complications brought along by frank 
Type 2 diabetes is also associated with increased risk for CVD. The dyslipidemia of 
insulin resistance appears to be a major player in the increased risk for CVD. Whether the 
increase in plasma FF A led to the development of insulin resistance or insulin resistance 
at the level of adipose tissue with increased hydrolysis of TGs led to the release of FF A 
into the circulation, insulin resistance is associated with a hypertriglyceridemia. Increased 
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entry of these FF A into the liver results in increased release of VLDL by the liver. The 
progression of insulin resistance towards CVD begins with this VLDL-associated 
hypertriglyceridemia, which then leads to low HDL cholesterol and increased small dense 
LDL particles due to the action of cholesteryl ester transfer protein (CETP) where 
collision of VLDL with HDL leads to the exchange of cholesteryl ester from HDL for TG 
from VLDL. The TG of HDL is then hydrolyzed by hepatic lipases and probably by LPL 
which generates a small HDL that sheds some of its surface, including apo A-1. Apo A-1 
is excreted through the kidneys making HDL unavailable for reverse cholesterol 
transport. In a similar fashion small dense LDL particles are formed with the exchange of 
LDL CE for VLDL TG in the presence ofCETP (Bruce et al, 1998, Horowitz et al, 1993) 
As reviewed by Ginsberg (2000) these changes can increase an individual's risk 
for CVD in several ways. First, the increased VLDL particles can enter the blood vessel 
wall and accumulate in atherosclerotic plaques. Due to the action of CETP, these VLDL 
contain more CE and therefore deliver more cholesterol per particle to the vessel wall. In 
addition, increased VLDL secretion competes for the chylomicron clearance pathways, 
leading to post-prandial hyperlipidemia, which is independently associated with coronary 
artery disease. Second, the diminished reverse cholesterol transport reduces the delivery 
of cholesterol to the liver along with an inability of HDL to fulfill its proposed functions 
as a direct antiatherogenic substance at the vessel wall. Scavenger receptor B 1 (SRB 1) is 
involved in selective delivery of cholesteryl esters to the liver for excretion via the biliary 
pathway without the endocytosis and delivery of the whole HDL particle (Acton et al, 
1996). The reduction in CE due to the action of CETP hinders this reverse cholesterol 
pathway. Third, the small dense LDL may be more likely to undergo oxidation or may 
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more readily enter the artery wall and therefore be more atherogenic than an equal 
number of larger more CE rich LDL particles. 
Fibrinogen, factor VII, and PAI-l, all of which are factors involved in clotting and 
fibrinolysis were shown to be increased in individuals with insulin resistance (Ginsberg, 
2000). Although the connection between insulin resistance and some of these factors is 
still under investigation P AI -1 levels seem to increase with increased levels of insulin as 
well as VLDL (Erikssen et al, 1998). These effects on clotting definitely add to the CVD 
risk posed by insulin resistance. 
1.11 Hey levels in insulin resistance and diabetes 
Despite the 4-6 fold increase in CVD risk found in diabetic patients compared to 
their non-diabetic counterparts a clear relationship between Hey levels and diabetes has 
not been established. Araki et al (1993) observed a significantly higher level of plasma 
Hey in Type 2 diabetic patients with macroangiopathy than in diabetic patients without 
macroangiopathy or non-diabetic subjects, with no difference in the plasma Hey levels 
between the two latter groups. Studying both Type 1 and Type 2 diabetic patients, Munshi 
et al (1996) did not observe any differences between plasma Hey levels in normal 
volunteers, diabetics without vascular disease or diabetics with vascular disease. 
However, after a methionine load they observed a higher frequency of HHcy in patients 
with Type 2 diabetes compared with age matched controls; HHcy was more common in 
those with macro vascular disease. Measurement of fasting plasma Hey levels in 122 Type 
2 diabetic patients identified 31% of the cohort as being hyperhomocysteinemic while the 
other 69% had normal values (Buysschaert et al, 2000). Here again the prevalence of 
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macroangiopathy was greater in the hyperhomocysteinemic group while they also 
exhibited impaired renal function evidenced by decreased creatinine clearance. 
A study conducted with 50 Type 1 and 30 Type 2 diabetic patients on the other 
hand, found the mean plasma Hey concentration in all diabetic patients to be significantly 
lower than in normal controls (Wollesen, et al, 1999). In Type 1 diabetic patients with no 
renal complications, plasma Hey levels were found to be lower than in healthy people 
while those patients with nephropathy had elevated plasma Hey levels (Matteucci et a!, 
2002). Robillon eta! (1994) also found decreased levels of plasma Hey in Type 1 diabetic 
patients. This decrease was also shown in an animal model of Type 1 diabetes, the 
streptozotocin-induced diabetic rat (Jacobs et al, 1998). 
Wollesen et a! (1999) were also able to show that the reduction in plasma Hey 
seen in the diabetic patients was accompanied by relative urinary hyperfiltration with the 
plasma Hey levels closely and independently associating with the glomeruler filtration 
rate (GFR). This association between plasma Hey and GFR could also explain the age-
related increases observed in plasma Hey. On the other hand the reduced plasma Hey 
seen in streptozotocin diabetic rats was associated with an increase in the removal of Hey 
via an accelerated transsulfuration pathway giving a metabolic perspective to the reduced 
plasma Hey in Type 1 diabetes (Jacobs eta!, 1998). 
Overt nephropathy however gives rise to increased plasma Hey levels. Chico et a! 
(1998) found Type 2 diabetic patients to have increased plasma Hey compared to non-
diabetic control subjects. They found the albumin excretion rate to show the strongest 
independent association with Hey. Patients with both types of diabetes, with nephropathy, 
had higher plasma Hey concentrations and the increase in Hey was related to the severity 
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of nephropathy. Ozmen et al (2002) also found HHcy in Type 2 diabetes to be associated 
with deteriorating renal function. Several other studies describing increased plasma Hey 
levels in Type 2 diabetes show an association between HHcy and decreased renal 
function (Emoto et al, 2001; Stabler et al, 1999; Davies et al, 2001). It is clear therefore, 
that plasma Hey in diabetes varies depending on the presence or the absence of 
nephropathy with levels being lower or normal with no nephropathy and higher when 
there is nephropathy. 
The literature on plasma Hey levels in the insulin resistant state, before the onset 
of frank diabetes is quite conflicting. Pergola et al (200 1) found the plasma Hey level to 
be independently associated with insulin resistance in normal weight, overweight and 
obese pre-menopausal women. They observed a gradual increase in plasma Hey levels 
across the quartiles into which the study group was divided according to their degree of 
insulin resistance as assessed by the Homeostatic model assessment (HOMA) (Pergola et 
al, 2001). In agreement with this finding Giltay et al (1998 B) also observed a significant 
association between insulin resistance and plasma Hey levels in healthy, non-obese 
subjects. The degree of insulin resistance was determined according to the 
hyperinsulinemic euglycemic clamp method in this study. The Framingham offspring 
study with 2011 subjects with no CVD or diabetes found HHcy and an abnormal urinary 
albumin excretion to be associated with hyperinsulinemia (Meigs et al, 2001). Rats made 
hyperinsulinemic and insulin resistant by feeding a high fat sucrose diet were examined at 
6 months and 2 years and were found to have increased plasma levels of Hey compared to 
rats fed a low fat complex carbohydrate diet (Fonseca et al, 2000). Similarly, patients 
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with polycystic ovary disease who were exhibiting insulin resistance were also found to 
have increased plasma Hey levels (Schachter eta!, 2003). 
In contrast to the above studies Abbasi et a! (1999) found the Hey levels to be 
similar in healthy volunteers who were classified as either insulin resistant (SSPG > 180 
mg/dl) or insulin sensitive (SSPG <1000 mg/dl) according to the steady-state plasma 
glucose (SSPG) concentration during the insulin suppression test. A negative correlation 
between plasma Hey and plasma insulin where hyperinsulinemic subjects had lower 
plasma Hey concentration compared to normoinsulinemic subjects has also been reported 
(Bar-on et a!, 2000). A similar negative relationship between insulin resistance and 
plasma Hey were obtained by Rosolva et al (2002) in healthy volunteers categorized 
according to their insulin sensitivity as quantitated by the SSPG concentrations after an 
insulin suppression period. 
These differences in plasma Hey levels in insulin resistance may arise due to the 
differences in the methods employed to measure insulin resistance and/or the degree of 
insulin resistance of the subjects at the time of experimentation. 
1.12 Hey and cardiovascular disease in diabetes 
Total plasma Hey, lipids and parameters of fibrinolytic activity was measured in a 
group of 145 Japanese patients undergoing routine coronary angiography to assess chest 
pain or suspected coronary artery disease (Okada et al, 1999). The presence of diabetes 
was identified and the severity of the coronary artery stenosis (CAD scoring) was graded 
as non stenotic, stenotic single-vessel, stenotic two-vessel, or stenotic three-vessel. They 
found plasma Hey to be significantly higher in patients with stenotic vessels than in 
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patients who were non-stenotic. Very interestingly thereafter they found that the number 
of stenotic coronary arteries was related to tHey level only in patients with diabetes 
mellitus. 39% of the patients studied exhibited HHcy with the CAD score being highest in 
the diabetic patients with HHcy. After adjustment for age, HHcy was associated with an 
odds ratio (OR) for coronary artery stenosis of 2.01 for all patients which increased up to 
6.6 in patients with diabetes. They concluded that plasma Hey level was independently 
associated with the CAD score only in the Diabetes mellitus group. 
The Room study, a cross-sectional survey of glucose tolerance and other 
cardiovascular risk factors in a 50-75 year old general white population, found the OR per 
Sflmol/liter increment in Hey for any cardiovascular disease was 1.38 in subjects with 
normal glucose tolerance, 1.55 in subjects with impaired glucose tolerance and 2.33 in 
subjects with Type 2 diabetes mellitus (Hoogeveen et al, 1998). They concluded that high 
serum Hey may be a stronger risk factor (1.6-fold) for CVD in subjects with Type 2 
diabetes mellitus than in non-diabetic subjects. Another study conducted using the same 
cohort showed after adjustment for major cardiovascular risk factors, serum albumin and 
HbAlc, the OR for 5-year mortality was 1.56 for HHcy and 1.26 per 5 flmol/liter 
increment of Hey (Hoogeveen et al, 2000). They found that the OR for 5-year mortality 
for HHcy was 1.34 in non-diabetic subjects and 2.51 in diabetic subjects and that it is a 
stronger risk factor (1.9 fold) for mortality in Type 2 diabetic patients than in non diabetic 
subjects. Similarly, another prospective study based on a cohort of 211 Type 2 diabetic 
patients showed that plasma tHey concentration is a significant predictor of six-year all-
cause and cardiovascular mortality, both in patients with normoalbuminuria and in those 
with microalbuminuria or macroalbuminuria (Stehouwer et al, 1999). Becker et al, 
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(2003), using the samples collected in the Hoom study, showed that the incidence rate of 
coronary events was 2.63 per 100 person-years among diabetic and 1.29 among non 
diabetic individuals. The risk of coronary events increased 28% for each 5 Jlmol/L 
increment of Hey among the diabetic subjects while among the non diabetic participants 
there was no such association. 
All of the above mentioned studies are concerned with Type 2 diabetes. Hoffman 
et al, (1998) were able to show that Type 1 diabetic patients with HHcy had higher 
plasma levels of thrombomodulin (TM) and a higher prevalence of macroangiopathy 
among other late diabetic complications. TM, a receptor for thrombin, is regarded as an 
important anticoagulant and is predominantly expressed on vascular endothelial cells. The 
form of TM that is found in plasma probably accounts for damaged blood vessels 
(Hoffman et al, 1998). The effect of increased plasma Hey on atherosclerosis has also 
been studied in insulin resistance. Rats that were made insulin resistant by feeding a high 
fat sucrose diet (HFS) were found to have higher plasma Hey levels along with higher 
post-endarterectomy intimal hyperplasia causing luminal stenosis compared to rats that 
had normal insulin sensitivity (Brown et al, 2003). In contrast to these studies Mazza et al 
(1999, 2000) reported that in 130 Type 2 diabetic patients without nephropathy, there was 
no association between the basal level of Hey or the MTHFR polymorphism and carotid 
intima-media thickness. 
These studies suggest an independent association between plasma levels of Hey 
and CVD. Interestingly, the association shown is much stronger in diabetic than non-
diabetic subjects. The association between all cause mortality and HHcy was also shown 
to be greater in diabetic than in non-diabetic patients. HHcy therefore, may play a major 
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role in the development of cardiovascular disease in diabetic patients along with the other 
known risk factors. 
1.13 HHcy and pathogenesis of atherosclerosis 
A unifying hypothesis for the mechanism of Hey mediated vascular injury has not 
yet been established. However, a few theories have been put forward in the literature. The 
most frequently described mechanism involves oxidative damage caused by Hey. Hey 
rapidly auto-oxidizes in plasma with its sulfhydryl ( -SH) group undergoing oxidation to 
disulfide (RSSR). In this process Hey gets converted to homocystine and mixed disulfides 
with the production of various ROS, including super oxide radicals, hydrogen peroxide 
and under certain circumstances hydroxyl radicals (Welch, 1998). It has been proposed 
that H20 2 mediated vessel injury exposes the underlying matrix and smooth muscle cells 
which in tum proliferate and promote the activity of platelets and leukocytes (Harker et 
al, 1974). Superoxide anion in particular is involved in lipid peroxidation at the level of 
the endothelial plasma membrane and within lipoprotein particles as well as in the 
generation of oxidized low density lipoproteins (LDL) (Loscalzo, 1996, Heinecke et al, 
1987). However, cysteine, with a plasma concentration 25 to 30 times greater than Hey, is 
not considered a risk factor for cardiovascular disease despite 94-95% of total plasma 
cysteine being present in the oxidized form (Jacobsen, 2001). 
Another mechanism that has been proposed is the creation of a pro-thrombotic 
environment by Hey. Hey has been shown to enhance the activities of factor XII (Ratnoff, 
1968) and factor V (Rodgers and Kane, 1986) and reduce the activation of protein C 
(Rodgers and Conn, 1990). Hey also induces the expression of tissue factor (Fryer eta!, 
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1993), and suppresses the expression ofTM (Lentz and Sadler, 1991) and heparin sulfate 
(Nishinaga et al, 1993) by the endothelium, thereby altering the normal antithrombotic 
properties of the endothelium. 
Hey also has several effects on the endothelium-derived vasoactive small 
molecule, NO. Formation of S-nitroso-Hcy by the nitrosation of the SH group of Hey by 
NO is regarded as a way the normal endothelial cell deals with the problems posed by 
accumulating Hey (Stamler et al, 1993). In addition to inhibiting the generation of ROS, 
S-nitroso-Hcy is also regarded as a potent platelet inhibitor and vasodilator (Stamler et al, 
1992). Long term exposure to high levels of Hey resulting in endothelial damage will 
limit the production of NO, compromising the protective effect of NO. Hey has also been 
shown to decrease the synthesis ofNO (Welch et al, 1997, Loscalzo, 1996), decrease the 
expression of NO synthase and directly degrade NO (Chin et al, 1992, Liao et al, 1995, 
Blom et al, 1995). Evidence is also there to show that Hey suppresses the expression of 
glutathione peroxidase, a key player in the cellular anti oxidative machinery (Upchurch et 
al, 1997). Hey is also a potent mitogen for vascular smooth muscle cells as shown in 
experiments where infusion of Hey into baboons leads to the formation of atheroma 
(Harker et al, 1983). In-vitro experiments have shown exposure to Hey to cause increased 
vascular smooth muscle cell proliferation brought about partly by increased expression of 
cyclin D1 and cyclin A (Tsai et al, 1994). 
Hey thiolactone, a cyclical oxidative product of Hey is also considered a potential 
mechanism involved in vascular pathology. Aggregates formed by the combination of 
Hey thiolactone with LDL were shown to be taken up by intimal macrophages to form 
. foam cells and be incorporated into atheromatous plaques (Naruszewicz et al, 1994). Hey 
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thiolactone is also incorporated into cellular and secretory proteins through lysine 
acylation leading to the dysfunction ofthe proteins (Jakubowski, 1997). 
Another hypothesis that may account for the mechanism of vascular damage by 
Hey is known as the molecular target hypothesis. This mechanism suggests that Hey itself 
may interact with specific molecular targets thereby modulating their activity (Jacobsen, 
2000). Treatment of rat aortic smooth muscle cells with DL Hey (0-500 J.!M) was shown 
to decrease glutathione peroxidase activity, increase superoxide dismutase in a dose-
dependent manner while catalase activity was unchanged (Nishio ad Watanabe, 1997). 
Hey was also able to inactivate purified bovine hepatic glutathione peroxidase in a dose-
dependent manner (Nishio and Watanabe, 1997). Upchurch eta/ (1997) also found Hey 
to decrease the expression of the cellular isoform of glutathione peroxidase in cultured 
bovine aortic endothelial cells. Hey was found to decrease the steady state mRNA for 
glutathione peroxidase by 90%. 
The members of the anti-oxidant machinery of the cell are not the only molecules 
that could be targeted by Hey. Hey is able to inhibit the conversion of plasminogen to 
plasmin by forming a mixed disulfide with cys 9 on annexin II, thereby inhibiting the 
binding of tissue plasminogen activator (Hajjar et al, 1998). Hey also forms a mixed 
disulfide with prometalloprotease 2, which activates the protease through a cysteine 
switch mechanism (Bescond et al, 1999). Contrary to the favorable picture painted by 
formation of nitrosothiol by the reaction of Hey with NO, this same mechanism is also 
described to reduce the bioavailability of NO by trapping it as nitrosothiol intracellularly 
(Jacobsen, 2000). Once entering the cell Hey can also act to modify intracellular targets 
(Jacobsen, 2000). 
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1.14 Endothelial dysfunction 
The endothelium, a single layer of cells lining the inner wall of the blood vessels 
lies in between the blood stream and the vessel wall and is considered the largest organ in 
the body. The endothelium is able to sense mechanical stimuli, such as pressure and shear 
stress and hormonal stimuli such as vasoactive substances and to release various agents 
involved in vasomotor function, inflammation and hemostasis (Endemann and Schiffrin, 
2004). NO, prostacyclin, endothelium-derived hyperpolarizing factor (EDHF), 
bradykinin, adrenomedullin, C-natriuretic protein are vasodilators released by the 
endothelium while endothelin-1, angiotensin-II, thromboxane A2, prostaglandins and 
ROS are vasoconstrictors (McGuire et al, 2001). NO, intercellular adhesion molecule -1 
(ICAM-1), vascular adhesion molecule-1 (VCAM-1), E-selectin, and NF-KB are 
inflammatory mediators released by the endothelium while modulators of hemostasis 
include plasminogen activator, tissue factor inhibitor, von Willebrand factor, NO, 
prostacyclin, thromboxane A2, plasminogen activator inhibitor-!, and fibrinogen 
(Endemann and Schiffrin, 2004). In addition to these functions the endothelium also plays 
a role in mitogenesis, angiogenesis, vascular permeability and fluid balance (Endemann 
and Schiffrin, 2004). 
Since the discovery of the requirement of the endothelium to exert the 
vasodilatory effects of acetylcholine (Furchgott and Zawadzki, 1980) to the first 
description of endothelial dysfunction in a human m 1990 (Panza et al, 1990), our 
understanding of the role of the endothelium in vascular homeostasis has greatly 
increased. Endothelial dysfunction is generally described as impaired vasodilation to 
specific stimuli such as acetylcholine or bradykinin but also includes impairment of 
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endothelial dependent regulation of hemostasis and inflammation (Endemann and 
Schiffrin, 2004). Endothelial dysfunction is implicated in the pathophysiology of several 
forms of cardiovascular disease such as hypertension, coronary artery disease, chronic 
heart failure, peripheral arterial disease, diabetes and chronic renal failure (Endemann and 
Schiffrin, 2004). Some studies have shown endothelial dysfunction to precede 
development of cardiovascular disease; for example offspring of hypertensive patients, 
despite being normotensive, have displayed endothelial dysfunction (Taddei et al, 1996). 
Similarly, symptom-free children and young adults at high risk for atherosclerosis have 
also displayed endothelial dysfunction (Celermajer et al, 1992). 
Saenz et al, 1989 reported endothelial dysfunction m human penile 
corpura cavemosa for both Type 1 and Type 2 diabetic patients. Endothelial dysfunction 
has also been described in the peripheral circulation of Type 1 (Johnstone et al, 1993) and 
Type 2 diabetic patients (Ting et al, 1996). Endothelial dysfunction has also been 
reported in non-diabetic but insulin- resistant obese individuals (Steinberg et al, 1996). 
Studies done using 3 different models of Type 2 diabetes and insulin resistance have 
shown hyperglycemia to be the major risk factor for endothelial dysfunction in diabetes. 
The study used db/db, ob/ob and TallyHo mice and endothelial dysfunction was only 
observed in the db/db and TallyHo mice, which displayed both hyperglycemia and 
dyslipidemia, and not in ob/ob mice that only exhibit dyslipidemia (Triggle et al, 2003). 
Oxidative stress, brought about by the production of various ROS in response to the 
hyperglycemia, is believed to be the cause of this endothelial dysfunction as ROS 
decrease the bioavailability of the nitric oxide synthase cofactor, tetrahydrobiopterin 
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(BH4) leading to "uncoupled eNOS". Uncoupled eNOS produces superoxide instead of 
NO (Triggle et al, 2003). 
1.15 Pathophysiology of endothelial dysfunction 
Endothelial dysfunction can be brought about by multiple mechanisms. Reduction 
in the levels of NO due to reduced activity of eNOS (due to exogenous or endogenous 
inhibitors of eNOS or due to unavailability of its substrate, L-arginine) or reduced 
bioavailability of NO leads to endothelial dysfunction. Under oxidative stress, ROS react 
with NO to produce the cytotoxic oxidant peroxynitrite, which causes nitration of proteins 
leading to their dysfunction and therefore to endothelial dysfunction (Koppenol et al, 
1992). Peroxynitrite is also responsible for oxidation of LDL (Griendling and Fitzgerald, 
2003) as well as the degradation of the eNOS cofactor BH4 leading to the "uncoupling" of 
eNOS (Milstein and Katusic, 1999). Oxidative stress also causes the reduction of BH4 to 
BH2 (Endemann and Schiffrin, 2004). "Uncoupling" of eNOS involves the reduction of 
its oxygenase activity, which is responsible for forming NO, and an increase in its 
reductase activity leading to the production of further ROS (Endemann and Schiffrin, 
2004). 
Along with the reduced levels of NO, the oxidative environment also leads to a 
pro-inflammatory state in the vessel wall with up-regulation of adhesion (VCAM-1 and 
ICAM-1) and chemotactic molecules (macrophage chemoattractant peptide-1 [MCP-1]) 
(Griendling and Fitzgerald, 2003). NAD(P)H oxidase is the enzyme responsible for most 
cellular ROS with xanthine oxidase, mitochondria and uncoupled eNOS also giving rise 
to some (Endemann and Schiffrin, 2004). 
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Reduction in the bioavailability of NO may also be caused by the endogenous 
competitive inhibitor of eNOS, asymmetric dimethylarginine (ADMA). ADMA is a 
product of protein turnover and is either excreted through the kidneys or degraded to 
citrulline by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Therefore 
increased levels of ADMA can be seen in both chronic renal failure as well as in hepatic 
disease (Nijveldt et al, 2003). 
HHcy has also been implicated in the pathophysiology of endothelial dysfunction 
as shown by many studies involving both animals and humans (Lentz, 2000, Faraci and 
Lentz, 2004). It has also been shown that HHcy causes endothelial dysfunction to a 
degree similar to other risk factors such as hypercholesterolemia and hypertension (Lentz, 
2000). One of the mechanisms by which HHcy has been shown to cause endothelial 
dysfunction is through the reduction in NO bioavailability by oxidative excess of several 
types of ROS like superoxide, hydrogen peroxide and peroxynitrite (Faraci and Lentz, 
2004). In addition to the direct production ofROS by the auto-oxidation of Hey, Hey also 
mediates a specific decrease in the expression of the cellular isoform of glutathione 
peroxidase (Gpx-1), as was shown in vitro as well as in vivo (Upchurch et al, 1997, 
Outinen et al, 1999). To complement these studies, Weiss et al, (2001) was able to show 
that over-expression of Gpx-1 compensates for the adverse effects of Hey on endothelial 
function. 
Another potential mechanism by which Hey may exert a deleterious effect is via 
the elevation of ADMA, as has been demonstrated in a non-human primate model of 
HHcy (Boger et al, 2000). Hey may cause elevation of ADMA by the inhibition of its 
catabolism through DDAH (Stuhlinger et al, 2003). Endoplasmic reticulum stress 
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(Outinen et al, 1999, Outinen et al, 1998), stimulation of pro-inflammatory processes 
(Ungvari et al, 2003), and alterations in the methylation of regulatory proteins such as 
Ras (Wang et al, 1997) have also been suggested as mechanisms by which Hey can 
activate endothelial apoptotic pathways leading to endothelial dysfunction. 
HHcy therefore appears to cause endothelial dysfunction through a multiplicity of 
mechanisms. These mechanisms may explain the increased cardiovascular risk posed by 
elevations in plasma Hey levels. 
1.16 Pathophysiological effects of endothelial dysfunction 
Endothelial dysfunction is regarded as an early event in the pathophysiology of 
the atherosclerotic process as reduced bioavailability of NO appears to lead to a number 
of proatherogenic processes (Celermajer et al, 1992, Suwaidi et al, 2000). Low NO 
bioavailability has been shown to upregulate VCAM-1 in the endothelial cell through the 
induction of NF-KB expression (Khan et al, 1996). This plays a role in the inflammatory 
process as VCAM-1 binds monocytes and T-lymphocytes, the first step in the invasion of 
the vessel wall by these cells (Libby, 2002). Reduction in NO also leads to the induction 
of MCP-1 expression leading to the recruitment of mononuclear phagocytes (Zeiher et al, 
1995). Lectin-like oxidized LDL receptor-! (LOX-1) which is highly expressed in blood 
vessels in hypertension, diabetes and dyslipidemia (Mehta and Li, 2002) scavenges 
oxidized LDL leading to a reduction in eNOS expression (Mehta et al, 2001) and further 
stimulation of adhesion molecule expression (Chen et al, 2001). Vascular smooth muscle 
cell growth and interstitial collagen synthesis gets stimulated by the growth factors 
secreted by macrophages found in the plaque (Libby, 2002). In addition to creating this 
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favorable environment for plaque formation, decreased NO may also be implicated in the 
rupture of the fibrous cap of the plaque with the resultant formation of a thrombus, as it 
was shown to activate matrix metalloproteinases MMP-2 and MMP-9 which weakens the 
fibrous cap (Uemura et al, 2001, Eberhardt, 2000). Platelet aggregation may also be 
enhanced in the face of reduced NO as NO is a known inhibitor of platelet aggregation 
(Radomski et al, 1987). 
1.17 Perspective 
It is clear that plasma Hey plays a major role in the etiology of several chronic 
diseases one of the most important being atherosclerotic cardiovascular disease. 
Cardiovascular disease is also recognized as the leading cause of death in diabetic 
patients. Is there any additional role played by plasma Hey in the development of CVD in 
diabetes? The many studies that have been published dealing with plasma Hey levels in 
both Type 1 and Type 2 diabetes as well as insulin resistance have yielded a multiplicity 
of results. This may very well reflect the many mechanisms involved in the regulatory 
process of plasma Hey. We strongly believe in the metabolic regulation of plasma Hey 
and have comprehensively shown the hormonal regulation of two major enzymes 
involved in the removal of plasma Hey; CBS and BHMT. Although not quite fully 
explained as yet there also appears to be a relationship between kidney function and 
plasma Hey. The kidney has been shown to be a major organ in the removal of Hey in 
rats but the same has not been able to be displayed in humans. However, most studies 
have been able to show a positive correlation between plasma Hey and plasma creatinine 
levels indicating the importance of the kidney in the regulation of plasma Hey. 
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Renal function in Type 2 diabetes appears to change with the progress of the 
disease; hyper-filtration in the early stages and progressive deterioration with the 
progression of diabetes. Diabetes therefore provides an interesting situation with changes 
in kidney functions being superimposed on the already existing changes in the metabolic 
milieu. 
1.18 Problems of investigation and objectives 
The main focus of this work was the examination of Hey metabolism in Type 2 
diabetes and insulin resistance before the impairment of kidney function in order to gain 
further understanding of the metabolic regulation of plasma Hey. We were also interested 
in identifying the changes that occur in other amino acids under these conditions as the 
available data on this subject deals mostly with Type 1 diabetes. The specific questions 
that we sought to find answers through this work include: 
1. The effects of Type 2 diabetes and insulin resistance on plasma Hey 
levels and Hey metabolism in the liver. 
2. The effects of Type 2 diabetes and insulin resistance on amino acid 
metabolism 
3. Effects of rosiglitazone ·treatment on Hey metabolism m insulin 
resistance and Type 2 diabetes 
4. Vascular function in insulin resistance and Type 2 diabetes and the 
effects of rosiglitazone treatment on vascular function. 
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Chapter 2 
Materials and Methods 
63 
2.1 Animals 
All procedures were approved by Memorial University's Institutional Animal 
Care Committee and were in accordance with the guidelines of the Canadian 
Council of Animal Care. Age-matched (5 and 11 weeks old) male ZDF (ZDF fa/fa) 
and (ZDF +/?) rats purchased from Charles River Laboratories (Indianapolis, 
Indiana, USA) were used as a model of Type 2 diabetes. Rats were given water and 
Purina 5008 chow ad libitum unless otherwise stated. Rats were housed in the Animal 
Care Facility using a 12 hour light: 12 hour dark cycle which began with lights on at 
8:00 am. In vascular assays, data were obtained from ZDF fa!+ and ZDF fa/fa rats 
at 6, 12 and 18 weeks of age. In the study of the effects of Rosiglitazone on Hey 
metabolism, data were obtained from ZDF fa!+ and ZDF fa/fa rats at 6 and 12 
weeks of age. 
2.2 Rosiglitazone Treatment Protocol 
ZDF fa/fa and the ZDF fa!+ rats were assigned randomly by drawing lots to 
equal groups of untreated and rosiglitazone-treated (RSG) at 6 weeks of age. 
Untreated rats continued to receive their unaltered diet (described above). RSG-
treated rats were given ad libitum access to water and Purina 5008 chow containing 
rosiglitazone maleate (received as a gift from GlaxoSmithKline, West Sussex, UK) 
which was estimated to give a dose of 10 )lmol/kg body weight /day (Finegood et al, 
2001). A set of untreated ZDF fa!+ and ZDF fa/fa rats were sacrificed at 6 weeks of 
age to obtain metabolism and vascular function data at baseline (time 0). Then equal 
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groups of untreated and RSG-treated rats were sacrificed after 6 and 12 weeks of 
treatment. 
2.3 Metabolism Assays 
Animals were anaesthetized with sodium pentobarbital (65 mg/kg i.p.) on the 
day of the experiment. After a midline abdominal incision, blood was drawn into a 
heparinized syringe from the abdominal aorta. Before withdrawal of the syringe 
from the abdominal aorta, a piece of the liver was rapidly removed and freeze-
clamped in liquid nitrogen. The rest of the liver was then removed and placed in ice-
cold 50 mM potassium phosphate buffer (pH 7.0). The freeze-clamped tissues were 
stored at -70°C until further use. The blood was centrifuged in a clinical centrifuge 
at 3700 g for 15 minutes. Plasma thus separated was kept at -20° C until further use. 
Fresh liver was diluted 1:5 (w/v) with 50 mM potassium phosphate buffer (pH 7.0) 
and homogenized using a polytron (Brinkmann Instruments, Toronto, Canada) for 
20s at 50% output. The homogenate was centrifuged at 18000 g for 30 min at 4°C 
and the supernatant was carefully separated. All enzyme assays were performed on 
this 18000g supernatant except for the activity of choline dehydrogenase which was 
measured using the 20% homogenate. 
2.4 Analytical procedure: 
2.4.1 Plasma Hey: 
Plasma tHey (which consists of protein-bound Hey and free, which is both in the 
reduced and the oxidized form) was determined according to the method described 
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by Vestor and Rasmussen (1991). 150J.tl of sample (plasma or hepatocytes) was first 
incubated at 4°C for 30 min with 20J.tl 10% tri-n-butyl phosphine in 
dimethylformamide to reduce disulfide bonds and liberate protein-bound Hey. After 
the reduction period, 125J.tl of 0.6M perchloric acid was added to deproteinize along 
with 50 J.tl of 0.2 mM 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS) which is 
used as an internal standard. The tubes were left at room temperature for 10 min 
and centrifuged at 14000 g (Brinkman instruments, Rexdale, ON, Canada) for 5 
min. 1 OOJ.tl of the resultant supernatant was collected and 200J.tl of 2 M Potassium 
Borate containing 5 mM EDTA (pH 10.5) and lOOJ.tl of 7-Fluorobenzo-2-oxa-1,3-
diazole-4-sulfonic acid (1mg/ml solution) in 2 M Potassium Borate (pH 9.5) were 
added. After a thorough mixing, the Eppendorf tubes were covered in aluminum foil 
and incubated at 60°C for 60 min. The tubes were then allowed to cool for 5 min in 
an ice bath and were centrifuged at 14000 g for 5 min. The samples were filtered 
through a 0.45J.tm syringe filter in preparation for analysis by HPLC. 
A Shimadzu High Performance Liquid Chromatography system from Man-
Tech Associates Inc., consisting of a SIL-l 0 A (Shimadzu auto-injector), LC-1 OAD 
(Liquid chromatograph Solvent Delivery Module), SCL-lOA (system controller 
module), FCV-10 AL (solvent selector), GT-104 (degasser) and a Shimadzu RF 535 
Fluorescence HPLC monitor fitted with a Hypersil ODS 5J.tm C18 column (150 mm 
x 4.6 mm) (Supelco Inc), was used to measure Hey. 
0.1 M Sodium Acetate buffer (pH 4.0) containing 2% v/v or 20% v/v 
methanol was used as buffer A or B respectively. The buffers were filtered through a 
0.45 J.lm Millipore filter before use. A 20 min linear gradient running from 100% 
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buffer A to 100% buffer B over 10 min, back to 100% buffer A over 5 min and a 
final 5 min equilibration period at 100% buffer A was used. 20f.ll of the sample was 
injected on to the column and the fluorescence signal was detected with excitation at 
385 nm and emission at 515 nm and integrated using a Man-Tech Shimadzu CR 501 
HPLC data processor. The standard curve for Hey is shown in Fig. 2.1. 
2.4.2 Plasma Glucose, creatinine and insulin: 
Plasma glucose was determined enzymatically as described by Bergmeyer et 
al. (1974). Plasma creatinine (Chapter 3) was measured using a kit (catalogue No. 
555A) from Sigma Diagnostics (St. Louis, MO), which uses the Jaffe reaction with 
some modifications. Plasma creatinine (Chapter 5) was measured by Dr. Ed Randell 
using SYNCHRON creatinine (CREm) reagent in conjunction with SYNCHRON 
LX AQUA CAL 1 and 2 as calibration standards on a SYNCHRON LX system. This 
method too is based on the Jaffe reaction. Plasma insulin was measured with a rat 
insulin ELISA kit (catalogue No. INSKR020) from Crystal Chern Inc., Downers 
Grove, IL, USA using anti rat /mouse insulin antibody, and standard rat insulin. 
2.5 Enzyme analysis 
Standard conditions of protein and time are giVen for each enzyme assay in 
Table 2.1. In all cases, protein and time were chosen to fall in the linear portion of 
the protein and time curves for each assay (see Figures 2.2 to 2.9). Protein 
concentrations were determined by the Biuret method using BSA as a standard. 
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Figure 2.1: Standard Curve for Hey. 
A typical graph is shown. 
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Table 2.1 Experimental conditions used in assaying enzyme activities 
Protein (mg) Time (min) 
Methionine adenosyltransferase 0.5 30 
Glycine-N-methyltransferase 0.075 30 
Cystathionine P-synthase 2 60 
Cystathionine y-lyase 1 10 
Methionine synthase 1 30 
Methylenetetrahydrofolate reductase 0.1 20 
Betaine:homocysteine methyltransferase 0.3 60 
Choline dehydrogenase 0.15 7.5 
Linearity with time and protein was established for each assay and the protein and 
time to be used in the experiments were chosen from the linear portion of the curve. 
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Figure 2.2: Dependence of hepatic methionine adenosyltransferase activity on 
protein and time. 
A 30 min incubation period was used to obtain the protein curve while 0.5 mg 
of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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Figure 2.3: Dependence of hepatic glycine N-methyltransferase activity on protein 
and time. 
A 30 min incubation period was used to obtain the protein curve while 0.075 
mg of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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Figure 2.4: Dependence of cystathionine production by hepatic cystathionine 13-
synthase on time and protein. 
A 60 min incubation period was used to obtain the protein curve while 2 mg 
of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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Figure 2.5: Dependence of hepatic cystathionine y-lyase activity on protein. 
A typical graph is shown. 
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Figure 2.6: Dependence of hepatic methionine synthase activity on time and protein. 
A 30 min incubation period was used to obtain the protein curve while 1 mg 
of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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Figure 2.7: Dependence of liver Methylenetetrahydrofolate reductase activity on 
time and protein. 
A 20 min incubation period was used to obtain the protein curve while 0.1 mg 
of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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Figure 2.8: Dependence of hepatic betaine:homocysteine methyltransferase on 
protein and time. 
A 60 min incubation period was used to obtain the protein curve while 0.3 mg 
of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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Figure 2.9: Dependence of hepatic choline dehydrogenase on protein and time. 
A 7.5 min incubation period was used to obtain the protein curve while 0.15 
mg of protein was used in each incubation to determine the linearity with respect to 
time. A typical graph is shown for each condition. 
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2.5.1 Methionine adenosyltransferase: 
Methionine adenosyltransferase activity was measured usmg a method based 
on Mudd et al (1965) and Duce et al (1988). The assay included 100 mM Tris HCI 
(pH 7.8), 200 mM KCI, 10 mM MgC}z, 1 mM DTT, 5 mM ATP, 5 mM 1-14 CH3-
Methionine (0.04 ~Ci) and 0.5 mg of liver protein in a final volume of 250 ~1. 
Incubations were started with the addition of 1-14C Methionine and were stopped 
with the addition of 750 ~1 of ice-cold H20 after an incubation period of 30 min at 
3 7°C. 700 ~1 of the stopped incubate was added to a column containing Biorad SOW-
X4 200-400 mesh H+-form resin with the counter-ion changed to NH/. The columns 
were washed with 5 x 4 ml of H20 and labeled SAM was eluted with 2 x 3 ml of 3 M 
NH40H. 10 ml of Scintiverse (Fisher Scientific, ON, Canada) was added to each vial 
and the radioactivity was measured with a LKB-1214 Rackbeta liquid scintillation 
counter. 
2.5.2 Glycine N-methyltransferase: 
The activity of Glycine N-methyltransferase was measured according to a 
method described by Rowling et al. (2002). 100 mM Tris HCL (pH 9.0), 2 mM 
Glycine, 5 mM DTT, 0.2 mM Methyl -3H -SAM in 50 mM potassium phosphate 
buffer (pH 7.0) and 0.15 mg of protein were incubated for 15 min at 25°C in a final 
volume of 200 ~1. The incubations were stopped by the addition of 100 ~1 of ice-cold 
10% TCA. 500 ~1 of acid washed charcoal suspension (38 mg/ml in 0.1 M Acetic 
Acid) was added to the tubes and they were allowed to stand on ice for 15 min. The 
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tubes were then centrifuged at 3200 g for 10 min and 500 111 of the supernatant was 
added to 10 ml Scintiverse to determine radioactivity as described before. 
2.5.3 Cystathionine f3 synthase 
Cystathionine f3 synthase activity was measured using an assay described by 
Mudd et a! (1965) and Taoka et a!. (1998). The assay included 125 mM Tris HCL 
(pH 8.3), 2.1 mM EDTA, 0.42 mM pyridoxal-5'-phosphate, 0.146 mM L-
cystathionine, 41.7 mM D,L-Hcy, 0.316 mM SAM, 2.1 mM propargylglycine and 25 
mM 1-14C Serine (0.1 11Ci) in a final volume of 0.6 mi. 2 mg of protein were used in 
each assay. fucubations were carried out for 1 hr at 37°C and were stopped with the 
addition of 300 111 of 15% TCA. The tubes were centrifuged at 1000 g for 10 min 
and 0.5 ml of the de-proteinized sample was added to a moist column containing 2 
ml of BioRad 50 W X 4 200-400 mesh H+ form resin. The columns were washed with 
2 X 4 ml of H20 and then 6 x 4 ml 1M HCL and finally with 4 x 4ml H20. 
Radiolabelled cystathionine was eluted with 5 ml of 3 M NH40H. 1 ml of the eluent 
was used to measure radioactivity after mixing with 10 ml of Scintiverse as 
described before. 
2.5.4 Cystathionine y-lyase 
This assay was conducted as described by Stipanuk (1979) with the 
spectrophotometric measurement of the disappearance of NADH at 340 nm at 37° C 
for 10 min. The assay cocktail included 100 mM Potassium Phosphate buffer (pH 
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7.5), 0.125 mM pyridoxal-5-phosphate, 0.32 mM NADH, 4 mM L-Cystathionine, 1.5 
units of Lactate dehydrogenase and 1 mg liver protein in a final volume of 2 ml. A 
blank was run for each sample with the above cocktail with no cystathionine. 
2.5.5 Methionine synthase 
The reaction mixture consisted of 64 mM potassium phosphate buffer (pH 
7.5), 29 mM dithiothreiotol (DTT), 7 mM mercaptoethanol, 10 !lM 
cyanocobalamine, 7.5 mM D, L-homocysteine, 0.25 mM SAM and 0.5 mM [5-14C] 
methyl tetrahydrofolate (0.25 j..tCi) in 1.064 mM sodium ascorbate (pH 7.0). This 
reaction mixture was incubated at 37° C in the dark for 30 min with 1 mg of protein 
in a final volume of 200 j..tl. The reaction was stopped with 400 j..tl of ice-cold H20 and 
the tubes were immediately transferred to an ice bath. After centrifugation, 14C 
methionine was separated from 14C methyltetrahydrofolate by adding the 
supernatant to an ion exchange column (BioRad AG 1-X8, 200-400 mesh, cr form, 
0.8 x 4 em). The columns were washed with 3 x 500j..tl of H20, the effluent was 
collected and the radioactivity was counted after adding 10 ml of Scintiverse as 
described before (Koblin eta!. 1981). 
2.5.6 Methylenetetrahydrofolate reductase 
Methylenetetrahydrofolate reductase activity was measured as described by 
Engbersen et a!. (1995). The reaction mixture for this assay consisted of 0.024 mM 1-
14 C methyltetrahydrofolate (0.3 j..tCi), 11.6 mM ascorbic acid, 0.18 M potassium 
phosphate buffer (pH 6.8), 54 j..tM FAD, 0.54 mM EDTA, 3.5 mM menadione and 0.1 
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mg of cytosolic protein. The reaction was started with the addition of menadione 
sodium bisulfate. The tubes were incubated at 3 7° C for 20 min in the dark and was 
stopped by the addition of 100 !J.l of 3 M potassium acetate (pH 4.5), 10 Ill of 1 M 
formaldehyde and 200 !J.l of 250 mM dimedone in ethanol: H20 1:1 sequentially. 
They were then heated at 95 °C for 15 min and were cooled on ice for 10 min before 
adding 3 ml of toluene. After mixing well, the tubes were centrifuged at low speed 
for 5 min. 2 ml of the toluene phase was removed and mixed with 10 ml of 
Scintiverse to measure radioactivity as described before. 
2.5. 7 Betaine:homocysteine methyl transferase 
The assay was conducted as described by Garrow (1996). The assay 
contained 5 mM D, L,Hcy, 2 mM 1-14C betaine (0.05-0.1 !J.Ci), 50 mM Tris HCL (pH 
7.5) and 0.3 mg of cytosolic protein in a final volume of O.Sml. The tubes were 
incubated at 37° C for 1 hr and were stopped with the addition of 2.5 ml of ice-cold 
H20. After centrifugation, 2 ml of the stopped reaction mixture was added to Dowex 
1-X4 (Cr) 200-400 mesh resin in which the counter-ion had been changed to OR". 
The columns were washed with 3 X 5 ml of H20 and radiolabelled methionine was 
eluted with 3 ml of 1.5 M HCL. The radioactivity in the eluant was measured as 
described before. 
2.5.8 Choline dehydrogenase 
Choline dehydrogenase activity was measured using a method modified from 
Grossman and Hebert (1989) and Haubrich and Gerber (1981). Each incubation 
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included 3.5 mM tris HCL (pH 7.6), 0.35 mM EDTA, 0.7 mM ~ mercaptoethanol, 
1.08 mM phenazine methosulfate (PMS)/0.35 mM CaCh, 0.5 mM 1_14 C choline 
chloride (0.2 J..!Ci) and 15 J..!l of liver homogenate containing 0.15 mg of protein. The 
tubes were incubated in the dark at 37° C for 7.5 min and were stopped with the 
addition of 20 J..!l 1M NaOH and were transferred to an ice bath. After mixing well, 
15 J..!l of 30% HzOz was added to the tubes and they were incubated at Room 
temperature for 1 hr. 415 J..!l of cold ddHzO was added to each tube and the contents 
were loaded on to columns containing Dowex 50W-X4 (100-200 mesh) H+-form resin 
with the counter-ion changed to Lt by washing with LiOH. The columns were 
washed with 6 X 833J..!l of HzO and the collected effluent was mixed with 10 ml of 
Scintiverse to be measured for 14C betaine in the scintillation counter. 
2.6 S-adenosylmethionine and S-adenosylhomocysteine 
For the determination of SAM and SAH, freeze clamped liver was quickly 
homogenized in 5 volumes of 8% ice-cold trichloroacetic acid. The samples were 
then centrifuged at 12,500 g for 5 min. After filtration, the supernatant was analyzed 
by HPLC using a Vydac C18 column (model 2187P54) with 50 mM NaH2P04 
containing 10 mM heptanesulfonic acid (pH 3.18-3.2) and 100% acetonitrile as 
buffers A and B respectively. A 15 min gradient from 96% A, 4% B to 80% A and 
20% B was used. UV absorbance at 258 nm was measured and the peaks were 
quantified using a Waters 7 43 data module integrator. Standard curves for SAM 
and SAH are given in Fig. 2.1 0. 
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Figure 2.10: Standard curves for SAM and SAH. • SAM, A SAH. 
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2.7 Reverse Transcriptase-PCR: 
Total RNA was isolated from fresh liver samples as previously described 
(Chomczynski and Sacchi, 1987). 2).!g of RNA was reverse transcribed using a one step 
reverse transcription kit (Qiagen, Mississauga, Canada) and was amplified by 15 
cycles. An upstream primer (5'- GCCTTCAGGACATCCAGTGT-3') and a 
downstream primer (5'- TCTTTCCGGGTCTGCTCACGGGC-3') corresponding 
to the type 3 rat CBS eDNA (Kraus eta!, 1998) were used to amplify a 1644-bp PCR 
fragment. For BHMT, an upstream pnmer (5' ACCGATTGCCGGCAAGAA-3') 
d d t (5 '-an a own s ream pnmer CTGTGCGGATTTGAA TTTTTG-3 ') 
corresponding to the rat BHMT eDNA was used to amplify a 1216 bp PCR-
fragment. 768 bp fragment of the rat P actin was co-amplified using amplimer set 
primers (CLONTECH laboratories, Palo Alto, CA). Once amplified the PCR 
products were separated on 0.8% (w/v) agarose. The bands were stained with 
ethidium bromide and were visualized under UV illumination. In the case of CBS 
mRNA, the gel was immersed in 0.25 M HCL, denatured in denaturing buffer, 
rinsed with dH20, soaked in neutralization buffer, incubated in lOx SSC, and 
transferred to an S and S Nytran SuPer charge nylon membrane. After transfer, the 
DNA was immobilized by UV cross-linking in a Hoefer UVC 500 UV cross-linker 
(Amersham Biosciences). The blots were simultaneously probed with 32P- labeled 
CBS eDNA and Radiolabeled P- actin eDNA probes (CLONTECH Laboratories, 
Palo Alto, Ca). Finally autoradiography was carried out using Kodak XAR or 
Biomax film. Autoradiographs were scanned on Chemilmager™ 4000, and RNA 
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levels were quantitated with Alpha Ease software (Alpha lnnotech Corporation, San 
Leandro, CA). 
2.8 Isolation of Hepatocytes 
Hepatocytes were isolated according to the method of Berry et al (1991). 0.1 
ml of heparin (1000 units/ml) was injected into the femoral vein of an anaesthetized 
rat. After a mid-line incision, ties were placed around the inferior vena cava above 
the renal artery and several around the portal vein. A cannula was inserted into the 
portal vein and tied in place. Flow-through perfusion with 500 ml of "Ca+2-free" 
Krebs-Henseleit medium (144 mM Na+, 6 mM K+, 1.2 mM Mg+2, 126 mM cr, 1.2 
mM H2P04-, 1.2 mM sol·, 25 mM HC03-) containing 2 mM EGTA, 20 mM glucose, 
2.1 mM lactate, and 0.3 mM pyruvate (pH 7.4) was started immediately at a flow 
rate of 40 ml/min. The Krebs-Henseleit medium was gassed with 95/5% 0 2/C02 for 
at least 20 min before use. To start flow through the liver the inferior vena cava was 
severed below the kidney. The flow through of Ca +2 free medium was followed by 
about 500 ml of "Ca+2-plus" medium (1.3 mM Ca+2) containing 20 mM glucose, 2.1 
mM lactate, and 0.3 mM pyruvate. A second cannula was inserted through the right 
atrium and into the inferior vena cava after opening the chest just above the heart 
and was tied off above the renal artery. With the completion of the second flow-
through, recirculation of Krebs-Henseleit Ca +2 medium containing 0.25 % (w/v) 
BSA and 30 mg/100 ml collagenase (Boehringer # 103586) was begun and the 
perfusion was continued until the liver became soft. The liver was removed into a 
Petri dish containing collagenase medium and gently teased with fingers to release 
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cells. The released cells were incubated at 37°C in a shaking water bath for 10 min 
while gassing with 95/5% 02/C02, filtered through a strainer and centrifuged at 600 
rpm for 2 min. The supernatant was poured off and the cells were resuspended in 
fresh Krebs-Henseleit Ca+2 medium, centrifuged again and the process repeated. 
Finally the cells were washed with Krebs-Henseleit Ca+2 medium containing 2.5% 
BSA. The supernatant was poured off and the cells were resuspended in Krebs-
Henseleit Ca +2 2.5% BSA medium (diluted 1: 18). 3 ml of the resulting cell 
suspension and 3 m1 of the 2.5% BSA Krebs-Henseleit medium were poured into 
separate tared petri dishes and were dried at 50° C for 24 hrs to measure dry weight. 
Cell viability was measured by 0.2% Trypan Blue exclusion with at least 95% of the 
cells being viable in all cases. 
2.9 Transsulfuration Flux 
Hepatocytes were isolated from ZDF fa/fa and ZDF +!? rats as described 
above. The transsulfuration pathway provides an outlet for methionine to leave the 
methionine metabolic cycle and get converted to cysteine and consists of the 
cystathionine P-synthase reaction, which converts Hey to cystathionine and a-
ketobutyrate, and cystathionine y-lyase, which converts cystathionine to cysteine. 1-
14C methionine gives rise to 1-14C a-ketobutyrate, which is metabolized via pyruvate 
dehydrogenase to produce 14C02. 1-14C a-ketobutyrate that does not get metabolized 
through this pathway will be decarboxylated to give 14C02 in the presence of 
hydrogen peroxide. The total transsulfuration flux was determined as the sum of the 
14C present in a-ketobutyrate and in 14 C02, as described by Stead et al. (2000). 1 ml 
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of hepatocytes and an appropriate volume of Krebs-Henseleit medium were pre-
incubated for 20 min with no betaine or 0.1, 0.3 or 1 mM betaine. The zero time 
flasks had 0.6 ml of 30% HCL04 added to them at the beginning of the assay. 20 111 
of 100 mM or 10 mM 1-14C methionine were added to the flasks (final volume 2 ml) 
and incubated for 30 min. At the end of 30 min the flasks were covered with a plastic 
septum, equipped with a centre-well containing 0.6 ml of NCS-II tissue solubilizer 
(Amersham International, Oakville, ON, Canada). 0.6 ml of 30% HCL04 (w/v) was 
added via a syringe through the center-well to stop the incubation, after which 14C02 
was collected for 1 hr. At the end of the hour, centre-wells were added to 
scintillation vials containing 10 ml of scintillation fluid (Toluene Omnifluor) and 
radioactivity was measured. A second rubber septum, equipped with a centre-well 
was fitted to the flasks and 0.3 ml of 30% H20 2 (w/v) was added through the septum 
by means of a syringe. 14C02 was collected again for an hour and the radioactivity in 
the second centre well measured. 
2.10 Hey export from isolated hepatocytes 
In a separate series of experiments, hepatocytes were incubated with 0.1 mM 
methionine ± 0.3 mM betaine to measure the rate of Hey export from isolated 
hepatocytes. After a 20 min pre-incubation of hepatocytes with betaine and Krebs-
Henseleit medium, methionine was added and the flasks were incubated for 30 min 
at 37°C. At the end of 30 min the contents of the flasks were quickly transferred to 
Eppendorf tubes and were centrifuged at 14000 g (Brinkman Instruments, Rexdale, 
ON, Canada) for 2 min to sediment the cells. An aliquot of the supernatant was 
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collected and stored at -20 ° C for the analysis of exported Hey. Hey was analyzed as 
described for plasma. 
2.11 Amino acid analysis: 
0.3 ml of plasma was deproteinized using 0.1 ml of ice-cold 10% (w/v) 
sulfosalicylic acid and the precipitated proteins were removed by centrifugation. 
The pH of the supernatant was adjusted to 2.2 with lithium citrate buffer. For the 
analysis of liver and muscle amino acids, a piece of the previously frozen tissue was 
ground to a fine powder in liquid nitrogen. 4 ml of 6% (w/v) HCl04 was added to 1 g 
of frozen powder and immediately homogenized with a motorized homogenizer. The 
samples were centrifuged at 18900 g for 20 minutes. To the resulting supernatant 
50% (w/v) K2C03, to a final concentration of 2.25% and 0.02 ml of universal 
indicator were added and the pH was brought to neutral with the drop-wise addition 
of 20% KOH. Aliquots of these neutralized samples were frozen at -20° C and the 
pH was adjusted to 2.2 with concentrated HCl on the day of amino acid analysis. 
These samples along with the plasma samples were analyzed on a Beckman model 
121-MB amino acid analyzer, using Benson D-X8, 0.25 cation Xchange resin and a 
single column 3 buffer lithium method as described in Beckman 121MB-TB-017 
application notes. The quantification of the results was done using a Hewlett 
Packard Computing Integrator Model 3395 A. 
98 
2.12 Calculation of intracellular concentrations of amino acids: 
The intracellular concentrations of amino acids (ICAA) m the liver were 
calculated using the following equation: 
Hepatic content of AA (nmoles/g) = {[plasma AA] nmoles/ml x ECF (mllg liver)} 
+ 
{[ICAA] nmoles/ml x ICF (ml/g liver)} 
The extracellular fluid volume (ECF) in the liver was taken as 0.25 ml/g while 
the intra- cellular fluid volume (ICF) was taken to be 0.45 ml/g liver, in accordance 
with previous studies from our laboratory (Qian and Brosnan 1998). The same 
equation was used to calculate the ICAA concentrations in skeletal muscle. The ECF 
volume was taken as 0.09 ml/g while the ICF volume was taken as 0.68 ml/g of 
skeletal muscle (Hundal et al. 1992). 
2.13 Isolated blood vessel assays 
2.13.1 Conditions for isometric tension measurements 
Rats were sacrificed by cervical dislocation. In preliminary studies, both 
aorta and mesenteric arteries were isolated and used in vascular function assays. 
Arteries were obtained from control-treated and RSG-treated rats on the same day 
(2 rats/day). Thoracic aorta and the intestines containing the mesenteric arterial 
arcade each were isolated quickly and then placed in ice-cold Krebs solution (pH 
7.4) consisting of 114 mM NaCI, 4.7 mM KCl, 0.8 mM KH2P04, 1.2 mM MgClz, 2.5 
mM CaClz, 11 mM D-glucose and 25 mM NaHC03 which was bubbled with 95% 02 
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15% C02 gas. With the aid of a light dissection microscope, surrounding fatty and 
loose connective tissues were cleaned from the aorta and second order mesenteric 
arteries. Two rings each ~ 2mm in length were cut from the lengths of the cleaned 
blood vessels. Mesenteric arterial rings were suspended between a micropositioner 
and a force transducer using a pair of tungsten wires (40 )..lm diameter) whereas 
aortic rings were suspended between two metal hooks (200 )..lm diameter) in a 
Mulvany- Halpern-style (Mulvaney, 1988) organ bath chamber (10 ml volume; 610 
Multi- Myograph system; J.P. trading, Copenhagen, Denmark) containing 95% 0 2-
5% C02 gas-bubbled Krebs solution at 37° C. Aortic rings set at a resting tension of 
20 mN and mesenteric arteries set at 1.5 mN were equilibrated for 1 h prior to 
obtaining data from the vascular function protocol. Drugs and compounds were 
added directly to the myograph chambers and changes to isometric tension were 
recorded on-line via a serial connection from the 610 myograph to a computer hard 
drive at a rate of 1 Hz. Software for data acquisition and analysis (Myodaq 
2.01/Myodata 2.02) were designed by J.P. Trading for use with the 610 Multi-
Myograph system. 
2.13.2 Vascular function protocol 
To assess viability and obtain an internal standard of contractile activity 
(isometric tension in mN) for individual blood vessels, arteries were first contracted 
with high concentration of KCl (120 mM). Following a washout period, cumulative 
concentration-contractile response relationships were obtained usmg the a-
adrenoreceptor agonist cirazoline (10 nM- 10 )..lM). Such relationships were used to 
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determine the concentrations of cirazoline to be used to produce contractions at 
submaximum values ( ~ 50-70% of Emax). To assess vascular smooth muscle 
relaxation activity, cumulative concentration-relaxation response relationships for 
acetylcholine (ACh; 10 nM - 10 J.tM), sodium nitroprusside (SNP; 10 nM-10 J.tM), 
bradykinin (10 nM-3J.tM), 2-furoyl-LIGRLO-amide (2fly; 10 nM-3J.tM), and 
arachidonic acid (AA; 10 nM-30J.tM) were obtained in each artery contracted 
submaximally with cirazoline (30-1 00 nM) in series. After each treatment in this 
series, the artery was washed with fresh Krebs solution until the recorded tensions 
returned to initial resting tension values followed by an additional 5 min in fresh 
Krebs solution before starting the next treatment. 
2.13.3 Relaxation inhibitor studies 
In 6 week old rats, the ACh-induced relaxation responses of contracted 
arteries were also tested after treatment for 15 min with NO synthases inhibitor L-
NAME (300 J.tM). In 12 and 18 week old rats, this L-NAME treatment was combined 
with various inhibitors including indomethacin (cylcooxygenases), apamin (small 
conductance Ca2+-activated K+ channels; SKca) and TRAM-34 (intermediate 
conductance Ca2+-activated K+ channel; IKca)· Following these treatments, the 
cumulative concentration-relaxation response to ACh was determined. 
2.13.4 Data analyses 
Values are represented by the mean ± standard error of the mean (error 
bars) unless otherwise indicated. N = number of rats (2 arteries per rat). Maximal 
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effect (Emax) of cirazoline is expressed as % of the contraction by 120 mM KCl. Emax 
for each vasodilator is expressed as % relaxation; 100% relaxation = complete 
reversal of cirazoline-induced contracted tone. For each compound, EC50 values 
were determined from the concentration-response relationship in individual arteries 
by intrapolation from the graph data. Potency is expressed by the negative 
logarithm of the ECso values for each compound. The data were analyzed separately 
within each age category. Student's unpaired t test was used to compare artery 
response of rat strains at 6 weeks of age. 2-way ANOV A were used to determine the 
effects of strain, treatment and interactions at 12 and 18 weeks of age and were 
followed by 1-way ANOVA with Newman-Keuls post hoc test for multiple 
comparisons of groups within each age category. A P of < 0.05 was taken to be a 
significant difference. 
2.14 Phospholipid metabolism 
These experiments were conducted using freeze clamped hepatic tissue by Dr. 
Rene Jacobs (University of Alberta). 
2.14.1 Cytosol and membrane preparation 
Livers were homogenized in 2 ml of buffer (50 mM Tris-HCL, pH 7.5, 150 
mM NaCl, 1mM DTT and 0.1 mM phenylmethylsulfonyl fluoride) with a mini-
polytron. Homogenization was followed by sonication for 30 sec. Samples were 
centrifuged at 99 K for 15 min and the supernatant (cytosol) was removed and the 
pellet (membranes) were resuspended in homogenization buffer. 
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2.14.2 CTP:phosphocholine cytidyltransferase 
CT activity was measured according to a method described previously (Choy 
et a!, 1977). Separated fractions (homogenate, cytosol and microsome) were 
incubated with 1 mM eHJ phosphocholine (20 !lCil!lmol), 1 mM CTP, 12 mM 
magnesium acetate, and 20 mM tris/succinate at 37 ° C for 15 min at a final volume 
of 0.1 ml (pH 6.4). The reactions were stopped by immersing the tubes in boiling 
H20 for 2 min. 20 111 of CDP-choline (50mg/ml) was added to the tubes as a carrier. 
CDP-choline produced was separated by thin layer chromatography with a solvent 
system of CH30H:0.6% NaCl:NH40H (50:50:5, v/v/v) for 30 min. The plates were 
sprayed with 0.1% 2,7-dichlorofluroesien and the CDP-choline band was visualized 
under ultraviolet light and scraped into vials. The radioactivity was determined 
using a liquid scintillation counter. 
2.14.3 Choline kinase 
Choline kinase activity was measured with mmor modifications to a 
previously described method (Ishidate and Nakazawa, 1992). Cytosols were 
incubated in a final volume of 100 111 reaction buffer containing 0.1 M Tris-HCl (pH 
8.75), 2 11M ATP, 15 mM MgCh, and 0.25 mM eHJ choline chloride (10.5 11Ci/ml) at 
37°C for 20 min. The phosphocholine produced was separated using a column filled 
with Bio-Rad AG1-X8 (200-400 mesh, OH- form) resin. 
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2.14.4 Phosphatidylethanolamine N-methyltransferase 
PEMT activity was measure using the method described by Ridgway and 
Vance (1992). Homogenates were incubated in a final volume of 100 1-11 reaction 
mixture containing 125 mM Tris-HCl (pH 9.2), 5 mM DTT, 1 mM Triton X-100, and 
0.4 mM PDME. The assay was initiated by the addition of [methyl-3H] SAM 
(21mCi/mmol) to a final concentration of 200 1-1M, and the tubes were transferred to 
a 37°C shaking water bath and incubated for 30 min. The assay was terminated by 
the addition of 2 ml of choloroform-methanol (2: 1 v/v). The samples were vortexed, 
centrifuged (2000 rpm, 10 min) and the upper (aqueous) phase discarded. The lower 
phase was washed 3x 2 ml with 0.5%NaCl:methanol:CHCh (50:50:4). 200 1-11 of 
lower phase was aliquoted into scintillation vials, dried down, and the radioactivity 
was counted. 
2.14.5 Phosphatidylethanolamine and phosphatidylcholine mass in liver and plasma 
0.01 mg of PE was added to 0.5 mg of liver homogenate or 100 1-11 of plasma as 
an internal standard. Samples were extracted as described by Folch et al (1957). 
Phospholipids were separated and quantified using an HPLC system equipped with 
a 4.8 x 100 mm silica column coupled to an evaporative light scattering detector. A 
mobile phase consisting of isopropyl alcohol/n-hexane/water run as a ternary 
gradient (58:40:8, v/v/v) in 10 min was followed by a stationary phase (52:40:8, 
v/v/v) for 35 min (Bergo et al, 2002) 
104 
2.15 Triacylglycerol 
Plasma and liver TG were measured by Adam Byrne. 
2.15.1 Extraction of lipid from liver 
50 mg of liver was homogenized in 2 ml of CHCh/methanol 2:1 using a Teflon 
homogenizer at 4°C. The homogenate was transferred to a glass tube and was mixed 
with 400 ~-tl of 50 mM NaCl and was kept at 4°C overnight to separate. The lower 
lipid-containing layer was transferred to a glass vial and was evaporated under 
nitrogen. 
2.15.2 Plasma and hepatic Triacylglycerol 
Lipids were extracted from the liver as stated above. 100 ~-tl of isopropanol 
was added to the extract and TG was quantified using a triglyceride assay kit # 
2150L101 from Stanbio laboratories, TX, USA. Plasma TG was measured using the 
same kit. 
2.16 Glomerular filtration rate 
Glomerular filtration rate (GFR) was measured by measuring the excretion 
and plasma level of creatinine. Therefore, 
GFR = Urinary concentration of creatinine (~-tmole/liter) x Urine flow (mllmin) 
Arterial plasma concentration of creatinine (~-tmoles/liter) 
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Chapter 3 
Homocysteine metabolism in ZDF (Type 2) diabetic rats 
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3.1 Background 
Patients with coronary, cerebrovascular or peripheral arterial disease have mean 
plasma tHey levels significantly higher than control subjects (Kang et al, 1992). Over the 
last decade, these findings led to the identification of HHcy as an independent risk factor 
for vascular disease (Kang et al, 1992). In addition, HHcy has also been identified as a 
risk factor for Alzheimer's disease (Seshadri et al, 2002) and osteoporotic fractures (van 
Meurs et al, 2004). 
Hey is formed after the donation of a methyl group from S-adenosylmethionine. It 
can then be metabolized by one of three enzymes. Methionine synthase and 
betaine:homocysteine methyltransferase (BHMT) catalyze the remethylation of Hey to 
methionine, and cystathionine ~-synthase (CBS) forms part of the transsulfuration 
pathway where Hey condenses with serine to form cystathionine. Figure 1.2 shows the 
pathway of methionine metabolism. 
Diabetes mellitus, whether Type 1 or Type 2, is associated with an increased risk 
of cardiovascular mortality, with the prevalence of atherosclerosis being 2-to 6-fold 
higher in diabetic patients than in people without diabetes (Brand et al, 1989). Insulin 
resistance, which precedes the development of Type 2 diabetes, is also associated with an 
increased risk of coronary artery disease (Rosolova et al, 2002). HHcy has been shown to 
be a stronger risk factor for cardiovascular disease and for mortality in patients with Type 
2 diabetes mellitus than in subjects without diabetes (Hoogeveen et al, 1998). 
Plasma tHey in diabetic patients is known to be dependent on the presence 
or absence of nephropathy. Both Type 1 and Type 2 diabetic patients with nephropathy 
have elevated levels of tHey (Hoogeveen et al, 1998, Hultberg et al, 1991). However, 
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Type 1 diabetic patients with no renal complications have plasma tHey levels lower than 
controls (Robillon et al, 1994). This decrease was also shown in an animal model of Type 
1 diabetes (Jacobs et al, 1998). 
We, therefore, examined the effect of insulin resistance and Type 2 diabetes on 
plasma tHey and its metabolism in the liver. We used the leptin-receptor defective Zucker 
Diabetic Fatty rat (ZDF), an excellent model for Type 2 diabetes (Peterson et al, 1990). 
Before developing frank diabetes, they go through a phase of insulin resistance, thereby 
giving us an opportunity to study the effects of both insulin resistance and of Type 2 
diabetes. 
3.2 Statistical Analysis: 
Data are presented as means± SD. Means were compared using Student's 
unpaired t test, or one way analysis of variance as appropriate. P <0.05 was taken to 
indicate a significant difference. Significant differences across the age groups are only 
reported for ZDF +/?rats as any age-related change in ZDF fa/fa rats will be confounded 
by the diabetes. 
3.3 Results 
Table 3.1 shows the body weight, hepato-somatic index, plasma insulin, creatinine 
and glucose concentrations. At 5 weeks, the concentrations ofplasma glucose (12.1 ± 1.7 
mmole/liter vs. 8.4 ± 1.3 mmole/liter) and insulin (8.8 ± 2.9 ng/ml vs. 0.83 ± 0.4 ng/ml) 
in the ZDF fa/fa and ZDF +/? rats, respectively, showed that the ZDF fa/fa rats had 
become insulin resistant. At 11 weeks, the concentrations of plasma glucose (30.3 ± 1.6 
mmole/liter vs. 10.9 ± 0.8 mmole/liter) and insulin (3.5 ± 0.8 ng/ml vs. 3.9 ± 0.6 ng/ml) 
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in the ZDF fa/fa and the ZDF +/? rats, respectively, showed that the ZDF fa/fa rats had 
become diabetic. Creatinine levels of ZDF fa/fa and control rats at 5 weeks were similar 
(32.4 ± 3.8 Jlmole/liter vs. 28.9 ± 3.1 Jlmole/liter), but at 11 weeks were lower in the ZDF 
fa/fa rats (18.9 ± 2.7 Jlmole/liter vs. 29.7 ± 6.1 Jlmole/liter) 
3.3.1 Plasma homocysteine and hepatic enzymes of homocysteine metabolism 
At 5 weeks, plasma tHey was about 25% lower in the ZDF fa/fa rats, while at 11 
weeks it was reduced by about 60% (Figure 3.1). The plasma tHey level in the ZDF +/? 
rats showed an increase with age. The reduced plasma tHey at 5 weeks in the ZDF fa/fa 
rats, was accompanied by changes in several enzymes that metabolize methionine (Table 
3.2). Of the enzymes responsible for producing Hey, MAT and GNMT showed slight, but 
significant, increases. Of the enzymes responsible for removing Hey, CBS, CGL and 
BHMT were increased respectively by about 54%, 18% and 36%. Methionine synthase 
showed a slight but significant decrease in the ZDF fa/fa rats. At 11 weeks, MAT, 
GNMT, CBS, CGL and BHMT all showed significant increases in activity. 
In addition to the differences in enzyme activity between the control and the 
experimental animals at each age group, MAT, CBS and GNMT all showed significant 
increases in their activity with age in the ZDF +/?rats. 
3.3.2 mRNA levels 
At 5 weeks the increased activity of CBS in the ZDF fa/fa rats was accompanied 
by a comparable increase in CBS mRNA level (Fig 3.2 A). The increased BHMT activity 
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Table 3.1. Body weight, plasma insulin, glucose and creatinine levels and the hepato-
somatic index of ZDF +/? and ZDF fa/fa rats at 5 and 11 weeks. 
5 weeks 11 weeks 
ZDF+/? ZDF fa/fa ZDF+I? ZDF fa/fa 
Body Weight (g) 134 ± 5 178 ± 7* 306 ± 11 348 ± 10* 
Insulin (ng/ml) 0.83 ± 0.4 8.8 ± 2.9* 3.9±0.6 3.5 ± 0.8 
Creatinine (f.lM) 28.9 ± 3.1 32.4 ± 3.8 29.7 ± 6.1 18.9 ± 2.7* 
Glucose (mM) 8.4 ± 1.3 12.1 ± 1.7* 11.0±0.8 30.3 ± 1.6* 
Hepato-Somatic Indexa 4± 0.1 4.5 ± 0.2* 3.8 ± 0.2 5. 1 ± 0.2* 
Data are given as means ± SD and were analyzed using Student's unpaired t test. * 
indicates P<0.05 when compared with lean controls (ZDF +/?) in each age group. n=6 for 
each group. a Liver (g) x 100/ body weight (g). 
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Figure 3.1. Plasma Homocysteine 
Values are expressed as J.Lmole/liter. Differences within each age group were compared 
using Student's unpaired t test. One way ANOVA followed by Newman-Keuls post-hoc 
test was used to compare the differences between the ages. Means ± SD for 6 rats are 
shown. At each age group differing letters indicate significant difference from each other. 
~ indicates significant difference in ZDF +/? rats at 11 weeks compared to 5 weeks. (P< 
0.05) 
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Table 3.2. Hepatic activities of enzymes of homocysteine metabolism 
5 weeks 11 weeks 
ZDF+/? ZDF fa/fa ZDF+I? ZDF fa/fa 
Methionine adenosyltransferase 124±4 131±6 323 ± 20 1 380 ± 11 
Glycine-N-methyltransferase 130 ± 14 160 ±4* 168 ± 201 220 ±20* 
Cystathionine ~-synthase 1000 ± 90 1540 ± 220* 1670± 270 1 2200 ± 370* 
Cystathionine y-lyase 4120 ± 500 4870 ± 520* 4380 ± 210 7550 ± 890* 
- Methylenetetrahydrofolate reductase 23 ±2 
-
24±2 22±4 22±4 w 
Methionine synthase 8±1 6 ± 0.4* 8±1 8±1 
Betaine:homocysteine methyltransferase 100± 8 157 ± 14* 92± 17 150 ± 18* 
Choline dehydrogenase 666 ± 131 700 ±145 527 ± 97 608 ± 108 
Data are given as means ± SD for six rats. Differences within each age group were compared using Student's unpaired t test. One way 
ANOV A followed by Newman-Keuls post-hoc test was used to compare the differences between the ages. In each group enzyme activities 
are expressed as nmoles of product synthesized per minute per gram liver. * signify significant differences within each age group. ~indicates 
significant difference in enzyme activity in ZDF +I? rats at 11 weeks compared to 5 weeks. (P< 0. 05) 
observed in the ZDF fa/fa rats at 5 and 11 weeks, were also accompanied by comparable 
increases in mRNA levels (Fig 3.2 B). 
3.3.3 S-adenosylmethionine, S-adenosylhomocysteine and SAM/SAH ratio 
The hepatic levels of SAM and SAH and the SAM/SAH ratio are shown in Table 
3.3. At both 5 and 11 weeks SAM was significantly increased in the ZDF fa/fa rats. The 
SAM/SAH ratio was significantly higher in the ZDF fa/fa rats at 5 weeks. Both SAM and 
the SAM/SAH ratio showed increases with age in ZDF +!? rats, consistent with the age-
related increase in MAT activity. 
3.3.4 Transsulfuration Flux 
In a preliminary study, we investigated the effect of betaine on the transsulfuration flux, 
as measured by the conversion ofL-[1_14C] methionine to 14C02 and 14C-a-ketobutyrate, 
by isolated hepatocytes from Sprague Dawley rats. All concentrations of betaine used 
(0.1, 0.3 or 1 mM) significantly reduced the catabolism of methionine, compared to 
incubations of hepatocytes with methionine alone (Figure 3.3). We then conducted 
studies with hepatocytes from ZDF rats, using 0.1mM L-[1-14C] methionine and 0.3 mM 
betaine. Incubation with 0.3 mM betaine significantly decreased the transsulfuration flux 
in hepatocytes of ZDF fa/fa rats at both ages, but the reduction seen in the hepatocytes of 
ZDF +/?rats was significant only at 11 weeks of age (Table 3.4). 
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Figure 3.2. mRNA abundance 
RT-PCR analysis of hepatic CBS mRNA (A) and BHMT mRNA (B). The relative 
amounts of each mRNA, measured by spot densitometry, are graphically represented. 
Both CBS and BHMT mRNA were normalized to f3-actin mRNA. Values are Means± 
SD for six rats. Differing letters at each age group indicate significant difference from 
each other. P<O.OS 
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Table 3.3 Hepatic SAM, SAH and SAM/SAH ratio. 
5 weeks 11 weeks 
ZDF +/? ZDF fa/fa ZDF +/? ZDF fa/fa 
SAM 88 ± 8.4 142.1 ± 11.3* 172.9 ± 0.0~ 199.9 ± 15.5* 
SAH 12.3 ± 1.2 11.6 ± 1.3 11.9 ± 2.3 11.7±2.2 
SAM:SAH 7.2 ± 0.7 12.3 ± 2.0 * 15.1 ± 4.7~ 17.5±3.5 
Values for SAM and SAH are expressed as nmoles/g liver. Means ± SD for six rats in 
each group are shown. Differences within each age group were compared using Student's 
unpaired t test. One way ANOVA followed by Newman-Keuls post-hoc test was used to 
compare the differences between the ages. At each age group, * indicates significant 
difference from the ZDF +/? rats. ~ indicates significant difference in ZDF +/? rats at 11 
weeks compared to 5 weeks. (P< 0.05) 
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Figure 3.3. Effect of betaine on transsulfuration flux from isolated hepatocytes. 
Hepatocytes were incubated with 0.1 mM L [1- 14 C] methionine alone or with 0.1, 0.3 
and 1 mM betaine. * indicates a significant difference from the result with no betaine. 
Means± SD for 3 rats are shown (P<0.05). 
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Table 3.4 
Transsulfuration flux in isolated hepatocytes. 
Transsulfuration Flux (nmoles/mg of dry weight/30 min) 
5 weeks 11 weeks 
ZDF+/? ZDF fa/fa ZDF+/? ZDF fa/fa 
L- [1_14C] Methionine 1.00 ± 0.25 1.08 ± 0.05 1.18±0.21 1.08±0.15 
L- [1-14C] Methionine 0.91 ± 0.32 0.87 ± 0.12* 0.96 ± 0.15* 0.86 ± 0.13* 
+Betaine 
Hepatocytes were incubated with 0.1 mM L- [1_14C] methionine ± 0.3 mM betaine to 
determine the transsulfuration flux. Data are means± SD. n = 3 for 5 weeks and n = 5 for 
11 weeks. * indicates a significant difference from the corresponding incubations without 
betaine (P<0.05). 
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3.3.5 Hey Export 
Hepatocytes from ZDF fa/fa and ZDF +!? rats, at both ages, showed a significant 
reduction in Hey export when incubated with 0.3 mM betaine (Table 3.5). However, at 
both ages the decrease observed in the ZDF fa/fa rats was about 2-fold greater than that of 
the ZDF +!? rats. 
3.3.6 Choline and related metabolites 
Table 3.6 shows the liver concentrations of choline and related metabolites. The 
liver betaine concentration was lower in the ZDF fa/fa rats at both 5 and 11 weeks while 
there was no difference in the choline concentration. One of the most remarkable findings 
was the high level of betaine found in the liver of the young animals and the reduction 
that occurs with age. Hepatic glycerophosphorylcholine (GPC) was significantly higher in 
the ZDF fa/fa rats at 5 weeks though at 11 weeks it was significantly lower. 
Phosphoryl choline (PCho) was significantly higher in the ZDF fa/fa rats at both ages. 
Both GPC and PCho levels increased with age in the ZDF +/? rats. Phosphatidylcholine 
was significantly decreased in ZDF fa/fa rats at 11 weeks while sphingomyelin was 
significantly reduced at both 5 and 11 weeks. 
Table 3.7 shows choline and related metabolite concentrations in the plasma. The 
only significant difference in plasma metabolites between the different rats was an 
increased phosphatidylcholine level in the ZDF fa/fa rats at 11 weeks. However, the 
plasma betaine concentration showed a decrease with age in ZDF +/? rats. 
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Table 3.5 
Homocysteine export from isolated hepatocytes. 
Homocysteine export (nmoles/mg dry weight/30 min) 
Methionine 
Methionine + Betaine 
5 weeks 
ZDF+I? ZDF fa/fa 
1.17 ± 0.23 1.21 ± 0.25 
0.86 ± 0.12* 0.52 ± 0.08* 
11 weeks 
ZDF+I? ZDF fa/fa 
1.64 ± 0.61 2.03 ± 0.92 
0.89 ± 0.45* 0.32 ± 0.26* 
Hey export was measured in hepatocytes incubated with 0.1 mM methionine ± 0.3 mM 
betaine. Data are means ± SD. n = 3 for 5 weeks and n = 5 for 11 weeks. * indicates a 
significant difference from corresponding incubations without betaine (P<0.05). 
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Table 3.6 
Choline and related metabolite concentrations in the liver of ZDF +/? and ZDF fa/fa 
rats aged 5 and 11 weeks. 
Metabolite 5 weeks 11 weeks 
ZDF +/? ZDF fa/fa ZDF +/? ZDffalfa 
Betaine 17.6±3.6 9.9 ± 1.4* 5.3 ± 0.7~ 2.5 ± 0.7* 
Choline 0.06 ± 0.03 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 
Glycerophosphorylcholine 0.6 ± 0.04 1.0±0.2 * 1.5 ± 0.1~ 1.0 ± 0.1 * 
Phosphoryl choline 1.2 ± 0.27 2.1 ± 0.3* 1.9 ± 0.3~ 2.9± 0.9 * 
Phosphatidylcholine 28.1 ± 2.8 29.2 ± 1.4 25.3 ± 5.2 19.3 ± 2.0 * 
Sphingomyelin 3.3 ± 0.3 2.9± 0.2* 3.4 ± 0.4 2.8 ±0.3* 
The data are expressed as means± SD ()lmol/g) for six rats. Differences within each age 
group were compared using Student's unpaired t test. One way ANOV A followed by 
Newman-Keuls post-hoc test was used to compare the differences between the ages. At 
each age group, * indicates significant difference from the ZDF +/? rats. ~ indicates 
significant difference in ZDF +/?rats at 11 weeks compared to 5 weeks. (P< 0.05) 
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Table 3.7 
Choline and related metabolite concentrations in the plasma of ZDF +I? rats and 
ZDF fa/fa rats at 5 and 11 weeks of age. 
Metabolite 
Betaine 
Choline 
Phosphatidylcholine 
5 weeks 
ZDF +/? 
0.17 ± 0.04 
0.08 ± 0.02 
0.86 ±0.27 
ZDF fa/fa 
0.17 ± 0.02 
0.08 ± 0.03 
0.95 ± 0.23 
11 weeks 
ZDF+/? 
0.12 ± 0.03~ 
0.07 ± 0.01 
0.80 ± 0.29 
ZDffa/fa 
0.09 ± 0.03 
0.08 ± 0.02 
1.69 ± 0.48* 
Data are expressed as means ± SD (J..Lmol/ml) for six rats. Differences within each age 
group were compared using Student's unpaired t test. One way ANOVA followed by 
Newman-Keuls post-hoc test was used to compare the differences between the ages. At 
each age group, * indicates significant difference from the ZDF +/? rats. ~ indicates 
significant difference in ZDF +/?rats at 11 weeks compared to 5 weeks. {P< 0.05). 
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3.4 Discussion 
This study describes the altered metabolism of methionine and Hey that occurs in 
insulin resistance and in early Type 2 diabetes. It is clear that the hormonal changes that 
are prevalent in these two disease states act at several sites in the pathway of methionine 
metabolism. Hyperphagia in the diabetic rats may also contribute to these metabolic 
changes. Indeed, we observed a 2-fold increase in food intake per lOOg body weight at 
the diabetic stage. However, there was no difference at 5 weeks. The increased hepatic 
CBS and BHMT activity at 5 weeks cannot, therefore, be attributed to increased protein 
intake. In addition, we have shown a direct effect of insulin in repressing CBS expression 
in both human and rat cultured hepatocytes (Ratnam et a!, 2002). Our finding of lowered 
plasma tHey in the 5 week ZDF fa/fa rats shows that insulin-resistance alone can decrease 
plasma tHey levels. 
The most striking finding in the present study concerns the role of betaine and 
BHMT in determining plasma tHey. Not only were BHMT activity and mRNA levels 
elevated but the hepatic betaine concentration was remarkably reduced in the diabetic 
rats. Furthermore, this increased BHMT was clearly effective in decreasing hepatic Hey 
output. This is evident from the data showing that addition of betaine to hepatocytes from 
ZDF fa/fa rats virtually eliminated Hey export from cells, compared to a lesser effect in 
hepatocytes from ZDF +/? rats (Table 3.4). Increased remethylation of Hey by BHMT 
also reduced the Hey available for flux through the transsulfuration pathway, which 
decreased in these cells (Table 3.3). Although the importance of the BHMT-catalyzed 
remethylation reaction in determining Hey levels has not received as much attention as 
the folate-dependent remethylation pathway, it should be recalled that Schwahn et a! 
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(2003) found a highly significant negative correlation between plasma betaine and plasma 
tHey concentrations in humans. Supplementation with betaine was shown to lower 
plasma tHey in humans (Steenge et al, 2003) and in mthfr +/+, +/- and-/- mice (Schwahn 
et al, 2003). Because of the elevated BHMT activity, betaine may be particularly 
efficacious in reducing plasma tHey in the later stages of Type 2 diabetes, when renal 
complications bring about HHcy. 
Our data suggest that there is enhanced utilization of betaine in the ZDf fa/fa rat. 
The observed decrease in hepatic phosphatidylcholine concentration (Table 3.6) is 
consistent with enhanced utilization of choline to form betaine in the livers of these rats. 
Sphingomyelin, which is derived from phosphatidylcholine, is also reduced in fa/fa 
liver. The increase in phosphorylcholine concentrations may reflect increased activity of 
the pathway for phosphatidylcholine biosynthesis that occurs when tissue 
phosphatidylcholine concentrations fall. The significant mcrease in plasma 
phosphatidylcholine concentrations in ZDF fa/fa rats at 11 weeks (Table 3.6) probably 
reflects increased secretion of lipoproteins from liver. 
Another remarkable feature of betaine metabolism is the extraordinarily high 
hepatic betaine concentration found in young rats. In the control animals (ZDF +/?) the 
hepatic betaine level was 17.6 !lmol/g at 5 weeks; this decreased to 5.3 !lmol/g at 11 
weeks. Assuming that hepatic betaine is evenly distributed in intracellular water and that 
rat liver contains 0.45 ml of cell water per gram (Qian and Brosnan, 1996), we can 
calculate a betaine concentration, in the 5 week-old control animals, of 39 mM. This 
should be compared with total osmolarity of about 305-310 mOsM in mammalian tissues 
(except for the renal medulla). 
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Davies et al (1988) have reported a very large urinary excretion of betaine in 
normal neonates and in young rats after weaning. High betaine concentrations are found 
in mammalian kidneys, particularly in the renal medulla. Renal betaine has been 
characterized as a "compatible osmolyte" (together with other trimethylamines and 
polyols) where it can offset the high extracellular osmolarity that arises as a result of the 
urinary concentrating mechanisms. In addition, these osmolytes may protect these cells 
from adverse effects ofurea, which is present at high concentrations (Becket al, 1998). 
Wettstein et a! (2000) have shown that betaine plays a role in cell volume 
homeostasis in perfused livers of adult rats. Whether this is also the function of the high 
betaine concentrations in neonatal liver is a focus of our current work. We must also 
comment on the ratio of hepatocellular to plasma betaine. Plasma betaine was fairly 
constant, in the 90 ).!M to 170 ).!M range, in all of the rats (Table 3.6). The liver/plasma 
concentration ratios for betaine were about 230, 130, 100 and 60, respectively, for ZDF 
+/? and ZDF fa/fa rats at 5 weeks and at 11 weeks of age. How such gradients are 
produced and maintained are important issues for future work. 
Diabetes is characterized not only by the lack of insulin or the resistance to the 
action of insulin, but also by increases in the counter-regulatory hormones, 
glucocorticoids and glucagon (Stubbs and York, 1991, Consoli et al, 1990). Hepatic MAT 
activity has been shown to be increased by glucocorticoid administration (Gil et al, 1997). 
Finkelstein et al (1971) examined the effects of administration of a number of hormones 
on BHMT activity. The principal findings were that hydrocortisone increased BHMT 
activity whereas thyroxin decreased it. This group also demonstrated increased activity in 
alloxan-diabetic rats. This latter finding has been confirmed by Nieman et al (2004) in 
127 
streptozotocin-diabetic rats. We are currently exploring the possibility that insulin may 
regulate BHMT expression. Insulin treatment of streptozotocin-induced diabetic rats was 
shown to restore the increased activity of CBS to normal levels (Jacobs et al, 1998), by 
acting at the level of CBS gene transcription to repress CBS promoter activity (Ratnam et 
al, 2002). Cyclic AMP, the intracellular messenger of glucagon, and glucocorticoids, 
increases CBS expression in rat hepatoma cells (Goss, 1986). The increased activity of 
CBS, brought about both by allosteric activation by the increased hepatic SAM levels 
(Finkelstein et al, 1975) and by increased expression, does not imply an increased 
transsulfuration flux. This flux is determined by the rate at which methionine enters into 
hepatic metabolism which will be largely determined by dietary methionine consumption. 
It seems that the major effect of increased CBS activity is to decrease the steady state Hey 
concentration at which transsulfuration occurs (Reed et a!, 2004). In this way it 
contributes to the decreased plasma tHey concentration. Similarly, the increased activity 
of BHMT does not necessarily imply an increased remethylation flux in vivo but, rather, 
it decreases the steady state Hey concentration at which remethylation via BHMT occurs. 
It is also possible that alterations in renal function may contribute, somewhat, 
to the decreased plasma tHey, at least when the rats are diabetic. The kidney is a major 
site for the removal and subsequent metabolism of Hey (Bostom et a!, 1995 A). 
Hyperfiltration is a characteristic sign of renal dysfunction in early diabetes (Thomson et 
a!, 2004). Such hyperfiltration has been reported to occur in ZDF fa/fa rats from about 7 
weeks of age and to continue until they are about 3 months old (Hoshi et al, 2002). Such 
an occurrence probably accounts for the decreased plasma creatinine seen at 11 weeks. 
The delivery of an increased quantity of Hey to the kidney via filtration could result in 
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increased renal catabolism of Hey and contribute to its reduced plasma concentration. 
However, this cannot contribute to the decreased Hey at the insulin-resistant stage where 
creatinine levels were unchanged. 
It is now clear that plasma tHey levels decrease in both Type 1 and Type 2 
diabetes when there is no renal damage. The present work showed that this is true even at 
the pre-diabetic, insulin-resistant stage. However, literature reports on the phenomenon 
show a variety of responses of Hey to insulin resistance (Rosol ova et al, 2002, Meigs et 
a!, 2001, Abbasi et al, 1999). This variability is likely to result from different degrees of 
insulin resistance as well as other factors such as impaired renal function. Our results at 5 
weeks were obtained in an animal model in which there was no evidence of impaired 
renal function as well as a consistent degree of insulin resistance, agree remarkably well 
with Rosolova's study of the relationship between Hey and insulin resistance in healthy 
human subjects (Rosolova et al, 2002). 
In summary, this study shows a decreased plasma tHey level in both insulin-
resistant and Type 2 diabetic rats. We show increased activities of BHMT and CBS in 
these states, as well as increased mRNA levels for these enzymes. We also show 
increased hepatic SAM levels, which will activate CBS. We report experiments in 
hepatocytes that directly demonstrate the role of betaine metabolism in enhanced Hey 
removal. These results emphasize the importance of BHMT in regulating Hey 
metabolism. 
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Chapter 4 
Amino Acid Metabolism in the Zucker Diabetic Fatty Rat: Effects of Insulin 
Resistance and of Type 2 Diabetes 
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4.1 Introduction 
The pathophysiology of Type 2 diabetes involves defects in three organ systems 
(Saltiel 2000). Metabolic defects in liver, in peripheral target tissues such as adipose 
tissues and skeletal muscle and in pancreatic P-cells all play major roles in the 
development of this disease. Higher than normal levels of circulating insulin are common, 
indicating that insulin resistance, rather than an absolute lack of insulin, is a major 
feature. The hormonal changes in diabetes, whether due to a lack of insulin (Type 1) or a 
resistance to insulin action (Type 2), and the subsequent changes in the counter-
regulatory hormones not only lead to the well-characterized derangements in glucose and 
lipid metabolism but also to changes in protein metabolism. Withdrawal of insulin 
treatment in patients with Type 2 diabetes has been shown to be associated with increased 
plasma levels of branched-chain amino acids (BCAA), increased urinary N loss and 
increased whole body protein turnover (Halvatsiotis et al. 2002). Bloxam et al (1972) 
reported on plasma and liver amino acids in streptozotocin-diabetic rats. The 
concentrations of many plasma amino acids were reduced whereas there was an increase 
in the level of BCAA. They also found increased levels of BCAA and proline in the liver 
of these rats. These findings were confirmed in our laboratory. Brosnan et al (1980) and 
Brosnan et al (1983) also observed a reduction in gluconeogenic amino acids in the 
plasma and liver of streptozotocin-diabetic rats. They found a decreased concentration of 
histidine and increased levels of proline, valine, isoleucine and leucine in muscles. The 
brain had an increase in the BCAA with reduced concentrations of a number of other 
amino acids. 
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In contrast to the wealth of knowledge concerning the free amino acids in Type 1 
diabetes, data on Type 2 diabetes are lacking. Several studies have shown increased 
urinary N loss and net whole body protein loss in Type 2 diabetic patients, even when 
hyperinsulinemic (Gougeon eta!. 1994; 1997; 1998). Halvatsiotis eta!. (2002) found no 
difference in plasma amino acid concentrations between Type 2 diabetic patients from 
whom insulin treatment was withdrawn transiently and patients who were given intensive 
insulin treatment for 11 days, except for a reduction in the glycine levels in the untreated 
patients. 
The leptin receptor-defective Zucker diabetic fatty (ZDF fa/fa) rat is considered to 
be an excellent model for the study of Type 2 diabetes (Peterson eta!. 1990; Unger 1997). 
In this model, diabetes develops, spontaneously, in all male rats and most females. The 
rats proceed from impaired glucose tolerance, through insulin resistance (normoglycemia, 
hyperinsulinemia) to frank Type 2 diabetes (Etgan and Oldham 2000) Diabetes in these 
rats is associated with the usual clinical symptoms of hyperphagia, polyuria, polydypsia, 
and impaired weight gain (Finegood eta!. 2001). We, therefore, employed ZDF rats to 
explore amino acid metabolism both in the pre-diabetic insulin- resistant stage and in 
frank Type 2 diabetes. 
4.2 Results: 
Table 3.1 provides data on body weight, plasma insulin, creatinine and glucose 
concentrations and the hepato-somatic index. At 5 weeks of age the ZDF fa/fa rats had a 
ten-fold elevation of plasma insulin compared to the ZDF +/? controls. Despite the 
hyperinsulinemia, plasma glucose levels were already significantly elevated in the ZDF 
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fa/fa rats, clearly demonstrating insulin resistance. By 11 weeks, plasma glucose was 
about 30 mM in the ZDF fa/fa rats while insulin levels had fallen and were no longer 
different from the controls. Therefore, at 5 weeks the ZDF fa/fa rats can be classified as 
insulin-resistant, but not diabetic. At 11 weeks, the similar insulin levels, together with 
the profound hyperglycemia indicate that they are frankly diabetic in addition to showing 
a resistance to the action of insulin. 
Plasma creatinine levels were measured in the rats so as to determine whether 
there was any indication of renal insufficiency. Although there was no significant 
difference between the creatinine levels of ZDF fa/fa and control rats at 5 weeks, there 
was a reduction in the plasma creatinine level of the ZDF fa/fa rats at 11 weeks. Hoshi et 
al (2002) have reported that the GFR is significantly elevated at 3 months in ZDF fa/fa 
rats and this may provide an explanation for the reduced plasma creatinine levels in our 
animals. The hepato-somatic index was significantly higher in the ZDF fa/fa rats at both 5 
and 11 weeks of age, indicating a relative increase in liver weight. 
4.2.1 Plasma amino acid concentration: 
Plasma amino acid concentrations are shown in Table 4.1. The plasma amino acid 
concentrations in the control group (ZDF +/?) were similar to those reported by Brosnan 
et al (1983) in non-diabetic animals. At 5 weeks of age, aspartate, serine, glutamine, 
glycine and histidine (all gluconeogenic amino acids) were lower in the plasma of ZDF 
fa/fa rats. Taurine, a-amino adipic acid, methionine, isoleucine, leucine, valine, 
phenylalanine, and tryptophan were significantly higher in the plasma. At 11 weeks of 
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Table 4.1: Plasma amino acid concentrations (J.lmole/liter) 
5 weeks 11 weeks 
Amino Acid 
ZDF+/? ZDF fa/fa ZDF+/? ZDF fa/fa 
Taurine 66±6 133 ± 10* 136±9 147 ± 21 
Aspartic Acid 22 ±2 18±2* 15 ± 1 15 ±2 
Hydroxy proline 55± 10 48±5 44±2 24 ±3* 
Threonine 219 ± 23 220±23 272± 59 137 ± 15* 
Serine 187 ± 19 135±9* 180±9 122 ± 9* 
Asparagine 33 ± 5 31 ±4 40±4 27 ±2 * 
Glutamic acid 60±7 64±7 97±7 134±22* 
Glutamine 556 ± 12 411 ± 14* 601 ±53 354 ± 26* 
a- amino adipic acid 16 ±I 22±3* 18 ± 1 24±3* 
Proline 174 ± 34 211 ± 26 190±20 166 ± 8* 
Glycine 289 ± 20 142 ± 18* 240± 15 109±11* 
...... Alanine 374 ± 37 396±44 425 ±44 449 ±61 
w 
..j:::.. Citrulline 61 ± 6 58±4 60±7 47±4* 
Valine 105 ± II 190 ± 29* 162 ± 15 263 ± 34* 
Cystine BLD BLD 4±0.2 4±0.3 
Methionine 28 ± 3 35 ±3* 54±3 40±4* 
Isoleucine 49±5 90± 16* 79± 10 116 ± 18* 
Leucine 80 ± 8 150 ± 26* 134± 16 202 ±42* 
Tyrosine 70 ± 11 67±7 115 ± 13 75 ± 12* 
Phenylalanine 34±3 53 ±7* 59± 5 65 ± 10 
Tryptophan 60± 8 75 ±9* 117 ± 9 82 ± 10* 
Ornithine 53± 27 56±9 62 ± 14 63 ±21 
Lysine 270±24 276±20 341 ± 20 250 ± 22* 
Histidine 53 ±3 46±4* 55 ±4 41 ±3* 
Arginine 97±24 116±21 136 ± 13 91 ± 13* 
TOTAL 3011 ± 206 3040±218 3634 ±195 3047 ± 196* 
Values are means± SD. * P< 0.05 when compared with lean controls (ZDF +/?)in each age group. BLD: Below the limits of 
detection by our system. n=6 for each group 
age, diabetic rats had a significantly lower plasma concentration of hydroxyproline, 
threonine, serine, aspartate, glutamine, proline, glycine, citrulline, methionine, tyrosine, 
tryptophan, lysine, histidine and arginine and significantly elevated concentrations of 
glutamic acid, a-amino adipic acid and the 3 BCAAs. 
4.2.2 Hepatic amino acids: 
The amino acid levels in the liver are shown in Table 4.2. At 5 weeks the livers of 
ZDF fa/fa rats showed lower levels of serine, asparagine, glutamic acid and glutamine 
with increased levels of taurine and proline. At 11 weeks diabetic rats showed lower 
levels of threonine, serine, glutamine, and glycine and increased levels of glutamic acid, 
valine and leucine. 
Hepatic/plasma concentration ratios for amino acids are shown in Table 4.3. The 
ratios for aspartate and glycine were increased at 5 weeks of age in the ZDF fa/fa rats 
while the ratios for glutamic acid, isoleucine, leucine and phenylalanine were decreased. 
At 11 weeks proline, glycine, methionine and tyrosine showed an increased ratio in the 
diabetic rats while the rest of the amino acids showed no difference. 
4.2.3 Skeletal muscle amino acids: 
The amino acid levels in the skeletal muscle are shown in Table 4.4. Levels of 
taurine, aspartate, proline, alanine, isoleucine and leucine were all higher in skeletal 
muscles while many of the gluconeogenic amino acids were significantly lower in the 
ZDF fa/fa rats, at 5 weeks of age. Concentrations of lysine, anserine and carnosine were 
also lower. At 11 weeks of age, tyrosine and lysine together with all the 
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Table 4.2: Hepatic amino acid levels (nmole/g) 
5 weeks II weeks 
Amino Acid 
ZDF+/? ZDF fa/fa ZDF+/? ZDF fa/fa 
Taurine 1243 ± 231 2146±616* 3422 ± 1233 2808 ± 849 
Aspartic Acid 1324 ± 529 1596±464 2829 ± 811 2225 ± 347 
Threonine 409 ± 108 320 ± 81 276 ±56 170 ± 32* 
Serine 760 ± 194 433 ± 86* 285 ± 34 213 ± 33* 
Asparagine 70± 17 46 ± 13* 67±28 50± 12 
Glutamic acid 1324 ± 298 950 ± 240* 1297 ± 345 2498 ± 556* 
Glutamine 3916 ± 891 2651 ± 381 * 4932 ± 1277 3496 ± 738* 
Proline 270 ± 61 382 ± 85* 591 ±171 867 ± 269 
Glycine 1430 ± 432 1366 ± 272 1848 ± 219 1539 ± 240* 
Alanine 1359 ± 262 1522 ± 387 2199 ± 658 3001 ± 1470 
........ Citrulline 53± 24 29± 14 55 ±48 16 ± 13 
w Valine 121 ±47 139±34 163 ± 37 293 ± 36* 0'1 
Cystine 3±3 1±2 59± 13 73 ± 25 
Methionine 39±9 36±9 94± 18 97 ± 21 
Isoleucine 77 ± 19 88 ± 16 105 ± 20 159 ±57 
Leucine 115 ± 38 143 ± 24 168 ± 31 249 ±44* 
Tyrosine 56±23 38 ±9 69±28 66± lO 
Phenylalanine 43 ± 13 40± 14 70± 18 67± 13 
Ornithine 142 ± 43 103 ± 25 154 ± 37 139 ± 23 
Lysine 378 ± 106 393 ± 68 525 ± 168 495 ± 143 
Histidine 412 ± 88 384 ± 79 506 ± 114 497 ± 123 
Arginine 30± 19 23±9 80±25 53 ±22 
TOTAL 13574 ±2989 12832 ± 2391 19794 ±3814 19071 ±4013 
Values are means± SD. * P< 0.05 when compared with lean controls (ZDF +/?)in each age group. n=6 for each group. 
Table 4.3: Intracellular/extracellular concentration ratios for hepatic amino acids 
5 weeks II weeks 
Amino Acid 
ZDF+/? ZDF fa/fa ZDF +/? ZDF fa/fa 
Taurine 42 ± 10 36 ±II 57±24 41±9.4 
Aspartic Acid 130 ±51 197 ±46* 412± Ill 347 ± 80 
Threonine 3.7 ± 1.3 2.6 ± 0.6 1.8 ± 0.7 2.2 ± 0.4 
Serine 8.5 ± 2.4 6.6 ± 1.2 3.0 ± 0.5 3.3 ± 0.4 
Asparagine 4.4 ± 1.8 2.7 ± 0.8 3.2 ± 1.6 3.5±0.8 
Glutamic acid 50± 14 32 ± 5.0* 29 ± 8.4 42± 12 
Glutamine 15 ± 3.5 14 ± 2.0 18 ± 4.4 22 ± 5.7 
Proline 3.0 ± 1.2 3.5 ± 0.5 6.5 ±2.4 11 ± 3.5* 
Glycine 10±3.3 21 ± 3.2* 17 ± 2.7 31 ±7.1* 
....... Alanine 7.6 ± 1.5 7.9 ± 1.5 11 ± 2.7 14 ± 5.7 (J.) 
-....) Citrulline 1.3 ± 0.8 0.6 ±0.6 1.4±1.5 0.2±0.6 
Valine 2.0 ± 1.0 1.1 ± 0.3 1.7 ± 0.5 1.9 ± 0.4 
Cystine 30 ± 6.1 40± 13 
Methionine 2.7 ± 0.8 1.9 ± 0.7 3.3 ± 0.6 4.9 ± 1.4* 
Isoleucine 2.9 ± 0.8 1.6 ± 0.4* 2.4 ± 0.5 2.5 ± 1.1 
Leucine 2.6±0.8 1.6 ± 0.3* 2.2 ±0.5 2.2±0.6 
Tyrosine 1.2 ± 0.6 0.7 ± 0.3 0.8±0.5 1.4 ± 0.3* 
Phenylalanine 2.3 ± 0.6 1.1 ± 0.6* 2.1 ±0.7 1.8 ± 0.6 
Ornithine 6.2 ± 3.0 3.8 ± 1.4 5.2 ± 1.8 4.6 ± l.l 
Lysine 2.6 ± l.l 2.5 ± 0.4 2.9 ± 1.0 3.9 ± 1.3 
Histidine 16.6 ± 3.5 18 ± 2.5 20± 5.0 26±6.7 
Arginine 0.2 ± 0.5 -0.1 ± 0.2 0.8 ±0.4 0.8 ±0.8 
Values are means± SD. * P< 0.05 when compared with lean controls (ZDF +/?)in each age group.- could not be calculated 
from available data. n=6 for each group. 
gluconeogenic amino acids that were lower at 5 weeks showed reduced concentrations in 
skeletal muscles of diabetic rats while the level of alanine, valine and leucine were 
significantly elevated. 
Intracellular/extracellular ratios for muscle amino acids are shown in Table 4.5. At 
5 weeks of age, the ratios for taurine, threonine, serine, glutamine, citrulline, valine, 
ornithine, lysine, histidine and arginine were decreased in the ZDF fa/fa rats while those 
for aspartate and alanine were increased. At 11 weeks, glycine and alanine showed an 
increase in the ratio of intracellular/ extracellular concentration. The rest of the amino 
acid ratios did not show any significant difference. 
4.2.4 Branched-Chain Amino Acids: 
Figure 1 shows the excellent correlation of the plasma level of the BCAAs to one another. 
The plasma concentrations of these three amino acids change in parallel. This is to be 
expected as they share a common transaminase (the branched-chain aminotransferase) 
followed by a common a-keto acid dehydrogenase (the branched-chain a-ketoacid 
dehydrogenase complex). These close relationships among the three BCAAs are similar 
to those previously found, in this laboratory, in streptozotocin-diabetic rats (Brosnan et al, 
1983). 
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Table 4.4: Skeletal muscle amino acid levels (nmole/g) 
5 weeks 11 weeks 
Amino Acid ZDF+/? ZDF fa/fa ZDF+/? ZDF fa/fa 
Taurine 8987 ± 256 14115 ± 1015* 12557 ± 732 13702 ± 2227 
Aspartic Acid 375 ± 25 560 ± 87* 615 ± 175 752 ± 258 
Hydroxy proline 306 ± 39 302 ±53 259±46 225 ± 99 
Threonine 743 ±60 590 ± 46* 602± 86 374 ± 103* 
Serine 917± 119 543 ± 70* 641 ± 81 466 ± 139* 
Asparagine 137 ± 29 94± 30* 150 ± 22 99 ± 32* 
Glutamic acid 1637 ±56 1661 ± 145 1438 ± 188 1497 ± 503 
Glutamine 4546 ± 125 3026 ± 268* 3517 ± 547 2152 ± 612* 
Proline 421 ±50 523 ± 42* 388 ± 76 475±151 
Glycine 6073 ± 375 2798 ± 354* 4731 ±797 3282 ± 926* 
Alanine 1460± 112 2036 ± 181 * 1509 ± 239 3351 ± 891 * 
-
Citrulline 262 ± 18 204 ± 33* 182 ± 18 170 ± 76 
w Valine 129 ± 36 168 ± 25 142 ± 24 264±90* \0 
Cystine BLD BLD 36±4 32±6 
Methionine 14± 10 31± 17 85 ± 16 66±22 
Isoleucine 40± 13 72 ± 8.8* 74±23 105 ±43 
Leucine 57± 11 103 ± 18* Ill ±21 167 ±53* 
Tyrosine 112 ± 15 103 ± 21 170 ±46 Ill± 36* 
Phenylalanine BLD BLD 70± 17 72± 28 
Ornithine 122 ± 15 108 ± 12 83 ± 11 76 ± 18 
Lysine 1850±74 1201 ± 98* 1501 ± 269 935 ± 257* 
Histidine 256 ± 25 160 ± 16* 141 ± 26 97±42 
Anserine 1559 ± 160 1247 ± 114* 5181 ± 599 5285 ± 1595 
Carnosine 3316±126 2970± 122* 4425 ± 598 4492 ± 1146 
Arginine 706±76 604±64* 744± 137 542 ± 149* 
TOTAL 34473 ±587 33579 ± 1958 39352 ±4099 38791 ± 9135 
Values are means± SD. * P< 0.05 when compared with lean controls (ZDF +/?)in each age group. BLD: Below the limits of 
detection by our system. n=6 in each group. 
Table 4.5: Intracellular/extracellular concentration ratios for skeletal muscle amino acids 
5 weeks 11 weeks 
Amino Acid 
ZDF+/? ZDF fa/fa ZDF +/? ZDF fa/fa 
Taurine 203 ± 23 157 ± 20* 137 ± 15 140 ± 36 
Aspartic acid 24±2 46±7* 59± 16 78±32 
Hydroxy proline 8±2 9±2 9±1 14±6.2 
Threonine 5 ±0.4 4±0.04* 3 ± l 4±1 
Serine 7±1 6 ± 1* 5 ± 1 6±2 
Asparagine 6 ± 1 4±2 5 ± 1 5±2 
Glutamic acid 41 ±6 38±4 21 ±4 16 ± 5 
Glutamine 12 ± 1 11 ± 1* 9±2 9±2 
Proline 4±0.4 4± 0.4 3±1 4±1 
Glycine 31 ±3 29±3 29±5 44 ± 12* 
....... Alanine 6±0.4 8 ± 1* 5 ± 1 11 ± 4* ~ 
0 Citrulline 6±1 5 ± 1* 4±1 5±2 
Valine 2±1 1 ±0.2* l ±0.2 1±0.4 
Cystine 12 ± 1 11 ± 2 
Methionine 1 ± 1 I ± 1 2±1 2±1 
Isoleucine 1 ± 1 I± 0.1 1 ±I 1 ± 1 
Leucine I ±0.2 I± 0.1 I ±0.3 1 ± 0.3 
Tyrosine 2 ±0.1 2±0.2 2±1 2±1 
Phenylalanine 2±1 2±1 
Ornithine 4±1 3±1 2±1 2±1 
Lysine 10± 1 6 ± 1* 6±1 5±2 
Histidine 7±0.4 5 ± 0.4* 3±2 3 ± 1 
Arginine 11 ±3 8 ±2* 8±2 9±3 
Values are means± SD. * P< 0.05 when compared with lean controls (ZDF +/?)in each age group.- could not be calculated 
from available data. n=6 for each group. 
Figure 4.1. 
Concentration of Valine (A) and Isoleucine (B) in arterial blood as a function ofleucine 
concentration and the concentration oflsoleucine (C) in arterial blood as a function of 
Valine concentration. For (A) r2=0.9578, P<O.OOOI, (B) r2=0.9705, P<O.OOOI, (C) 
r
2
=0.9853, P<O.OOOI 
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4.3 Discussion: 
Both at 5 weeks and at 11 weeks, all three branched-chain amino acids (BCAA) 
were significantly elevated in the plasma of ZDF fa/fa rats. In skeletal muscle and in the 
liver, also, the BCAA were increased at both ages although the difference was not always 
statistically significant. The increase in BCAA in this model of Type 2 diabetes is 
consistent with the reports on Type 1 diabetes by Bloxam et al. (1972), Brosnan et al. 
(1980), and Brosnan et al. (1983) in streptozotocin-diabetic rats. 
Isoleucine, leucine and valine are essential amino acids. A reversible 
transamination step, catalyzed by the branched-chain aminotransferase is the first step in 
the catabolism of all three BCAAs. Removal of the carboxyl group of the keto acid thus 
formed is also catalyzed by a common enzyme-complex, the branched-chain a-ketoacid 
dehydrogenase complex (BCKDC). After these two common initial steps, the three 
BCAAs take different routes of catabolism, with isoleucine yielding acetyl CoA and 
succinyl CoA, valine yielding succinyl CoA and leucine yielding acetoacetyl CoA and 
acetyl CoA. Thus, despite the initial common steps in their catabolism, valine is 
glucogenic, leucine is ketogenic and isoleucine is both glucogenic and ketogenic. 
However, Figure 4.1 explicitly shows that the plasma concentrations of these three amino 
acids correlate with each other extremely well, providing strong evidence for the common 
metabolic regulation of the catabolism of these three amino acids. 
The activity of the BCKDC has been shown to be regulated by nutritional and 
hormonal stimuli. Gibson et al. (1993) have reported a reduction in the activity of 
BCKDC, which was reversed by insulin treatment in streptozotocin-induced severe 
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ketotic diabetes in rats. However, there are also studies that have shown an increase in the 
activity state of BCKDC in the liver (Lombardo et at. 1998; Li et al. 2001) and in skeletal 
muscles (Lombardo et al. 1999) of rats with experimentally induced-diabetes. 
The elevation of BCAA in Type 1 diabetes has been attributed to the increased 
proteolytic state of body tissues and hyperphagia in the diabetic animals (Rodriguez et al. 
1997; Crandall and Fernstrom 1983). There is evidence for both of these factors in ZDF 
rats. Increased gluconeogenesis is likely to demand increased proteolysis. In addition 
ZDF rats are also known to be hyperphagic (Finegood et al. 2001). 
One important consequence of the increase in BCAA could be a possible effect on 
brain uptake of large neutral amino acids. Brosnan et al. (1984) have shown that in Type 
1 diabetes the decreased brain uptake and the decreased brain level of tyrosine is due to 
the high circulating levels of BCAA. The brain uptake of tyrosine is proportional to 
[Tyr] I I [LNAA], where [Tyr] represents the plasma concentration of tyrosine and 
I [LNAA] represents the sum of the plasma concentrations of the other large neutral 
amino acids that share this transporter (phenylalanine, tryptophan, methionine, histidine, 
isoleucine, leucine and valine) (Pardridge, 1983). This ratio is 0.17 ± 0.02 and 0.10 ± 
0.02, respectively for the control and the ZDF fa/fa rats at 5 weeks, and 0.17± 0.02 and 
0.09±0.02 respectively, for the control and the ZDF fa/fa rats at 11 weeks. At both ages 
these numbers were significantly different from each other. Thus, the elevated BCAA in 
this model also, may compromise tyrosine uptake by the brain. 
Fujimoto eta!. (2004) have reported that, at 8 weeks of age, ZDF fa/fa rats show 
markedly higher total glucose output compared to lean rats under basal conditions. They 
also showed that ZDF fa/fa rats have defects in the suppression of hepatic glucose 
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production and total glucose production in response to increased plasma glucose and 
insulin (Fujimoto et a!. 2004). It is likely that amino acids are important substrates for 
hepatic gluconeogenesis in this situation. At five weeks of age, although the animals do 
exhibit insulin resistance, it is clear that there is some appreciable insulin action since 
blood glucose is only slightly elevated. The plasma concentrations of only five of the 
glucogenic amino acids (aspartate, serine, glutamine, glycine and histidine) are decreased. 
The plasma concentrations of five other glucogenic amino acids (valine, methionine, 
isoleucine, phenylalanine and tryptophan) are actually increased. However, at 11 weeks 
blood glucose is massively increased and it is clear that these animals experience very 
little insulin action. Under these circumstances one expects much higher rates of 
gluconeogenesis. Consistent with this expectation, we have observed that the plasma 
concentrations of twelve of the glucogenic amino acids (hydroxyproline, threonine, 
serine, asparagine, glutamine, proline, glycine, methionine, tyrosine, tryptophan, histidine 
and arginine) are decreased. On the other hand, only three glucogenic amino acids 
(glutamate, valine, and isoleucine) increase their plasma concentrations. 
Specific mention must be made of the regulation of the metabolism of a number of 
glucogenic amino acids. Alanine and glutamine are the most important amino acid 
precursors for hepatic gluconeogenesis during starvation and severe illness. In our model 
of Type 2 diabetes, glutamine was decreased in plasma, liver and skeletal muscle while 
alanine concentrations were comparable with the controls in plasma and liver while 
showing increased levels in the muscle at both 5 and 11 weeks. In streptozotocin-diabetic 
rats Williamson et a!. (1967) and Brosnan et al. (1980) had shown decreased levels of 
both alanine and glutamine in plasma. Hundal et al. (1992) observed a reduction in intra-
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sarcolemmal glutamine levels in streptozotocin-diabetic rats. In the face of this reduced 
intramuscular glutamine level, and a low muscle/plasma distribution ratio (observed by us 
also in 5 weeks old rats) they also observed an increased efflux of glutamine from muscle, 
indicating an increase in the V max/Km ratio (i.e. the first order rate constant) of the 
glutamine transporter in muscle. Glutamine and alanine were shown to account for almost 
70% of the amino acids released by muscle of streptozotocin-diabetic rats, while they 
comprised 56% of the gluconeogenic amino acids removed by the liver (Brosnan et al. 
1983). It has also been shown that hepatocytes from streptozotocin-induced diabetic rats 
use glutamine more rapidly than do hepatocytes from normal or insulin-maintained 
diabetic rats (Squires et al. 1997). The activity of glutaminase itself was shown to be 
increased in livers of Type 1 diabetic rats (Squires et al. 1997). This may contribute to the 
reduced glutamine levels observed in the livers of the ZDF fa/fa rats and indicate 
increased gluconeogenic flux from glutamine. Although there is increased efflux of 
glutamine from the skeletal muscles, the increased uptake by the liver in the face of 
increased gluconeogenic flux will lead to the reduction in plasma levels of this amino 
acid. Interestingly, skeletal muscle glutamine showed a lower distribution ratio while 
alanine showed an increased distribution ratio, both in the insulin-resistant and the 
diabetic stages. This is consistent with the idea that glutamine loss is primarily driven by 
an alteration in the kinetics of its transport (Hundal et al. 1992), while increased alanine 
release is a result of increased tissue levels. 
Serine, threonine and glycine are all gluconeogenic ammo acids, which are 
converted to pyruvate. We saw a reduction in the levels of all three of these amino acids 
in the plasma, liver and the skeletal muscles at 11 weeks. At 5 weeks of age, all three 
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amino acids were decreased in the skeletal muscles, while senne and glycine were 
decreased in the plasma with only serine showing a decreased level in the liver. These 
decreases are in agreement with increased rates of gluconeogenesis. Serine/threonine 
dehydratase is induced in diabetes, as is serine: pyruvate aminotransferase (Freedland and 
Avary 1964; Kanamoto et al. 1991; Mak et al. 1981; Suet al. 1990; Rowsell et al. 1973). 
These effects may be brought about by glucagon (Jost et al. 1968; Suet al. 1990; Rowsell 
et al. 1973; Fukishima et al. 1978). Flux through the glycine cleavage system has also 
been shown to be stimulated by glucagon, epinephrine and norepinephrine (Brosnan et a!. 
1990). Glucagon has also been shown to increase oxidation of threonine as well as its 
transport into hepatocytes (House et al. 2001). Histidine:pyruvate aminotransferase has 
been reported to be identical with serine:pyruvate aminotransferase (Noguchi et al. 1978). 
Thus, the observed reduction in histidine too may be due to the increased activity of its 
degradative enzyme. 
We also calculated the muscle/plasma and liver/ plasma distribution ratios for the 
amino acids. At 11 weeks, proline and methionine both showed an increased liver/plasma 
distribution ratio in the diabetic rats. This increase in the distribution ratio of proline was 
also observed in our laboratory in rats treated with glucagon (M. Haslett and M. Brosnan 
unpublished). Treatment with glucagon was also shown to increase the liver/plasma ratio 
of methionine, which was associated with a marked stimulation of methionine transport 
into liver cells (Jacobs et al. 2001). 
In conclusion, this work describes, for the first time, plasma as well as tissue 
levels of amino acids in this model of Type 2 diabetes. It is clear that insulin resistance 
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alone caused alterations in amino acid metabolism. Many of the effects observed in frank 
Type 2 diabetes were similar to those found in models of Type 1 diabetes. 
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Chapter 5 
Effect of Rosiglitazone on homocysteine metabolism in ZDF (Type 2) 
diabetic rats. 
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5.1 Background 
Increased levels of plasma Hey, an intermediate in the pathway of methionine 
metabolism, have been identified as an independent risk factor for vascular disease (Kang 
et al, 1992), Alzheimer's disease (Seshadri et al, 2002) and osteoporotic fractures (van 
Meurs et al, 2004). An elevation in plasma Hey by even as small an amount as 5 
J.Lmol/liter can increase the risk of coronary artery disease by 60% in men and 80% in 
women (Boushey eta/, 1995). 
As discussed in the introduction, both Type 1 and Type 2 diabetes mellitus as well 
as the metabolic syndrome of insulin-resistance, are associated with an increased risk of 
coronary artery disease. The prevalence of atherosclerosis is reported to be 2-to 6-fold 
higher in diabetic patients than in people without diabetes (Brand et al, 1989). However, 
the association between HHcy and cardiovascular disease and mortality has been found to 
be strongest in Type 2 diabetes mellitus (Hoogeveen et al, 1998). 
Our earlier study conducted in ZDF rats in the insulin-resistant and the 
frank diabetic stages showed that plasma tHey is significantly lower in ZDF fa/fa rats 
when compared to Untreated rats. This reduction was brought about by several changes in 
the enzymes involved in Hey metabolism. 
RSG, a thiazolidinedione, is an agonist of the peroxisome proliferator-activated 
receptor y (PPAR- y) subfamily of nuclear receptors. It is an anti-diabetic agent used to 
treat patients with Type 2 diabetes and is known to enhance insulin sensitivity and to 
improve metabolic control in these patients. RSG has also been shown to reduce insulin 
resistance and prevent the loss of ~-cell mass in ZDF rats by maintaining ~-cell 
proliferation and preventing net ~-cell death (Finegood eta!, 2001). 
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In this study, we examined Hey metabolism under conditions of improved insulin 
sensitivity after treatment with RSG with the aim of gaining more understanding of the 
regulation of Hey metabolism. 
5.2 Results 
5.2.1 Body Weight, Hepato-somatic index, fat pad weight, food intake, water intake 
and urinary output 
Body weight, hepato-somatic index, fat pad weight, food and water intake and 
urinary output are shown in Table 5.1. ZDF fa/fa rats were 47% heavier than the ZDF 
fa/+ rats at 6 weeks of age but by 12 weeks, although still being significantly heavier than 
the untreated rats the difference had dropped to 14%. The ZDF fa/fa (RSG) rats on the 
other hand were able to maintain the weight difference initially observed. The ZDF fa/fa 
(untreated) rats, had a significantly higher hepato-somatic index compared to their RSG 
treated counterparts as they had greatly enlarged livers. Fat pad weight was measured 
only at 12 weeks of age. Both groups of ZDF fa/fa rats had a significantly higher fat pad 
weight than the ZDF fa!+ rats. However, the fat pad weight of the ZDF fa/fa (RSG) rats 
was significantly higher than the ZDF fa/fa (untreated) rats. Very interestingly, the ZDF 
fa/fa (untreated) rats also had a much higher feed intake /1 OOg body weight as well as a 
higher water intake and urinary output compared to the other 3 groups. The ZDF fa/fa 
(untreated) rats therefore are showing the classical features of diabetes mellitus of 
polyphagia, polydypsia and polyuria along with a failure to gain weight. 
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Table 5.1. Body Weight, Hepato-somatic index, fat pad weight, feed intake, water intake and urinary output of RSG 
treated and untreated ZDF fa/+ and ZDF fa/fa rats. 
ZDF fa/+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-treated 
Bodv wei!!ht ( Q:) 
6 weeks 127± 7 187 ± 12b 
12 weeks 299 ± 7a 308 ± 21a 339 ± 17b 457 ± 23c 
Hepato-somatic index 
6 weeks 5 ± 1a 6 ± 1a 
12 weeks 3 ± 0.2a 3 ± 0.1a,c 5 ± 0.3b 3 ± 0.3c 
~ Fat pad weight (g) Vl 
N 6 weeks 0.3 ± 0.01a 1.7±0.2b 
12 weeks 2 ± 1a 2 ± 1a 6 ± 0.4b 13 ± 1c 
Feed Intake g/100 g BW 
6 weeks 12± 2a 13 ± 2a 
12 weeks 6 ± 1a 6 ± 0.3 a,c 12 ± 1 b 7 ± 0.3 c 
Water Intake (ml/100 g BW) 
6 weeks 14± 1a 17 ± 2.1a 
12 weeks 7 ± 1a 8 ± 1a 39±4b 7 ± 1a 
Urinary output (mlllOOg BW) 
6 weeks 5 ± 1a 9 ± 1b 
12 weeks 4± 1a 4±0.0a 44± 3b 5 ± 1a 
Mean ± SD for 6 rats are shown. Differing superscripts within each row indicate significant difference from each other 
5.2.2 Plasma glucose, insulin, creatinine and the glomeruler filtration rate 
Plasma levels of glucose, insulin and creatinine and the calculated GFR are shown 
in Table 5.2. The ZDF fa/fa rats were insulin-resistant at 6 weeks of age, as indicated by 
the 5- fold greater increase in plasma insulin needed to maintain a normal plasma glucose 
level. By 12 weeks, the ZDF fa/fa (untreated) rats have progressed to the diabetic stage 
with a 3-fold increase in their plasma glucose, while the plasma insulin level dropped and 
was no longer different from the ZDF fa/+ rats. This could probably be due to the loss of 
P cells that occur with the progression of diabetes as shown by Finegood et al (2001). The 
ZDF fa/fa (RSG) rats still maintained a significantly higher plasma insulin albeit much 
lower than the level seen at 6 weeks. Plasma glucose however, was normalized in the 
ZDF fa/fa (RSG) rats by the RSG treatment. These results could indicate the preservation 
of some P-cells as well as an increase in insulin sensitivity brought about by the RSG 
treatment. 
Since renal function is one of the major determinants of plasma Hey in humans we 
measured plasma and urinary creatinine levels and calculated the GFR from these values 
and the total urinary output per day. Plasma creatinine was significantly increased in the 
ZDF fa/fa (untreated) rats at 12 weeks and at both ages they excreted more creatinine in 
their urine. GFR however, was only increased at 6 weeks of age suggesting a state of 
hyper-filtration at this age. At 12 weeks, the increase seen in both plasma and urinary 
creatinine in the face of a normal GFR may indicate the increased plasma creatinine to be 
a result of a higher production and not be due to failing kidney function. 
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Table 5.2. Plasma glucose, insulin, creatinine, total urinary creatinine and GFR of RSG treated and ZDF fa/+ and ZDF 
fa/fa rats. 
ZDFfa/+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-treated 
Plasma Glucose (mM) 
6 weeks 10 ± 1a 11 ± 1a 
12 weeks 11 ± 1a 11 ± 1a 32±3b 11 ± 2a 
Plasma Insulin (ng/ml) 
6 weeks 4 ± 1a 21 ± 9b 
12 weeks 4 ± 1a 4 ± 1a 6±2a 8 ± 1b 
....... 
Plasma Creatinine (!lM) 
VI 6 weeks 27 ± 3a 28 ± 3a 
..j::. 
12 weeks 27 ± 3a 31 ±sa 46± 6b 29±4a 
Urinary creatinine loss (!lMoles/day) 
6 weeks 56± 9a 89 ± 17b 
12 weeks 129 ± 9a 127 ± 13a 184 ± 13b 138 ± 9a 
GFR (ml/min) 
6 weeks 1.4 ± 0.3a 2.2 ± 0.2b 
12 weeks 3.3 ± 0.5a 2.9±0.8a 2.8±0.3a 3.4 ± 0.5a 
Mean ± SD for 6 rats are shown. Differing superscripts within each row indicate significant difference from each other. 
5.2.3 Plasma Homocysteine 
Plasma Hey levels at 6 and 12 weeks are shown in Figure 5.1. Plasma tHey was 
41% lower in the ZDF fa/fa rats when compared to the ZDF fa/+ rats at 6 weeks of age. 
RSG treatment for 6 weeks returned the tHey level in the ZDF fa/fa (RSG) rats towards 
normal. 
5.2.4 Hepatic activities of enzymes of Homocysteine metabolism 
Table 5.3 shows the activities of the enzymes involved in Hey metabolism. We 
have already seen, in Chapter 3 of this thesis, the changes in enzyme activities that lead to 
decreased plasma Hey levels in insulin resistance and early Type 2 diabetes. In this study 
we show that the RSG treatment is able to return the lowered plasma Hey level towards 
normal. We were therefore interested in identifying the enzymes that respond to the 
increased insulin sensitivity brought about by the RSG treatment. 
The baseline enzyme activities at the beginning of the study before the 
commencement of RSG treatment were similar to those in the first study (Table 3.2) 
except for the reduced MTHFR activity in the ZDF fa/fa rats. After 6 weeks of RSG 
treatment, methionine adenosyltransferase activity, which was increased in the ZDF fa/fa 
(untreated) rats, was normalized. Two-way ANOVA showed cystathionine ~-synthase 
activity to be significantly higher in the ZDF fa/fa rats compared to the ZDF fa!+ rats but 
the difference was slight. Contrary to what we expected, the RSG treatment did not affect 
its activity. 
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Table 5.3. Hepatic activities of enzymes of homocysteine metabolism 
ZDFfal+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-treated 
Methionine adenosyltransferase 
360± 32 b 6 weeks 298 ± 38 a 
12 weeks 232 ± 97 a 254 ± 99 a 484 ± 209 b 309 ±58 a 
Glycine-N-methyltransferase 
360 ± 32 b 6 weeks 298 ± 38 a 
12 weeks 416 ±50 a 483 ± 30 b 538 ±52 b 545 ±59 b 
Cystathionine !3-synthase 
1073 ± 89 b 6 weeks 944 ±66 a 
12 weeks 1879 ± 202 2079 ± 282 2288 ± 194* 2160 ± 308* 
Cystathionine y-lyase 
4284 ± 631 b ....... 6 weeks 3211 ±310 a 
Vl 12 weeks 4025 ± 784 a 4081 ± 673 a 6238 ± 849 b 4365 ± 808 b 00 
Methylenetetrahydrofolate reductase 
14±2 b 6 weeks 17 ± 3 a 
12 weeks 17 ± 3 17 ± 3 16± 6* 14± 5* 
Methionine synthase 
9 ± 0.4 b 6 weeks 12 ± 1a 
12 weeks 14 ± 1 12 ± 2§ 11±2* 11 ± 1 *§ 
Betaine:homocysteine methyltransferase 
6 weeks 170±52 a 377 ±57 b 
12 weeks 170 ±38 222 ± 67§ 259± 31* 351 ±52*§ 
Choline dehydrogenase 
6 weeks 981 ± 49 a 942 ± 78 a 
12 weeks 1217 ± 100 a 1202 ± 237 a 1428 ± 106 b 1395 ± 288 b 
Data are given as mean ± SD for six rats. Enzyme activities are expressed as nmoles of product synthesized per minute per gram 
liver. Differences in superscript letters signify significant differences within each horizontal row (P< 0.05) with one-way 
ANOV A. * and § signify significant difference due to genotype and RSG treatment respectively, with Two-way ANOV A. 
On the other hand, the second transsulfuration enzyme, CGL showed a marked 
increase in the ZDF fa/fa (untreated) rats and was returned to normal by the RSG 
treatment, possibly contributing to the normalization of plasma Hey. MTHFR activity 
was slightly, though significantly lower in ZDF fa/fa rats compared to ZDF fa/+ rats but 
the RSG treatment did not have any additional effects. In the case of methionine synthase, 
both RSG treatment and the genotype had significant effects on its activity, with the ZDF 
fa/fa rats showing a lower level of activity than the ZDF fa!+ rats while the RSG 
treatment was also effective in lowering its activity. The activity of BHMT was once 
again observed to be significantly higher in the ZDF fa/fa rats with the RSG treatment 
also acting to increase its activity. 
5.2.5 S-adenosylmethionine, S-adenosylhomocysteine and SAM/SAH ratio 
SAM, SAH and the SAM/SAH ratio are shown in Table 5 .4. Hepatic SAM as well 
as SAH levels were significantly higher in ZDF fa/fa rats at 6 weeks of age. At 12 weeks, 
the ZDF fa/fa (untreated) rats still maintained a significantly higher level of SAM than the 
rest of the groups, which is consistent with the higher activity observed in MAT. Along 
with the normalization of MAT seen with RSG treatment we also observe a lowering of 
this increased SAM level in ZDF fa/fa (RSG) rats. However, the inability of SAM to 
completely return to normal could arise from the increase in the activity of BHMT seen in 
these rats. Analysis of the data using two-way ANOV A shows both the genotype and the 
interaction between the genotype and the treatment to be significant for SAM. However, 
the treatment itself did not have a significant effect. In the case of SAH, both RSG 
treatment and the genotype showed significant effects with the ZDF fa/fa rats 
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Table 5.4. S-adenosylmethionine, S-adenosylhomocysteine and the SAM/SAH ratio 
ZDF fa/+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-treated 
S-adenosvlmethionine (nmoles/g liver) 
6 weeks 107 ± 21a 143 ± 26b 
12 weeks 132.8 ± 10.1 a 140.6 ± 10.9a,c 169.5 ± 7.0b 146.9 ± 9.2c 
S-adenosylhomocysteine (nmoles/g liver) 
6 weeks 12.4 ± 1.6a 15.1±1.9b 
12 weeks 16.5 ± 0.9 18.8 ± 1.3§ 18.3 ± 0.9* 19.9 ± 2.3*§ 
SAM/SAH 
....... 
9.3±1.1a 11.7± 1.1b 0\ 6 weeks 0 
12 weeks 8.1 ± 0.9a 7.5 ± 0.5a 9.3 ± 0.7b 7.5 ±0.9a 
Data are given as means ± SD for six rats. Differences in superscript letters signify significant differences within each row (P< 
0.05). *and§ signify significant difference due to genotype and RSG treatment respectively, with Two-way ANOVA. 
having a higher level of SAH than the ZDF fa/+ rats and the RSG treatment also having a 
positive effect. At 6 weeks, the SAM/SAH ratio was significantly higher in the ZDF fa/fa 
rats and continued to remain so in the ZDF fa/fa (untreated) rats at 12 weeks. The RSG 
treatment normalized the ratio in the ZDF fa/fa (RSG) rats. 
5.2.6 Relative mRNA levels of CBS and BHMT 
RT-PCR analysis of BHMT mRNA showed a significant increase in mRNA 
abundance in the ZDF fa/fa rats compared to the ZDF fa/+ rats (Figure 5.2 B) which is in 
agreement with the genotypic effect observed in the enzyme activity. However, CBS 
mRNA did not differ between the groups (Figure 5.2A). 
5.2. 7 Hepatic activities of enzymes of phospholipid metabolism 
This work on phospholipid metabolism was done by Dr. Rene Jacobs of the 
University of Alberta. The activities of the enzymes involved in phospholipid metabolism 
are shown in Table 5.5. CTP: phosphocholine cytidylyltransferase (CT) is the rate 
limiting enzyme in the Kennedy pathway of PC synthesis. The activity of CT was 
measured in liver homogenates as well as in the cytosolic and microsomal fractions. At 6 
weeks, CT activity did not show any significant differences between the ZDF fa/fa and 
the ZDF fa/+ rats in any of the fractions tested. However, at 12 weeks the liver 
homogenates from ZDF fa/fa rats showed a higher level of CT activity than the ZDF fa/+ 
rats; RSG-treated ZDF fa/fa rats showed the highest activity. Cytosolic CT activity, too, 
was highest in the ZDF fa/fa (RSG) rats with RSG treatment and the genotype having 
significant effects. The genotypic difference in CT activity was also evident in the 
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Table 5.5. Hepatic activities of enzymes of phospholipid metabolism 
ZDF fa!+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-Treated 
CTP:phosphocholine 
cytidylyltransferase (Homogenate) 
6 weeks 1.8±0.2 2.0± 0.3 
12 weeks 1.3 ± 0.1 1.5 ± 0.2§ 1.9 ± 0.3* 2.3 ± 0.4*§ 
CTP:phosphocholine 
cytidylyltransferase (Cytosol) 
6 weeks 1.0 ± 0.2 1.2±0.1 
12 weeks 0.6 ± 0.1 3 0. 7 ± 0.02a,b 0.7 ± 0.1b 0.9 ±0.1b,c 
CTP:phosphocholine 
...... cytidylyltransferase (Microsome) 0\ 
+>- 6 weeks 2.5 ± 0.8 2.2±0.6 
12 weeks 3.2 ± 0.2a 3.1 ± 0.23 4.0 ± 0.4b 3.9 ± 0.4b 
Choline kinase 
6 weeks 9.0 ± 2.1 8.0 ± 3.1 
12 weeks 7.6± 0.9 8.4 ± 1.8 7.7 ± 1.0 6.9±2 
Phosphatidylethanolamine N-
methyl transferase 
6 weeks 0.7 ± 0.1 0.6 ± 0.1 
12 weeks 0.7 ± 0.1 0.7 ± 0.02 0.8 ± 0.1 * 0.8 ± 0.1 * 
Data are given as means ± SD for six rats. Enzyme activities are expressed as nmoles of product synthesized per minute per mg 
protein. Differences in superscript letters signify significant differences within each row (P< 0. 05). * and § signify significant 
difference due to genotype and RSG treatment respectively, with Two-way ANOV A. 
microsomal fraction but RSG treatment did not show any additional effects. Choline 
kinase activity did not show any differences between the groups either at 6 weeks or at 12 
weeks. Phosphatidylethanolamine methyltransferase (PEMT) catalyzes the conversion of 
phosphatidylethanolamine to PC in an alternate pathway to the Kennedy pathway. At 12 
weeks the activity of PEMT showed a small, though significant, increase in the ZDF fa/fa 
rats compared to the ZDF fa!+ rats; RSG treatment did not produce any additional effects. 
5.2.8 Phosphatidylcholine and Phosphatidylethanolamine levels 
Table 5.6 shows the levels of PC and PE in the liver and plasma. Hepatic PC and 
PE and plasma PC was similar in both groups of rats at 6 weeks of age. At 12 weeks, 
plasma PC was significantly higher in the ZDF fa/fa group; RSG treatment increased 
plasma PC further. Liver PC and PE both were significantly lower in the ZDF fa/fa rats 
compared to the ZDF fa!+ rats; RSG treatment had no significant effects. 
5.2.9 Hepatic and plasma Triacylgycerollevels 
Table 5.7 shows the hepatic and plasma Triacylglycerol (TG) levels. Both plasma 
and hepatic TG levels were greatly increased, at 12 weeks, in the ZDF fa/fa (untreated) 
rats. Two-way ANOV A revealed the genotypic and the treatment effects to be significant, 
with ZDF fa/fa rats showing a higher level of both plasma and hepatic TG than the ZDF 
fa/+ rats and RSG treatment acing to reduce it. 
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Table 5.6. Phosphatidylcholine and Phosphatidylethanolamine levels 
ZDF fa/+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-Treated 
Plasma Phosphatidylcholine (nmoles/ml) 
6 weeks 1137±191 1367 ± 557 
12 weeks 810 ± 123a 900 ± 152a 2332 ± 478b 3836 ± 495c 
Hepatic Phosphatidylcholine 
(nmoles/mg protein) 
6 weeks 136 ± 41 128 ± 24 
12 weeks 138 ± 9a 138 ± 7a 103 ± 16b 112 ± 9b 
Hepatic Phosphatidylethanolamine 
(nmoles/mg protein) 
...... 6 weeks 90 ± 18 83 ± 10 0"1 83 ± 6a 84 ± 15a 58± 16b 64 ± 15b 0"1 12 weeks 
Data are given as means± SD for six rats. Differences in superscript letters signify significant differences within each row (P< 
0.05). 
Table 5.7. Hepatic and plasma Triacylglycerollevels 
ZDF fa/+ ZDF fa/fa 
Untreated RSG-treated Untreated RSG-Treated 
Hepatic Triacylglycerol (mg/mg protein) 
o.o3 ± o.oo§ 12 weeks 0.04 ± 0.01 0.15 ± 0.04* 0.10 ± 0.02*§ 
Plasma Triacylglycerol (mmoles/ml) 
12 weeks 0.20 ± 0.06a 0.30 ± 0.04a§ 7.05 ± 3.9b* 1.90 ± 0.4a§* 
Data are given as mean ± SD for six rats. Differences in superscript letters signify significant differences within each row (P< 
;; 0.05) with one-way ANOVA. *and§ signify significant difference due to genotype and RSG treatment respectively, with Two-
-J 
wayANOVA. 
found to be significant on the hepatic TG levels with ZDF fa/fa rats showing a higher 
level of TG and the RSG treatment acting to lower the level. 
5.3 Discussion 
This study reinforces prevwus work from this laboratory which showed the 
regulation of homocysteine metabolism by insulin and its counter-regulatory hormones. 
In the streptozotocin-induced diabetic (type 1) rat model we have shown that plasma 
homocysteine is reduced in the untreated diabetic rats and that this reduction is prevented 
when the diabetic rats are treated with insulin (Jacobs et al, 1998). This was the first 
demonstration of the involvement of insulin in the regulation of Hey metabolism; this was 
followed by the demonstration in hyperglucagonemic rats of the contribution of the 
counter-regulatory hormone, glucagon (Jacobs et al, 2000). These two studies clearly 
illustrated the opposing effects of these metabolic hormones on the regulation of Hey 
metabolism. 
The current study deals with Type 2 diabetes mellitus, where insulin-resistance 
rather than the absolute lack of insulin is the major contributing factor. Therefore, we 
treated the rats with the thiazolidinedione, RSG, which along with other TZDs such as 
troglitazone and pioglitazone have been shown to improve insulin action in a variety of 
insulin resistant and diabetic rat models as well as in human Type 2 diabetic patients 
(Olefsky and Saltiel, 2000). RSG was clearly able to restore insulin sensitivity in ZDF 
fa/fa rats studied here as shown by their plasma glucose and insulin levels. The insulin 
level in the ZDF fa/fa (RSG) rats at 12 weeks of age, although greatly reduced from the 
level seen at 6 weeks was higher than in the ZDF fa/fa (untreated) rats. This may indicate 
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the prevention of B cell death and the maintenance of its mass by RSG treatment as 
previously shown in this rat model by Finegood et al, (2001). 
Here, again, we observe that plasma Hey is decreased in insulin-resistance as well 
as in early Type 2 diabetes. We also observe that the increase in insulin sensitivity by 
RSG treatment is able to restore the Hey level in ZDF fa/fa (RSG) rats towards normal 
similar to what was reported in type 1 diabetic rats treated with insulin (Jacobs et al, 
1998). However, unlike insulin treatment of Streptozotocin-diabetic rats, RSG treatment 
of ZDF fa/fa rats was unable to restore the Hey levels to complete normalcy. 
This discrepancy could be explained by a very interesting change observed in the 
activity of one of the enzymes involved in Hey removal. Betaine:homocysteine 
methyltransferase (BHMT), catalyzes the reaction where Hey is remethylated to 
methionine using a methyl group donated by betaine. Our earlier studies both in type 1 
(Ratnam et al, 2006) and Type 2 (Wijekoon et al, 2005) diabetes showed that the 
reduction observed in plasma Hey in both these types of diabetes was accompanied by 
increases in the activity of BHMT. Nieman et al (2004) have also found this increased 
activity of BHMT in streptozotocin-diabetic rats. The present study too was able to show 
an increase in hepatic BHMT activity at the insulin resistant as well as the diabetic stage. 
Surprisingly, we also observed a significantly positive effect of RSG treatment on BHMT 
activity: both ZDF fa/+ (RSG) and ZDF fa/fa (RSG) rats showed higher BHMT activity 
than the respective untreated groups. This is surprising in the light of the work done in 
our lab by Ratnam et al (2006) where, in the type 1 diabetic model, insulin treatment was 
shown to return the increased BHMT activity back to the level seen in the control rats. In 
a rat hepatoma cell line (H4IIE cells), Ratnam et al showed that treatment with 
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glucocorticoids increased the level of BHMT mRNA and the rate of BHMT mRNA 
synthesis while insulin reduced the abundance of BHMT mRNA as well as the de novo 
transcription rate of the gene (Ratnam et a!, 2006). Thereby, they were able to show very 
convincingly the direct effects of both insulin and glucocorticoids on BHMT gene 
expression. However, in the present study, we observed a further increase in the activity 
of BHMT rather than a reduction that would be expected according to the above 
information. 
This phenomenon could be explained by looking at how ZDF fa/fa rats become 
diabetic, the mode of action of RSG in modifying Type 2 diabetes and finally the 
contribution made by BHMT to phospholipid (PL) metabolism, in addition to its direct 
action in remethylating Hey. It is now generally accepted that Type 2 diabetes is 
associated with obesity. More specifically, the ectopic accumulation of fat in muscle, 
liver as well as ~ cells is widely regarded to be instrumental in the etiology of insulin 
resistance and possibly in the ultimate destruction of pancreatic ~ cells, leading to the 
development of Type 2 diabetes (McGarry, 2002). The mutation in the leptin receptor, 
OB-R, is the only genetic abnormality that has been identified in ZDF rats (Unger, 1997). 
The ensuing leptin resistance results in obesity and a generalized intracellular fat overload 
in adipocytes as well as non adipocytes (Unger, 1997). The importance of intracellular 
TG accumulation in liver and skeletal muscle in the etiology of insulin resistance has 
been shown comprehensively in humans as well as in animals (McGarry, 2002). That 
ectopic accumulation of fat especially in the ~ cells, leading to their destruction, is the 
cause of diabetes in ZDF rats is supported by the finding that pair-feeding of pre-diabetic 
ZDF fa/fa rats to their lean counterparts leads to the reduction in islet TG content, and 
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prevents hyperglycemia, loss of ~ cell GLUT 2 and minimizes the loss of glucose-
stimulated insulin secretion (Ohneda eta!, 1995). 
The importance of betaine as well as BHMT, overlooked over the years in favor 
of the more famous counterparts such as the B vitamins of Hey metabolism and the 
transsulfuration enzymes, is beginning to gain recognition as a major player in regulation 
of Hey metabolism. Betaine supplementation has been shown to be effective in 
preventing a rise in plasma Hey after methionine intake in subjects with mild HHcy 
(Steenge et a!, 2003), and doses of betaine in the range of dietary intake were shown to 
reduce fasting and post-methionine loading plasma Hey concentrations in healthy men 
and women (Olthof eta!, 2003). Schwahn eta! (2003) showed betaine supplementation to 
lower plasma Hey levels in mice heterozygous or homozygous for the disruption of the 
mthfr gene as well as in their wild type littermates. Very interestingly, they were also able 
to show a significant negative relationship between plasma Hey and betaine 
concentrations in humans with cardiovascular disease. The same group also reported the 
ability of betaine to lower plasma Hey in a mouse model of moderate HHcy due to a 
heterozygous disruption of the Cbs gene (Schwahn eta!, 2004). 
These effects on plasma Hey levels by betaine feeding and the resultant increase 
in the flux through BHMT are not surprising given the role of BHMT in removal of Hey. 
However, BHMT is also thought to play a role in phospholipid (PL) metabolism. In the 
mouse, the daily flux of PL through the liver is estimated to approximate the entire 
hepatic PL pool (Walkey eta!, 1998). The CDP-choline or the Kennedy pathway occurs 
in all nucleated cells and accounts for 60-80% of hepatic phosphatidylcholine (PC) 
biosynthesis (Sundler and Akesson, 1975). The second mode of PC synthesis, 
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quantitatively significant only in the liver, converts phosphatidylethanolamine (PE) to PC 
with the consecutive transfer of three methyl groups from three SAM molecules, 
catalyzed by the enzyme phosphatidylethanolamine methyltransferase (PEMT). BHMT is 
regarded as the first enzyme in the three-enzyme pathway culminating in the conversion 
ofPE to PC, the other two being MAT and PEMT (Sehayek eta/, 2003). In line with this, 
both BHMT and PEMT have been found in the bile canalicular membrane of mice where 
they are believed to be involved in local canalicular PC biosynthesis and secretion of PL 
into bile (Sehayek et a/, 2003). A recent study by Jacobs et a/ (2005) in liver specific 
CT-o. knockout mice showed flux through PEMT to be increased two-fold and this 
increase was accompanied by increases in the activity of both BHMT and MAT. 
In addition to being the predominant PL in bile and eukaryotic cell membranes, 
PC is also the primary PL in all classes of lipoproteins in mammals (Vance and Vance, 
1985) and is required for the secretion ofVLDL (Yao and Vance, 1988, Yao and Vance, 
1989a, Yao and Vance, 1989b, Vermeulen et al, 1997). Although the Kennedy pathway 
has been shown to be essential for the maintenance of normal plasma VLDL levels 
(Vermeulen et al, 1997) PC derived from PE has also been shown to be necessary for 
normal VLDL secretion (Nishimaki-Mogami eta!, 2002). Recently, hepatocytes isolated 
from male Pemr1- mice were found to secrete 50% less TG in VLDLILDL lipoprotein 
fractions than hepatocytes from Pemt +!+mice (Noga eta/, 2002). They also observed a 
70% reduction in the secretion of apoB100 in VLDLILDL. Transfection of McArdle 
hepatoma cells lacking PEMT with PEMT eDNA was also shown to increase the 
secretion ofTG in VLDL. Noga and Vance (2003) found Pemt -!-mice to have a defect in 
VLDL and apoB100 secretion compared with Pemt1+ mice when fed a high fat/high 
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cholesterol diet, but with a gender specificity. In addition PEMT knockout mice were 
shown to have hepatic steatosis and abnormal levels of hepatic choline metabolites 
despite ingesting the recommended dietary intake of choline (Zhu eta!, 2003). 
BHMT, because of its association with PEMT and therefore with secretion of 
VLDL from the liver, appears to play a role in lipid mobilization and secretion. In support 
of this assumption is the large increase in apoB mRNA abundance and secretion seen in 
BHMT -transfected McArdle cells (Sowden et a!, 1999). A recent publication by the same 
group was able to confirm these findings in-vivo where feeding rats a methionine-
restricted betaine-supplemented diet resulted in a 4-fold induction of hepatic BHMT and a 
3-fold induction of ApoB mRNA compared with methionine restriction alone (Sparkes et 
a!, 2006). This group also observed an increased secretion of VLDL along with a 45% 
reduction in liver TG. These experiments are reinforced by the finding that ethanol 
feeding increases BHMT activity (Barak eta!, 1987) as well as apoB mRNA and apo B 
secretion (Wang eta!, 1994). Very interestingly, dietary betaine is known to promote the 
generation of hepatic SAM and protect the liver from ethanol-induced fatty infiltration 
(Barak et al, 1993). BHMTs involvement with fatty liver was further demonstrated by the 
finding that synthesis of BHMT is continuously enhanced in fatty livers of 
thyroidectomized chickens (Shibata et al, 2003). 
Therefore, our finding of increased BHMT activity in ZDF fa/fa (untreated) rats 
comes as no surprise. What is interesting is the increased activity seen in the RSG-treated 
rats. As stated earlier, this finding appears to be at variance with our previous report 
where BHMT expression was shown to be negatively regulated by insulin (Ratnam et a!, 
2006). An exploration of the mode of action of TZDs suggests an explanation for this 
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phenomenon. One means by which TZDs improve insulin sensitivity is by increasing 
insulin-dependent glucose disposal and reducing hepatic glucose output (Saltiel and 
Olefsky, 1996). Another well documented effect of TZDs is adipocyte differentiation, in 
both white (Tontonoz et al, 1994) and brown (Tai et al, 1996) adipose tissue. Partitioning 
of circulating lipids away from muscle and liver into adipose tissue, known as "lipid 
steal" is attributed to TZDs (Ye et al, 2004). In favour of this mechanism, TZDs have 
been shown to reduce circulating levels of lipids as well as lowering their accumulation in 
ectopic locations such as liver, skeletal and cardiac muscle and pancreatic islets 
(Spiegelman 1998, Oakes et al, 1994, Oakes et al, 1997, Zhou et al, 2000, Shimabukuro 
et al, 1998, Riga et al, 1999). In addition, TZDs have been shown to directly increase 
FFA exchange between plasma and adipose tissue in ZDF rats (Oakes et al, 2001). Ye et 
al (2004) found a two-fold increase in adipose tissue fatty acid uptake after treatment of 
normal rats with RSG for 7 days. Our data also displayed a reduction in plasma as well as 
hepatic levels of TG with RSG treatment. Along with these reductions we observed a 
highly significant increase in the fat pad weight which implies a redistribution of lipids. 
Redistribution of lipids from the liver to the periphery is accomplished by the release of 
mainly TG-rich VLDL from the liver. Therefore, the involvement of BHMT with VLDL 
production, as outlined above, could very well account for the increased BHMT activity 
seen with RSG treatment. Although the rat BHMT promoter region is not yet mapped it 
would be interesting to find whether it contains a PP AR response element. 
In the present study, the activity of CT, the rate limiting enzyme in the 
CDP-choline pathway of PC synthesis is significantly increased in the ZDF fa/fa rats 
compared to the ZDF fa/+ rats, which could be attributed to the increased hepatic TG 
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levels in the ZDF fa/fa rats. What would then be the cause for the increase in CT activity 
in the ZDF fa/fa (RSG) rats, as they had a decreased hepatic TG level? This may provide 
clues as to the means by which RSG brings about this reduction in hepatic TG. If this 
reduction is due to the increased flux of TG from the liver to the adipose tissue then there 
will be an increased need to produce VLDL, the major phospholipid of which is PC. The 
increase in CT activity seen with the RSG treatment favors this argument. In addition, we 
also see a significant increase in plasma PC in the ZDF fa/fa rats with the ZDF fa/fa 
(RSG) rats having a significantly higher level of PC than the ZDF fa/fa (untreated) rats. 
Hepatic PEMT however only showed a very slight, but significant, increase in the ZDF 
fa/fa rats compared to the ZDF fa/+ rats with no effects of the RSG treatment. We also 
see a significant reduction in both PE and PC in the liver in the ZDF fa/fa rats which may 
indicate an increased contribution from the PEMT pathway to the increased plasma PC 
level. The effect of RSG on PC production through the PEMT pathway is difficult to 
assess, however, without conducting flux studies, as RSG treatment was successful in 
increasing the activity of BHMT, decreasing the activity of MAT and had no effect on 
PEMT itself. 
The increase in the activity of MAT in the ZDF fa/fa (untreated) rats and its 
normalization by insulin sensitization agrees with the findings of Gil eta! (1997) where 
they showed the induction of MAT expression by glucocorticoids and its inhibition by 
insulin. We also observed an increase in the activity of the transsulfuration enzymes, CBS 
and CGL, in the ZDF fa/fa rats compared to the ZDF fa/+ rats at both 6 and 12 weeks 
similar to our earlier findings. Although significant, the increase in CBS activity in the 
ZDF fa/fa group was very small and was not corrected by the RSG treatment. However, 
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the RSG treatment was able to significantly reduce the liver weight of the treated ZDF 
fa/fa rats, which would reduce the total CBS activity in the treated rats. CGL, which 
converts cystathionine into cysteine on the other hand, was very effectively normalized 
by the RSG treatment. The possible regulatory role of CGL has been generally ignored. 
However, the importance of this enzyme in the transsulfuration flux is evident in 
premature infants, whose hepatic CGL activity is absent or low in concentration and who 
have low plasma cysteine levels and glutathione synthesis rates (Vina et al, 1995). The 
same group has also shown that in rats exposed to surgical stress, CGL activity is reduced 
by ~40%, leading to reduced rates of cysteine synthesis in isolated hepatocytes (Vina et 
al, 1992). Therefore, the normalization of CGL activity to the lower level seen in the ZDF 
fa!+ rats could play a role in the increase in plasma Hey brought about by RSG treatment. 
It would be of interest to measure cystathionine levels in these situations. 
Our data also indicate a reciprocal regulation of the two remethylation reactions. 
At 6 weeks of age the increase in the activity of BHMT in the ZDF fa/fa rats was 
accompanied by a significant decrease in the activity of methionine synthase which we 
also observed at 12 weeks of age. Remarkably the increase in BHMT activity that 
occurred with the RSG treatment was also accompanied by a reciprocal reduction in 
methionine synthase activity. This attempt to balance the rate of remethylation may also 
contribute towards the normalization of plasma Hey but, without flux studies, firm 
conclusions cannot be drawn. Similar changes in the two enzymes have also been shown 
by Nieman et al (2004) in streptozotocin-induced diabetic rats and are also a common 
occurrence in alcoholic liver diseases where a reduction in the activity of methionine 
synthase is accompanied by increased BHMT activity (Barak et al, 1996). 
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The significantly higher food intake seen in the ZDF fa/fa (untreated) rats and its 
normalization upon RSG treatment may also be responsible for some of the changes 
observed in this study as it is well established that diet plays a major role in the regulation 
of Hey metabolism. 
In conclusion, it is clear that the hormonal changes that are prevalent in insulin-
resistance and Type 2 diabetes act at several sites in the pathway of methionine 
metabolism. It would be interesting to further investigate the direct effects of RSG on 
BHMT activity as it will provide us with insight into the physiological functions of this 
remarkable enzyme. 
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Chapter 6 
Type 2 Diabetes and vascular function: effects of Rosiglitazone 
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6.1 Background 
The first evidence of the importance of the endothelium for vascular homeostasis 
was the discovery of the absolute necessity of an endothelial cell layer for acetylcholine-
induced relaxation of rabbit aorta (Furchgott and Zawadzki, 1980). Since then endothelial 
dysfunction has been implicated in the pathophysiology of a number of forms of 
cardiovascular disease including hypertension, coronary artery disease, chronic heart 
failure, peripheral artery disease and chronic renal failure (Endemann and Schiffrin, 
2004). Most often endothelial dysfunction in vitro has been described by a reduction in 
endothelium-dependent relaxation of vascular smooth muscle (Endemann and Schiffrin, 
2004). 
During the active manifestation of Type 1 and Type 2 diabetes, blood vessels have 
been reported to display the same in vitro characteristic of endothelial dysfunction as in 
cardiovascular diseases (De Vriese et al, 2000; Pannirselvam et al, 2003; Saenz et al, 
1989; Johnston et al, 1993; Ting et al, 1996). In fact, insulin resistance prior to the 
development of Type 2 diabetes was found to be associated with endothelial dysfunction 
in blood vessels (Steinberg et al, 1996). Hyperglycemia per se has been suggested to be a 
major factor in the development of endothelial dysfunction in diabetes in both humans 
and animals (Williams et al, 1997, Triggle et al, 2003). One explanation of this 
endothelial dysfunction has been that an increased oxidative stress caused by 
hyperglycemia decreases the bioavailability of a co-factor of nitric oxide synthase 3 
(endothelial NO synthase; eNOS), tetrahydrobiopterin. This leads to an uncoupling of the 
normal electron transfer to L-arginine during eNOS catalytic activity, which instead 
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produces super oxide; NO is identified as the pnmary mediator of ACh-induced 
relaxation in large caliber blood vessels (Triggle et al, 2003). 
HHcy has been identified as an independent risk factor for atherosclerosis; up to 
40% of patients diagnosed with premature coronary artery and peripheral vascular disease 
and venous thrombosis have increased plasma homocysteine levels (Clarke et al, 1991, 
den Heijer et al, 1996, Selhub et al, 1995). Homocysteine has also been shown to cause 
endothelial dysfunction and apoptotic cell death in endothelial cells (Hossaine et al, 2003, 
Zhang et al, 2001) as well as smooth muscle cells (Buemi et al, 2001). In apolipoprotein 
E ( apo E)-deficient mice, the induction of hyperhomocysteinemia either by dietary or 
genetic means was shown to accelerate atherosclerosis (Zhou et al, 2001). Likewise a 
reduction of plasma Hey with folic acid or a combination of B vitamins in these animals 
was shown to attenuate the development of atherosclerosis, and thus, implicated Hey as 
being a causative agent (Zhou et al, 2003, Hofmann et al, 2001). The mechanism by 
which Hey causes endothelial dysfunction has not been fully elucidated. A mechanism 
involving oxidative stress-induced reduction in the bioavailability of NO has been 
proposed for endothelial dysfunction associated with hyperglycemia, and may mediate 
some of the effects of Hey-induced endothelial dysfunction (Faraci and Lentz, 2004). 
In Chapter 3 we found that plasma Hey levels were actually decreased in both 
insulin resistant (6 weeks of age ZDF fa/fa) and diabetic rats (12 weeks of age ZDF fa/fa). 
The purpose of this study was to determine if arteries from these rats exhibited in vitro 
characteristics of endothelial dysfunction in spite of the reduced plasma levels of Hey. 
We hypothesized that if either hyperinsulinemia alone or hyperglycemia was sufficient to 
produce endothelial dysfunction then the arteries of ZDF fa/fa rats would exhibit less 
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endothelium-dependent relaxation of vascular smooth muscle than the untreated ZDF fa/+ 
rats in an age-dependent manner. Furthermore we expected that arteries from 
rosiglitazone-treated diabetic rats would be protected from such vascular dysfunction 
because the mechanism of action for this agonist of peroxisome-proliferator activated 
receptor gamma (PPAR-y) includes an apparent ability to reduce oxidative stress along 
with normalization of plasma insulin and glucagon. 
6.2 Results 
6.2.1 Contractile function of arteries from ZDF rats 
Contractions induced by 120 mM KCl were used to assess the viability of arteries 
from ZDF fa!+ and ZDF fa/fa rats. These KCI-induced increases in isometric tension were 
not different between these strains at 6, 12 and 18 weeks (Table 6.1). Likewise, KCl-
induced contractions of arteries from RSG-treated rats were not different than untreated 
rats of each strain at 12 and 18 weeks of age (Table 6.1 ). Contractions of arteries induced 
by the a 1-adrenoreceptor agonist cirazoline were not significantly different between 
groups at 6, 12 and 18 weeks of age (Table 6.2, Fig. 6.1). The cirazoline-induced 
contractions of arteries from RSG-treated rats were not different from the contractions of 
arteries from untreated rats of each strain at 12 and 18 weeks of age (Table 6.2, Fig, 6.1 ). 
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Table. 6.1 Contractile responses of ZDF rat arteries induced by high extracellular concentration of KCl 
Age (weeks) 6 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDF fa/+ ZDF fa/fa ZDffal+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Contraction 6.5 ±0.6 6.7±0.7 10.0 ± 0.4 9.6±0.6 9.0±0.6 8.2 ± 0.6 10.4 ± 0.4 8.7 ± 1.1 7.9 ± 1.1 10.6 ± 1.5 
(mN) 
...... Rings of rat mesenteric arteries (2 mm lengths) were mounted in myograph chambers under isometric tension conditions using a 
00 
N 
resting baseline tension of 2.5 mN. Contractile activity was measured by the increase in force above resting tension caused by the 
application ofhigh concentration ofKCl (120 mM) to each artery. Data are means± SEM (n = 4 for each group) and were 
analyzed separately within each age category. Student's unpaired t-test was used to compare artery responses of rat strains at 6 
weeks of age. 2-way ANOV A was used to determine the effects of strain, treatment and interaction of strain with treatment at 12 
and 18 weeks of age and was followed by 1-way ANOVA with Newman-Keuls post-hoc test for multiple comparisons of 
groups within each age category. P>0.05, all statistical comparisons. 
Table 6.2 Maximal contractile effect and potency for the a 1-adrenoreceptor agonist cirazoline in mesenteric arteries of 
untreated and RSG-treated ZDF rats at 6, 12 and 18 weeks of age. 
Age {weeks) 6 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDF fa!+ ZDF fa/fa ZDffa!+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Emax (%) 197 ± 5 211 ± 13 168 ± 7 173 ± 9 188 ± 12 206 ±24 176 ± 23 175 ± 12 211 ± 17 167 ± 7 
log ECso -7.5±0.1 -7.7 ±0.2 -7.5 ± 0.1 -7.6±0.1 -7.5±0.1 -7.6±0.2 -8.1 ± 0.6 -7.9 ± 0.3 -8.1 ± 0.4 -8.1 ± 0.2 
Emax values represent contractile responses standardized to% of contraction responses-induced by 120 mM KCl (see Table 6.1). 
Data are means± SEM (n = 4 for each group) and were analyzed separately within each age category. Student's unpaired t test 
was used to compare artery response of rat strains at 6 weeks of age. 2-way ANOV A was used to determine the effects of strain, 
treatment and interactions at 12 and 18 weeks of age and was followed by 1-way ANOVA Newman-Keuls post hoc test for 
multiple comparisons of groups within each age category. P > 0.05, all statistical comparisons. 
Figure 6.1. Cumulative concentration-contraction response relationships for the a1-
adrenoreceptor agonist cirazoline in mesenteric arteries of RSG-treated and 
untreated ZDF rats at 6, 12 and 18 weeks of age. 
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6.2.2 Acetylcholine-induced Endothelial function of the small mesenteric arteries 
from ZDF rats 
6.2.2.1 Acetylcholine-induced relaxations 
Acetylcholine (ACh)-induced relaxations of arteries from ZDF fa/fa rats were not 
different than relaxations of arteries from ZDF fa/+ rats at 6, 12 and 18 weeks of age (Fig 
6.2, Table 6.3). These ACh-induced relaxations were not different between RSG-treated 
and untreated rats of each strain at 12 and 18 weeks of age (Fig 6.2, Table 6.3). 
The NO synthases inhibitor L-NAME (300 11M), was able to significantly reduce 
the ACh-induced relaxation at all ages (Fig 6.2). Arteries from 12 weeks old ZDF fa/+ 
(untreated) and ZDF fa/fa (untreated) were reduced by ~ 18 % and ~ 29 %, respectively, 
relative to the relaxation caused by Ach in the absence of L-NAME. The relaxation of 
arteries from ZDF fa/+ (RSG) and ZDF fa/fa (RSG) rats were reduced by ~39 % and 51 
% respectively. At 18 weeks of age, L-NAME treatment of arteries from ZDF fa/+ 
(untreated) and ZDF fa/fa (untreated) rats reduced ACh-induced relaxations by- 32 % 
and~ 39 %, respectively, relative to relaxation caused by Ach alone. The reduction seen 
in the ZDF fa/+ (RSG) and ZDF fa/fa (RSG) rats was ~ 56% and ~45 % respectively. 
However, ACh-induced relaxations of L-NAME-treated arteries from ZDF fa/+ and ZDF 
fa/fa rats were not statistically different than arteries that were not treated with L-NAME 
at 6 weeks of age (Table 6.4, Fig 6.2). 
In the presence of the cyclooxygenases inhibitor indomethacin (10 11M) plus the 
presence of L-NAME (300 11M), ACh-induced relaxations of ZDf fa/+ (untreated), ZDF 
fa/fa (untreated), ZDF fa/+ (RSG) and ZDF fa/fa (RSG) rats were reduced by~ 66 %, ~ 
55 %, ~ 64 % and~ 72 % respectively, relative to Ach alone at 12 weeks of age. This 
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combination of indomethacin + L-NAME reduced ACh-induced relaxations of arteries 
from ZDF fa/+ (untreated), ZDF fa/fa (untreated), ZDF fa/+ (RSG) and ZDF fa/fa (RSG) 
by - 66 %, -66 %, - 85% and -69% respectively, relative to Ach alone at 18 weeks of 
age (Table 6.4, Fig 6.3). 
Combined treatment of arteries from ZDF fa/+ and ZDF fa/fa rats with IKca 
inhibitor TRAM-34 (10 )lmole/liter) plus L-NAME (300 )lmole/liter) reduced ACh-
induced relaxations by - 91%, -85 %, -91% and -88% respectively for ZDF fa/+ 
(untreated), ZDF fa/fa (untreated), ZDF fa/+ (RSG) and ZDF fa/fa (RSG), respectively, 
relative to Ach induced relaxation in the absence of any inhibitors at 12 weeks of age. 
This combination of TRAM-34 and L-NAME reduced ACh-induced relaxations of 
arteries from ZDF fa/+ (untreated) and ZDF fa/fa (untreated) by - 81 % and - 66 %, 
respectively, and ZDF fa/+ (RSG) and ZDF fa/fa (RSG) by -89% and -78% respectively 
relative to Ach alone at 18 weeks of age (Table 6.4, Fig 6.3 ). 
In the presence of the combination of SKca inhibitor apamin (1 )lmole/liter) + 
TRAM-34 (10 )lmole/liter) + L-NAME (300 )lmole/liter), ACh-induced relaxations of 
arteries from ZDF fa/+ (untreated) and ZDF fa/fa (untreated) rats were reduced by- 74% 
and- 92 %, respectively, relative to Ach alone at 12 weeks of age. The reduction seen in 
the ZDF fa/+ (RSG) and ZDF fa/fa (RSG) rats were -91% and -93% respectively. The 
combination of apamin + TRAM-34 + L-NAME reduced ACh-induced relaxations of 
arteries from ZDF fa/+ (untreated), ZDF fa/fa (untreated), ZDF fa/+ (RSG) ZDF fa/fa 
(RSG) rats by -84 %, - 78 %, -98% and -90% respectively, relative to Ach alone at 18 
weeks of age (Table 6.4, Fig 6.3). 
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Table 6.3. Maximum relaxation effect and potency of acetylcholine on cirazoline-contracted mesenteric arteries of 
untreated and RSG-treated ZDF rats. 
Age (weeks) 6 12 18 
Strain ZDF fa!+ ZDF fa/fa ZDF fa/+ ZDF fa/fa ZDffa!+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Emax {%) 59±7 60± 13 74±4 80± 5 85 ±4 86± 1 74±6 84±2 68± 15 86±2 
log ECso -7.0 ± 0.2 -7.1±0.2 -9.0± 0.5 -8.3 ± 0.2 -8.2 ± 0.2 -8.3 ± 0.1 -7.4 ± 0.3 -7.4 ± 0.1 -7.6 ± 0.3 -7.8±0.1 
Emax values represent % relaxation responses standardized by the reversal of cirazoline-induced submaximal contraction (1 00 % 
relaxation = complete reversal of contraction). Data are means ± SEM (n = 4 for each group) and were analyzed separately 
within each age category. Student's unpaired t test was used to compare artery response of rat strains at 6 weeks of age. 2-way 
ANOVA was used to determine the effects of strain, treatment and interactions at 12 and 18 weeks of age and was followed by 
1-way ANOVA with Newman-Keuls post hoc test for multiple comparisons of groups within each age category. P > 0.05, 
compared to untreated for all comparisons. 
Figure 6.2: Effects of L-NAME on cumulative concentration-relaxation response 
relationships for acetylcholine in small mesenteric arteries of untreated and RSG-
treated ZDF rats at 6, 12 and 18 weeks of age 
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Table 6.4. Maximum ACh-induced relaxations of cirazo1ine-contracted mesenteric arteries from ZDF fa/+ and ZDF fa/fa rats in 
the presence of various combinations of inhibitors ofNO synthases, cyclooxygenases, IK.ca and SKca. 
Age (weeks) 6 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDF fa/+ ZDF fa/fa ZDF fa/+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
L-NAME 42± 14 38 ± 17 61 ± 8 49±3 60 ± 11 42±9 50±22 37±6 41 ± 17 47±9 
L-NAME+ - - 25± 8* 29±4* 38 ± 11 * 24±9* 25 ± 11 * 13 ± 5* 23 ±9* 27±6* 
Indomethacin 
L-NAME + TRAM-34 - - 7± 2*t 7±6*t 13 ± 8*t 10 ± 3*t 14± 7* 9± 7* 23 ± 5* 19 ± 10* 
L-NAME + TRAM-34 - - 19 ± 7*t 7±4*t 7±2*t 6 ± 1*t 12 ± 8*t 2±2*t 15 ± 4*t 9±6*t 
+Apamin 
Rings of mesenteric arteries from ZDF rats were treated with various combinations of inhibitors of NO synthase (L-NAME), COX 112 
(indomethacin), IKca (TRAM-34) and SKca (apamin) prior to obtaining ACh-induced relaxation responses of cirazoline-contracted tissues. 
These data were obtained during the same experiments described for the arteries in Table 6.2, but are presented separately. Data are 
presented as mean± SEM (n = 4 for each experimental group) and were analyzed using 2-way ANOV A followed by 1-way ANOV A and 
Newman-Keuls post hoc test for multiple comparisons between groups. * P<0.05, compared to L-NAME treated arteries. t P<0.05, 
compared to treatment with L-NAME + Indomethacin. A dash symbol indicates that the experimental group was not completed. 
Figure 6.3. ACh-induced relaxations of mesenteric arteries from untreated and 
RSG-treated ZDF rats in the presence of L-NAME + indomethacin (A and D), L-
NAME + TRAM-34 (B and E) and L-NAME + TRAM-34 + Apamin (C and F) at 12 
and 18 weeks of age. 
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6.2.3 SNP-induced relaxations 
SNP-induced relaxation of arteries from untreated ZDF fa/fa rats was not 
significantly different than relaxation of arteries from untreated ZDF fa/+ rats at 6, 12 and 
18 weeks of age (Table 6.5, Fig 6.4). However, SNP-induced relaxations of arteries from 
RSG-treated ZDF fa!+ and RSG-treated ZDF fa/fa rats, were increased by ~ 100 % and 
~50%, respectively, relative to the untreated rats at 12 weeks of age (Table 6.5, Fig. 6.4). 
Likewise SNP-induced relaxations of arteries from RSG-treated ZDF fa!+ and RSG-
treated ZDF fa/fa rats, were increased by ~50 % and ~ 100 %, respectively, relative to 
untreated rats at 18 weeks of age. 
In the presence of the NO synthase inhibitor L-NAME (300 Jlmole/liter) (Table 
6.6, Fig 6.4) SNP-induced relaxations of arteries from the untreated ZDF fa!+ and ZDF 
fa/fa rats increased by ~80% and 67%, respectively, relative to arteries that were not 
treated with L-NAME at 12 weeks of age. L-NAME treatment of arteries from untreated 
ZDF fa!+ and ZDF fa/fa increased SNP-induced relaxation by ~ 136 % and ~ 123 %, 
respectively, relative to relaxation caused by SNP alone at 18 weeks of age. 
SNP-induced relaxations ofL-NAME-treated arteries from RSG-treated ZDF fa!+ 
rats increased by ~5% and ~32% respectively from the relaxation caused by SNP alone at 
12 and 18 weeks of age. SNP-induced relaxations ofL-NAME treated arteries from RSG-
treated ZDF fa/fa rats increased by ~38% from the relaxation seen in the absence of L-
NAME at both 12 and 18 weeks of age. 
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Table 6.5. Maximum relaxation responses and potency for SNP in cirazoline-contracted mesenteric arteries of untreated and 
RSG-treated ZDF rats. 
Age (weeks) 6 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDF fa/+ ZDF fa/fa ZDffa/+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Emax (%) 67 ± 11 54± 14 38 ± 5 78± 8* 43 ± 8 65± 6* 33 ±7 48±7* 26±9 53 ±6* 
log ECso -6.3 ± 0.5 -6.2 ± 0.4 -7.1 ± 0.2 -6.7±0.2 -7.4 ± 0.5 -6.7±0.2 -7.0 ± 0.5 -7.4 ± 0.4 -6.2 ± 1.7 -6.0 ± 0.4 
Data are means± SEM (n = 4 for each group) and were analyzed separately within each age category. Student's unpaired t test 
was used to compare artery responses of the rat strains at 6 weeks of age. 2-way ANOV A was used to determine the effects of 
strain, treatment and the interaction of strain with treatment at 12 and 18 weeks of age. 1-way ANOVA with Newman-Keuls post 
hoc test was used for multiple comparisons of groups within each age category. * P<0.05, compared to untreated rat. 
Figure 6.4. Effects of L-NAME on cumulative concentration-relaxation response 
relationships for sodium nitroprusside (SNP) in mesenteric arteries of untreated and 
RSG-treated ZDF rats at 6, 12 and 18 weeks of age. 
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Table 6.6. Maximum SNP-induced relaxations of cirazoline-contracted mesenteric arteries from untreated and RSG-treated ZDF 
rats in the presence of the inhibitor ofNO synthases L-NAME (300 J.lmole/liter). 
Age (weeks) 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDffa/+ ZDF fa/fa 
Treatment Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Emax 0/o 68± 8 82± 7* 72±3 86±2* 78 ±7 66± 5 58±7 73 ± 5 
log ECso -6.9 ± 0.4 -7.1±0.3 -7.2 ± 0.2 -6.8 ± 0.2 -7.2±0.3 -6.7±0.5 -6.6 ± 0.4 -6.9± 0.2 
These data were obtained in the same experiments described in Table 6.5. To make the presentation of data more clear, L-NAME 
treated arteries have been separated from the arteries represented in Table 6.5. Emax values represent% relaxation responses 
standardized by the reversal of cirazoline-induced sub-maximal contraction (100% relaxation= complete reversal of 
contraction). Data are means± SEM (n = 4 for each group) and were analyzed separately within each age category. 2-way 
ANOV A was used to determine the effects of strain, treatment and interactions and was followed by 1-way ANOV A with 
Newman-Keuls post-hoc test for multiple comparisons of groups. Group analyses included the data from Table 6.5. * P < 0.05, 
compared to untreated rats. 
6.2.4 PAR2 agonist-induced relaxations 
The relaxation responses of arteries to P AR2 activation were tested with the 
potent PAR2 agonist 2-furoyl-LIGRLO-amide (2fli) (McGuire et al, 2004). 2fli-induced 
relaxations of arteries from ZDF fa/fa rats were not different than relaxations of arteries 
from ZDF fa/+ rats at 6, 12 and 18 weeks of age (Fig 6.7, Table 6.5). These 2fli-induced 
relaxations were not different between RSG-treated and untreated rats of each strain at 12 
and 18 weeks of age (Table 6.7, Fig. 6.5). 
In the presence of the NO synthases inhibitor L-NAME (300 11mole/liter), 2fli-
induced relaxations of arteries from untreated and RSG-treated ZDF fa/+ rats were 
reduced by~ 16% and ~30 %, respectively, relative to 2-fli alone at 12 weeks of age. This 
treatment with L-NAME reduced 2fli-induced relaxations of arteries from untreated and 
RSG-treated ZDF fa/fa by ~22 % and ~55 %, respectively, relative to 2-fli alone at 12 
weeks of age (Fig. 6.5). 
In the presence of the NO synthase inhibitor L-NAME (300 11mole/liter), 2fli-
induced relaxations of arteries from untreated and RSG-treated ZDF fa/+ were reduced by 
~30% and ~66 %, respectively, relative to 2-fli alone at 18 weeks of age. This treatment 
with L-NAME reduced 2fli-induced relaxations of arteries from untreated and RSG-
treated ZDF fa/fa by ~24% and ~25 %, respectively, relative to 2-fli alone at 18 weeks of 
age (Fig. 6.5). 
6.2.5 Arachidonic acid induced relaxations 
The relaxation responses of arteries to treatment with arachidonic acid were 
tested. Arachidonic acid-induced relaxations of arteries from ZDF fa/fa rats were not 
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Table 6.7. Maximum relaxation responses and potency for 2fli in cirazoline-contracted mesenteric arteries of untreated- and 
RSG-treated ZDF rats. 
Age (weeks 6 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDF fa/+ ZDF fa/fa ZDffa/+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Emax 0/o 81 ± 6 82± 6 81 ± 6 82±2 83 ±4 87± 3 78± 5 83 ±4 73 ± 11 80± 5 
log ECso -7.1±0.1 -7.1 ± 0.1 ---- ---- ---- ---- ---- ---- ---- ----
Emax values represent % relaxation responses standardized by the reversal of cirazoline-induced sub-maximal contraction (1 00 % 
relaxation = complete reversal of contraction). Data are means ± SEM (n = 4 for each group) and were analyzed separately 
within each age category. Student's unpaired t test was used to compare artery response of rat strains at 6 weeks of age. 2-way 
ANOVA was used to determine the effects of strain, treatment and interactions at 12 and 18 weeks of age and was followed by 
1-way ANOV A for multiple comparisons of groups within each age category. P > 0.05, compared to untreated for all 
comparisons. ---- indicates that the values could not be determined from the concentration-response relationships. 
Figure 6.5. Effects of L-NAME on cumulative concentration-relaxation response 
relationships for P AR2 agonist 2fli in mesenteric arteries of untreated and RSG-
treated ZDF rats at 6, 12 and 18 weeks of age. 
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different than relaxations of arteries from ZDF fa/+ rats at 6, 12 and 18 weeks of age (Fig 
6.8, Table 6.6). These arachidonic acid-induced relaxations were not different between 
RSG-treated and untreated rats of each strain at 12 and 18 weeks of age (Table 6.8, Fig. 
6.6). 
6.3 Discussion 
6.3.1 General Findings 
The primary purpose of this study was to assess the arteries from insulin resistant-
non-diabetic ZDF and diabetic ZDF rats for evidence of endothelial dysfunction in spite 
of low plasma levels of Hey in these animals. In insulin-resistant ZDF fa/fa rats (6 weeks 
old) and fully diabetic ZDF fa/fa rats (12 and 18 weeks old), the endothelial-dependent 
relaxations of arteries by ACh and 2fli were found to be equivalent to those observed in 
age-matched untreated ZDF fa/+ rats. These endothelium-dependent relaxations were 
similar to those observed in age-matched RSG-treated ZDF fa/fa rats, whose plasma Hey 
levels were brought towards normal by the RSG treatment. Thus, we did not find any 
evidence of endothelial dysfunction in small caliber arteries from ZDF fa/fa rats at either 
low or relatively normalized plasma levels of Hey. These results suggest that the presence 
of insulin-resistance alone or hyperglycemia alone is not sufficient to produce endothelial 
dysfunction, which may require additional factors including those associated with the 
presence of HHcy. 
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Table 6.8. Maximum relaxation responses and potency for arachidonic acid in cirazoline-contracted mesenteric arteries of 
untreated and RSG-treated ZDF rats. 
Age (weeks) 6 12 18 
Strain ZDF fa/+ ZDF fa/fa ZDF fa/+ ZDF fa/fa ZDffa/+ ZDF fa/fa 
Treatment Untreated Untreated Untreated RSG Untreated RSG Untreated RSG Untreated RSG 
Emax% 83 ± 9 91 ±2 83 ± 3 73 ± 5 70±7 75 ± 6 60± 7 68 ±9 71 ± 7 75 ±4 
log ECso -6.2±0.3 -5.6± 0.2 -5.9± 0.2 -5.7 ± 0.4 -6.2± 0.5 -5.5 ± 0.4 -5.3 ± 0.2 -5.3 ± 0.1 -5.1±0.1 -5.7±0.2 
Emax values represent % relaxation responses standardized by the reversal of cirazoline-induced sub-maximal contraction (1 00 % 
relaxation = complete reversal of contraction). Data are means± SEM (n = 4 for each group) and were analyzed separately 
within each age category. Student's unpaired t test was used to compare artery response of rat strains at 6 weeks of age. 2-way 
ANOV A was used to determine the effects of strain, treatment and interactions at 12 and 18 weeks of age and was followed by 
1-way ANOVA with Newman-Keuls post-hoc test for multiple comparisons of groups within each age category. P > 0.05, 
compared to untreated for all comparisons. 
Figure 6.6. Cumulative concentration-relaxation response relationships for 
arachidonic acid Na Salt in small mesenteric arteries of untreated and RSG-treated 
ZDF rats at 6, 12 and 18 weeks of age. 
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6.3.2 Relaxations by ACh 
The present study did not find any differences between the relaxations to ACh of 
small mesenteric arteries of the groups studied at any of the ages. These data do not 
support previous findings of general age-dependent development of endothelial 
dysfunction of arteries in the ZDF fa/fa rat. Brodsky et al (2004) and Oltman et al. (2006) 
have reported that Ach-induced relaxations of aortic rings from ZDF fa/fa rats were 
reduced relative to controls. In contrast to these studies, our study used primarily small 
caliber arteries. Oltman et al. (2005, 2006) reported that Ach-induced vasodilation of 
pressurized mesenteric arteries, epineurial arterioles and coronary arteries from 
hyperglycemic ZDF fa/fa rats were reduced relative to age-matched ZDF-lean (+/?) rats. 
Nevertheless, a negative finding relating to endothelial dysfunction which was similar to 
ours has been reported in small caliber arteries. Bohlen and Lash (1995) reported that 
vasodilations in the intestinal microvasculature of both 22-25 and 35-40 weeks old ZDF 
fa/fa rats were similar to lean littermates. Based on these studies, some types of arteries 
from ZDF fa/fa rats have appeared to display characteristics of endothelial dysfunction, 
while some have not. When our results have been included with these studies however, 
the data appear to favor a conclusion that ACh-induced relaxations of mesenteric arteries 
from ZDF fa/fa rats are not impaired. 
6.3.2.1 Mechanisms of ACh relaxations: 
Previous studies with ZDF fa/fa rats reported a loss of ACh-mediated 
endothelium-dependent hyperpolarization of mesenteric smooth muscle as characteristic 
of endothelial dysfunction (Burnham et al., 2006a, 2006b ). Whereas the L-arginine-nitric 
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oxide pathway is recognized as the major vasodilator pathway in response to ACh in large 
caliber arteries, other mechanisms collectively referred to as EDHFs (endothelium-
derived hyperpolarization factors) cause vasorelaxation in small caliber arteries (McGuire 
et al, 2001 ). Indeed this distinction was evident by the inability of the NOS inhibitor, L-
NAME to completely abolish vasorelaxation in response to ACh, since arteries were still 
able to display a considerable relaxation in the presence of L-NAME. We therefore, 
conducted further inhibitor studies based on similar studies with rat mesenteric arteries to 
identify the possible alternative mechanisms responsible for this vasodilatory process; 
primarily, COX-1/2 products (indomethacin) and Ca2+-activated K-channels (TRAM-34 
and apamin). Our results showed that both COX and the Kca channels were involved in 
NOS independent vasorelaxation as seen by the reductions in relaxation in the presence of 
their respective inhibitors. Kca channels have been shown to play an essential role in the 
actions of EDHF (McGuire et al., 2001 for review). This was also evident in the present 
study as inhibition of the Kca channels clearly had a greater effect on vasorelaxation than 
inhibition of COX. In contrast to the observations by Burnham et al., (2006a, 2006b) of 
reduced ACh-induced membrane hyperpolarisations, the current isometric tension data 
failed to give any indication of a reduction in either NO or EDHF vasodilation 
mechanisms, which would have been taken as evidence for the presence of endothelial 
dysfunction in this model. However, it is possible that those observations by Burnham et 
al (2006a, 2006b) do not translate to functional deficiencies in vascular smooth muscle 
relaxation. 
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6.3.3 Relaxations by P AR2 agonist 
In support of the data obtained using ACh, maximal relaxation of mesenteric 
arteries by activation of endothelial Proteinase-Activated Receptor 2 (P AR2; G protein 
coupled receptor 11) in ZDF fa/fa rats was not different than in the non diabetic rats. This 
is the first study to describe the effects of PAR2 activation in the ZDF fa/fa rat. P AR2 is 
an endothelial receptor whose activation either after the proteolytic cleavage of its N-
terminus by several trypsin-like serine proteinases or sans enzyme, by specific activating 
peptides which mimic the proteolytic activation, causes vascular smooth muscle 
relaxation (Hollenberg and Compton, 2002). 2fli has been shown to be the most potent 
and selective activating peptide agonist for PAR2 (McGuire et al., 2004). Nevertheless 
we interpret these results with some caution because it would appear from the cumulative 
concentration-response relationships to P AR2 agonist that there was in fact an increase in 
sensitivity to 2fli for ZDF fa/fa rats after 6 weeks of age. P AR-2 expression has been 
shown to increase during stress to the vasculature and also in the presence of various 
cytokines and pro-inflammatory substances (McGuire, 2004). Increased P AR2 expression 
may be considered consistent with displayed increases in pro-inflammatory substances in 
the ZDF rat model also (Hotamisligil et al, 1993). Similarly, in non-obese diabetic (NOD) 
mice, a model of Type I diabetes, high or severe glycosuria was shown to provoke an 
increase in the vasodilatory response to P AR2 stimulation (Roviezzo et al. 2005). 
Notwithstanding these observations, an increased sensitivity to 2fli-induced vasodilation 
could indicate any number of upregulations involving signal transduction of P AR2. P AR2 
vasodilator response in small caliber arteries is reported to be mediated by endothelium-
dependent hyperpolarization of vascular smooth muscle via Ca2+ -activated K+ channels in 
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mice and rats (McGuire, 2004; McGuire et al, 2002a, 2004a, 2004b ). In large caliber 
arteries NO is reported to mediate the vascular smooth muscle relaxation responses in 
humans, rats and mice (McGuire et al, 2002b; McGuire, 2004). Our current results were 
consistent with these former observations since inhibition of NOS by L-NAME resulted 
only in a partial inhibition of the response to 2fli. Together these data obtained with a 
P AR2 agonist are consistent with our conclusions that no dysfunction of endothelial 
vasodilator function by either NO mediated or EDHF mediated mechanisms was 
observed. 
6.3.4 Relaxations by Arachidonic-Acid 
We did not observe any differences in the vasorelaxation in response to exogenous 
application of AA in any of the groups of mesenteric arteries. These results are not 
consistent with the general results of 2 previous studies. In the first study it was reported 
that dilation of small mesenteric arteries by exogenous application of arachidonic acid 
appeared to be impaired in ZDF fa/fa rats (Zhou et al. 2005). Arachidonic acid is an 
important endogenous precursor of vasoactive eicosanoids and is converted to vasoactive 
mediators via three major enzymatic pathways; lipoxygenase (LOX), cytochrome P450 
epoxygenase and cyclooxygenase (COX). The products formed by these pathways are 
important regulators of vasoreactivity with the cytochrome P450 pathway being 
responsible for AA mediated dilation of human coronary arterioles (Miura and 
Gutterman, 1998) while the LOX pathway is responsible for dilation of rat mesenteric 
arteries (Miller et al, 2003). Zhou et al (2005) identified a reduction of 12-lipoxygenase 
protein and activity as the cause of impairment. In a second study, dilation of small 
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coronary arteries of ZDF rats was also shown to be impaired in response to exogenous 
application of AA and was associated with impairment of the activation of the large 
conductance Ca +2 activated K+ channels due to reduced PGh synthase activity (Lu et a!, 
2005). Aside from different arteries being used in the second study, in both of the above 
mentioned studies, data were obtained from ZDF rats after - 4 weeks of hyperglycemia. 
This would make these rats approximately the same age as the 12 weeks old rats in the 
present study. We conclude that we could not reproduce the findings of these previous 
studies and that there was no evidence of a reduction in responsiveness to AA in the 
vascular smooth muscle of ZDF fa/fa rats. 
6.3.5 Relaxations by SNP 
The data obtained using SNP to cause relaxations did not provide any evidence of a 
reduction in vascular smooth muscle responsiveness to NO in arteries from ZDF fa/fa 
relative to arteries from ZDF fa!+ rats. However, both the ZDF fa/fa (untreated) and the 
ZDF fa!+ (untreated) rats showed a reduced relaxation responsiveness to SNP relative to 
these values reported in the literature (Zhou et al, 2005). Nonetheless, these data were 
consistent with previous studies which did not find any changes (Zhou et al, 2005). 
6.3.6 Rosiglitazone effects on vascular function. 
Rosiglitazone treatment in vivo failed to affect the relaxations of arteries from ZDF fa/+ 
and ZDF fa/fa rats by ACh, 2fli and AA relative to untreated animals. These data could be 
considered simply as being consistent with the lack of observed indicators for vascular 
dysfunction in our study of ZDF fa/fa rats. However, Walker et al. (1999) have reported 
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that RSG treatment was able to partially prevent the impairment of ACh induced 
relaxation in Zucker Fatty rats, a model of insulin resistance with hyperinsulinemia and 
normoglycemia. Ours is the first study to test the effects of RSG treatment on P AR2 and 
AA relaxations, but its implications are not clear to us. When SNP-induced relaxations 
were assessed in RSG-treated rats by way of assessing RSG action on vascular smooth 
muscle sensitivity to NO, we found that RSG treatment of rats enhanced SNP-induced 
maximum relaxations of arteries from all groups of rats. These enhanced SNP relaxations 
in arteries from RSG-treated rats at 12 weeks were similar to the relative values reported 
in untreated ZDF rats in other studies (Zhou et a!, 2005). These data are consistent with a 
study which reported of improved endothelium-independent vasodilation in response to 
another NO donor, Nitroglycerine, in non-diabetic patients with the metabolic syndrome 
after treatment with RSG (Wang et a!, 2004). SNP releases NO spontaneously and is 
independent of eNOS and thus, is able to bypass the requirement for the endothelium in 
causing vasorelaxation. Relaxation caused by SNP is regarded as endothelium-
independent, in contrast to the endothelium-dependent vasorelaxation caused by ACh. 
NO generated from SNP is thought to follow the same downstream mechanisms as 
endothelial-derived NO such as by ACh in the vascular smooth muscle cells of large 
arteries to cause vasorelaxation. Since the response of these arteries to ACh mediated NO 
vasodilation appears to be preserved we suggest that the effect of RSG was not due to an 
action on the downstream mediators of NO i.e. guanylyl cyclase and cyclic GMP. One 
can only speculate that somehow the RSG action enables an exogenous source of NO to 
cause vascular smooth muscle relaxation differently than endothelial derived NO. We 
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deemed this effect of RSG to at least indicate that the selected dose of RSG had indeed 
caused a change in vascular function that was detected and measurable by the assay. 
NOS inhibition by L-NAME caused the same degree of block of relaxations by 
ACh and 2fli in arteries from RSG-treated rats relative to untreated rats. These results 
would appear to support the evidence for normal endothelial derived NO and EDHF in 
the arteries from ZDF fa/fa rats. To our knowledge the effects of RSG treatment on ACh-
induced EDHF relaxations have not been reported earlier. L-NAME treatment enhanced 
the relaxations by SNP of arteries from all groups of rats tested at both 12 and 18 weeks 
except for the already extra responsive arteries from rosiglitazone-treated ZDF fa/+ rats. 
L-NAME treatment of arteries has been known for some time to enhance SNP-induced 
relaxations (Moncada et al. 1991 ). The leading hypothesis remains that a decrease in the 
basal levels of cyclic GMP arising from eNOS inhibition (or physical removal of the 
endothelium) leads to greater fold-increases in cyclic GMP upon exogenous activation of 
soluble guanylyl cyclase (Moncada et al. 1991). The data did not inform us of any 
specific mechanistic explanation for the loss of this nitrovasodilator sensitization effect 
by L-NAME in RSG-treated ZDF fa!+ rats. We speculate that sensitization could have 
already been maximized prior to L-NAME treatment of arteries in these rats. This study 
did not have sufficient evidence to elucidate a possible mechanism, but has provided 
sufficient to warrant further investigation of this action of RSG treatment. 
6.3. 7 Hey plasma levels, rosiglitazone, vascular function 
ZDF fa/fa (untreated) rats had significantly lower plasma Hey levels at all three 
ages which were studied. Lentz et al (2000) reported that relaxation of aortic rings in 
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response to acetylcholine did not differ in CBS +I+ and CBS +I- mice fed a control diet, but 
greatly differed between the 2 groups when fed a folate-deficient diet with the relaxation 
being markedly impaired in CBS +I- mice. Plasma Hey did not differ between the two 
groups on the control diet, but was greatly elevated in the CBS +I- mice on the folate 
deficient diet. These results would support the notion that plasma Hey was a determinant 
of vascular relaxation. Diabetic hyperglycemia is also described as a causative 
determinant for the endothelial dysfunction observed in diabetes (Triggle et al, 2003). 
Initially it was simply thought that the reduction in Hey that we observed in ZDF fa/fa 
rats may have been able to counterbalance the increase in plasma glucose and thus, 
normalized net endothelial function in the present study. This interpretation would be 
consistent with the data obtained in the ZDF rats studied by Bohlen and Lash (1995) 
which also displayed hyperglycemia despite their normal response to ACh. However, 
RSG treatment of ZDF fa/fa rats was able to normalize hyperglycemia while increasing 
the plasma Hey level towards normal, but had no apparent effect on endothelial-
dependent relaxations relative to untreated rats. Therefore, it seems reasonable to 
conclude that hyperglycemia alone was not sufficient to produce endothelial dysfunction 
in the mesenteric arteries of ZDF fa/fa rats. We propose that elevation of plasma levels of 
homocysteine in this model would lead to endothelial dysfunction. 
6.3.8 Impact of information regarding vascular function, homocysteine, 
hyperglycemia, diabetes. 
In conclusion endothelium-dependent and -independent vasorelaxation were 
preserved during insulin resistance as well as during frank diabetes. The normalizing 
214 
effects of RSG on plasma levels of glucose and Hey and yet, its lack of enhancement 
effect on endothelial vasodilator function supports the idea that plasma Hey may serve as 
a balance point for development of endothelial dysfunction in this model of Type 2 
diabetes. 
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Chapter 7 
General Discussion and conclusions 
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Mild hyperhomocysteinemia has been identified as a risk factor for many 
diseases, including cardiovascular disease. A 5 jlmol/liter increase in total plasma Hey has 
been shown to be comparable to an increase in cholesterol of 0.5 mmol/liter, in increasing 
the risk of coronary artery disease. 
Recently, however, uncertainty has arisen regarding the degree of risk associated 
with elevated plasma Hey. This may be related to one form of Hey being more important 
in causing vascular disease than total Hey as well as to the specific location of Hey 
(Stamm and Reynolds, 1999). It is also likely that the Type of cardiovascular disease is 
important. The recent Heart Outcome Prevention Evaluation (HOPE) 2 study, which used 
vitamin B therapy to reduce plasma Hey found no beneficial effects on the risk of death 
from cardiovascular causes or myocardial infarction but there was a reduction in stroke 
incidence (Lonn et a!, 2006). There are certain situations however, where the risk posed 
by elevated Hey is undisputable. Type 2 diabetes in one of these and HHcy has been 
shown to be a stronger risk factor for cardiovascular disease and for mortality in Type 2 
diabetic patients than in non-diabetics (Hogeveen et al, 1998). 
The principal objective of our work was to identify the changes that occur in 
plasma Hey in insulin resistance and Type 2 diabetes and to identify the metabolic steps 
that lead to these changes. For this, we used the leptin-receptor-defective Zucker Diabetic 
Fatty rats which are known to go through an initial insulin resistant phase before going on 
to develop frank Type 2 diabetes. 
As discussed in Chapter 3 of this thesis, we were able to show that hormonal 
changes that occur in insulin resistance and Type 2 diabetes act at several points of the 
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methionine metabolic pathway leading to alterations in methionine and Hey metabolism. 
Our study showed that, similar to what has been shown in Type 1 diabetic humans and 
rats, plasma total Hey is reduced in insulin resistance as well as in Type 2 diabetes 
(Figure 3.1). We also saw that this reduction is brought about by increases in the 
transsulfuration as well as the remethylation routes of Hey removal through increases in 
the activities of CBS, CGL and BHMT (Table 3.2). The increase in the transsulfuration 
enzymes did not come as a surprise as it has been demonstrated previously in glucagon-
treated as well as streptozotocin diabetic rats (Jacobs et al, 2001, Jacobs et al, 1998). 
Work in our lab has also shown the direct effect of insulin and glucagon on CBS 
expression (Ratnam et al, 2002). What was interesting and novel was the effect that 
betaine and BHMT had on determining plasma Hey. We saw that BHMT activity and 
mRNA levels were increased in both the insulin resistant and diabetic stages with a 
concomitant reduction in hepatic betaine concentration. These data suggest that increased 
BHMT activity is driving the Hey levels down and is depleting hepatic betaine stores. In 
support of these findings, Schwahn et al (2003) have previously shown a negative 
correlation between plasma betaine and plasma tHey in humans while supplementation 
with betaine has been shown to reduce plasma Hey (Steenge et al, 2003). Furthermore, 
the fact that BHMT was more active in ZDF fa/fa rats was further evident in the virtual 
elimination of Hey export from isolated hepatocytes incubated with methionine and 
betaine compared to the significantly lowered effect betaine had on Hey export from cells 
isolated from ZDF fa/? rats (Table3.5). The extraordinarily high level of hepatic betaine 
found in the young rats was another remarkable finding, the function of which we are 
currently exploring (Table 3.6). 
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We then went on to explore the changes that occur in amino acid metabolism in 
insulin resistance and Type 2 diabetes. We measured plasma, liver and skeletal muscle 
amino acid levels and also calculated the intracellular/extracellular concentration ratios 
for hepatic and skeletal muscle amino acids. Consistent with previous reports on Type 1 
diabetic models (Bloxam, 1972, Brosnan et al, 1980, 1983) we observed a significant 
increase in plasma BCAA in both insulin resistant and diabetic stages (Table 4.1 ). Similar 
changes were seen in the liver and skeletal muscle with valine and leucine being 
increased in both tissues at 11 weeks while isoleucine and leucine showed increases in 
skeletal muscle at 5 weeks (Tables 4.2 and 4.4). The literature on the activity of the rate 
limiting step in the catabolism of BCAA, the branched chain a-ketoacid dehydrogenase 
in diabetes is controversial with some studies showing a reduction (Gibson et al, 1993) 
and others showing increases (Lombardo et al, 1998, Li et al, 2001, Lombardo et al, 
1999). However, it appears that increased proteolysis along with Hyperphagia could be 
the cause for this increase in BCAA, similar to what has been suggested for Type 1 
diabetes (Rodriguez et al, 1997, Crandall and Fernstrom 1983). We were also able to 
provide strong evidence for a common metabolic regulation of these three amino acids, as 
shown by the almost perfect correlation between the plasma concentrations of the three 
amino acids (Figure 4.1). 
A number of glucogenic amino acids showed decreased concentrations in plasma, 
liver and skeletal muscle in the ZDF fa/fa rats compared to ZDF fa/? rats (Tables 4.1, 4.2 
and 4.4). This is consistent with their use as substrates for glucose synthesis in the ZDF 
fa/fa rats who have been shown to have defective suppression of hepatic glucose 
production and, therefore, an increased total glucose output (Fujimoto et al, 2004). The 
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reduction of one glucogenic amino acid in particular, serine, stands out in the context of 
this thesis as our central focus is Hey. We see reductions in the level of serine in all three 
tissues studied at both ages. Since serine is an essential substrate for the cystathionine B-
synthase reaction, this reduction may somewhat limit Hey removal through the 
transsulfuration pathway. Interestingly, although our in-vitro studies did show an 
increased activity of CBS we did not find a difference in the transsulfuration flux in the 
presence of methionine alone between the ZDF fa/fa and the ZDF fa/? rats at either age. 
This will further highlight the importance of the BHMT reaction in the· removal of Hey 
under insulin resistant and diabetic conditions. 
The study on the effect of Rosiglitazone on Hey metabolism was able to validate 
the conclusion made at the end of the first study that changes in the level of or the 
sensitivity towards insulin and its counter-regulatory hormones are responsible for the 
changes observed in Hey metabolism in insulin resistance and diabetes. The restoration 
of insulin sensitivity by Rosiglitazone brought the reduced Hey level towards normal but 
was unable to completely normalize it. Here again the changes that were observed in the 
activity of BHMT proved to be very interesting. Although, BHMT has been shown to be 
under the regulation of insulin and the counter-regulatory hormones (as is CBS), RSG 
treatment and the resulting increases in the sensitivity towards insulin did not provide us 
with the expected results. We saw that the increased activity of BHMT observed in the 
ZDF fa/fa rats were further increased by the RSG treatment rather than the expected 
normalization. An explanation for this phenomenon could be obtained from the 
involvement of BHMT in lipid and lipoprotein metabolism. The insulin resistance and 
diabetes in the ZDF rats is known to be lipogenic; indeed, the accumulation of fat in liver, 
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muscle and pancreatic ~ cells is hypothesized to be pathogenic. RSG increases insulin 
sensitivity by causing adipocyte differentiation with increased FF A deposition in adipose 
tissue (Oakes eta!, 2001). RSG therefore is able to lessen the accumulation of lipids in 
ectopic locations. The interesting involvement of BHMT in the PEMT pathway of PC 
synthesis, and therefore in VLDL secretion which needs to be increased to accomodate 
this relocation of FF A, may provide an explanation as to the increased activity of BHMT 
under the influence of RSG. The direct effect of RSG on BHMT activity as well as the 
possible role of betaine in VLDL secretion in the presence of RSG should be investigated 
in the future to gain a full understanding of the function of this enzyme. 
Although the exact mechanism by which Hey causes endothelial dysfunction has 
not been elucidated, hyperhomocysteinemia has been shown to be a causative agent for 
endothelial dysfunction (Hossaine et a!, 2003) as well as atherosclerosis (Zhou et a!, 
2003). Diabetes mellitus and insulin resistance have also been shown to be associated 
with endothelial dysfunction. It was therefore very interesting to examine the effect of 
lowered plasma total Hey on endothelial function in insulin resistance and diabetes. 
The endothelium-dependent vasorelaxation was observed to be preserved in both insulin 
resistant and Type 2 diabetic rats as seen by the response of mesenteric arteries to 
acetylcholine, 2-fli and arachidonic acid. We speculate that the reduced Hey levels may 
have been able to counterbalance the increase in plasma glucose in rescuing endothelial 
function especially in the diabetic stage. 
In the face of this normal endothelium dependent vasorelaxation we were 
surprised to observe a defect in the endothelium independent vasorelaxation as seen by 
the response of mesenteric arteries to Na-Nitroprusside. Both groups of untreated rats 
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(ZDF fa/fa and ZDF fa/+) were defective in their response to SNP with the RSG treated 
rats responding significantly better. However, in the presence of the NOS inhibitor L-
NAME, the vessels isolated from the untreated rats were able to respond similar to the 
RSG treated vessels. This led us to consider that the defective response to SNP arose 
from a sensitization of the vessels to NO as iN OS is known to be up-regulated in the ZDF 
rats. The response of the RSG treated vessels also complements this notion as PPAR-y is 
a known anti-inflammatory agent with inhibition of the activation of iNOS as one of its 
functions. 
In conclusion, our work was successful in demonstrating the importance of 
hormones in the regulation of Hey metabolism. We saw that the changes in insulin and 
the counter-regulatory hormones that occur in insulin resistance and Type 2 diabetes were 
instrumental in lowering the plasma homocysteine level and that this was achieved 
through changes in the activity of several enzymes involved in methionine and Hey 
metabolism. Specific attention was drawn by our work towards the enzyme BHMT 
which proved to be a multi-functional enzyme involved in both amino acid and lipid 
metabolism. 
We were also able to describe the changes that occur in amino acid levels in 
plasma, skeletal muscle and the liver in insulin resistance and Type 2 diabetes. Finally, 
our work on endothelial function may indicate Hey as an important determinant of 
cardiovascular function in diabetes. 
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